
<html lang="en"     class="pb-page"  data-request-id="d6864e06-7db8-4e0a-8475-ce659784e018"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2020.63.issue-15;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b02035;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase" /></meta><meta name="dc.Creator" content="Volker K.  Schulze" /></meta><meta name="dc.Creator" content="Ulrich  Klar" /></meta><meta name="dc.Creator" content="Dirk  Kosemund" /></meta><meta name="dc.Creator" content="Antje M.  Wengner" /></meta><meta name="dc.Creator" content="Gerhard  Siemeister" /></meta><meta name="dc.Creator" content="Detlef  Stöckigt" /></meta><meta name="dc.Creator" content="Roland  Neuhaus" /></meta><meta name="dc.Creator" content="Philip  Lienau" /></meta><meta name="dc.Creator" content="Benjamin  Bader" /></meta><meta name="dc.Creator" content="Stefan  Prechtl" /></meta><meta name="dc.Creator" content="Simon J.  Holton" /></meta><meta name="dc.Creator" content="Hans  Briem" /></meta><meta name="dc.Creator" content="Tobias  Marquardt" /></meta><meta name="dc.Creator" content="Hartmut  Schirok" /></meta><meta name="dc.Creator" content="Rolf  Jautelat" /></meta><meta name="dc.Creator" content="Rolf  Bohlmann" /></meta><meta name="dc.Creator" content="Duy  Nguyen" /></meta><meta name="dc.Creator" content="Amaury E.  Fernández-Montalván" /></meta><meta name="dc.Creator" content="Ulf  Bömer" /></meta><meta name="dc.Creator" content="Uwe  Eberspaecher" /></meta><meta name="dc.Creator" content="Michael  Brüning" /></meta><meta name="dc.Creator" content="Olaf  Döhr" /></meta><meta name="dc.Creator" content="Marian  Raschke" /></meta><meta name="dc.Creator" content="Bertolt  Kreft" /></meta><meta name="dc.Creator" content="Dominik  Mumberg" /></meta><meta name="dc.Creator" content="Karl  Ziegelbauer" /></meta><meta name="dc.Creator" content="Michael  Brands" /></meta><meta name="dc.Creator" content="Franz  von Nussbaum" /></meta><meta name="dc.Creator" content="Marcus  Koppitz" /></meta><meta name="dc.Description" content="Inhibition of monopolar spindle 1 (MPS1) kinase represents a novel approach to cancer treatment: instead of arresting the cell cycle in tumor cells, cells are driven into mitosis irrespective of DN..." /></meta><meta name="Description" content="Inhibition of monopolar spindle 1 (MPS1) kinase represents a novel approach to cancer treatment: instead of arresting the cell cycle in tumor cells, cells are driven into mitosis irrespective of DN..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 27, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b02035" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02035" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b02035" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02035" /></link>
        
    
    

<title>Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b02035" /></meta><meta property="og:title" content="Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0035.jpeg" /></meta><meta property="og:description" content="Inhibition of monopolar spindle 1 (MPS1) kinase represents a novel approach to cancer treatment: instead of arresting the cell cycle in tumor cells, cells are driven into mitosis irrespective of DNA damage and unattached/misattached chromosomes, resulting in aneuploidy and cell death. Starting points for our optimization efforts with the goal to identify MPS1 inhibitors were two HTS hits from the distinct chemical series “triazolopyridines” and “imidazopyrazines”. The major initial issue of the triazolopyridine series was the moderate potency of the HTS hits. The imidazopyrazine series displayed more than 10-fold higher potencies; however, in the early project phase, this series suffered from poor metabolic stability. Here, we outline the evolution of the two hit series to clinical candidates BAY 1161909 and BAY 1217389 and reveal how both clinical candidates bind to the ATP site of MPS1 kinase, while addressing different pockets utilizing different binding interactions, along with their synthesis and preclinical characterization in selected in vivo efficacy models." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b02035"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02035">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b02035&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b02035&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b02035&amp;href=/doi/10.1021/acs.jmedchem.9b02035" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 8025-8042</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b02115" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.0c01184" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Volker K. Schulze</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Volker K. Schulze</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>V.K.S.: email, <a href="/cdn-cgi/l/email-protection#a1d7cecdcac4d38fd2c2c9d4cddbc4e1c3c0d8c4d38fc2cecc"><span class="__cf_email__" data-cfemail="bdcbd2d1d6d8cf93ceded5c8d1c7d8fddfdcc4d8cf93ded2d0">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Volker+K.++Schulze">Volker K. Schulze</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0158-1789" title="Orcid link">http://orcid.org/0000-0002-0158-1789</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ulrich Klar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ulrich Klar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ulrich++Klar">Ulrich Klar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dirk Kosemund</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dirk Kosemund</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dirk++Kosemund">Dirk Kosemund</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Antje M. Wengner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Antje M. Wengner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Antje+M.++Wengner">Antje M. Wengner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gerhard Siemeister</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gerhard Siemeister</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gerhard++Siemeister">Gerhard Siemeister</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Detlef Stöckigt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Detlef Stöckigt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Detlef++St%C3%B6ckigt">Detlef Stöckigt</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Roland Neuhaus</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Roland Neuhaus</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roland++Neuhaus">Roland Neuhaus</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Philip Lienau</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philip Lienau</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philip++Lienau">Philip Lienau</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Benjamin Bader</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Benjamin Bader</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Benjamin++Bader">Benjamin Bader</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stefan Prechtl</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefan Prechtl</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Prechtl">Stefan Prechtl</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Simon J. Holton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simon J. Holton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simon+J.++Holton">Simon J. Holton</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hans Briem</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hans Briem</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hans++Briem">Hans Briem</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tobias Marquardt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tobias Marquardt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 42113 Wuppertal, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tobias++Marquardt">Tobias Marquardt</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hartmut Schirok</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hartmut Schirok</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 42113 Wuppertal, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hartmut++Schirok">Hartmut Schirok</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rolf Jautelat</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rolf Jautelat</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 42113 Wuppertal, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rolf++Jautelat">Rolf Jautelat</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rolf Bohlmann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rolf Bohlmann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rolf++Bohlmann">Rolf Bohlmann</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Duy Nguyen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Duy Nguyen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Duy++Nguyen">Duy Nguyen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4534-745X" title="Orcid link">http://orcid.org/0000-0002-4534-745X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Amaury E. Fernández-Montalván</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amaury E. Fernández-Montalván</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amaury+E.++Fern%C3%A1ndez-Montalv%C3%A1n">Amaury E. Fernández-Montalván</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9156-0000" title="Orcid link">http://orcid.org/0000-0001-9156-0000</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ulf Bömer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ulf Bömer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ulf++B%C3%B6mer">Ulf Bömer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Uwe Eberspaecher</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Uwe Eberspaecher</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Uwe++Eberspaecher">Uwe Eberspaecher</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Brüning</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Brüning</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Br%C3%BCning">Michael Brüning</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Olaf Döhr</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Olaf Döhr</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Olaf++D%C3%B6hr">Olaf Döhr</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marian Raschke</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marian Raschke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marian++Raschke">Marian Raschke</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bertolt Kreft</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bertolt Kreft</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bertolt++Kreft">Bertolt Kreft</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dominik Mumberg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dominik Mumberg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dominik++Mumberg">Dominik Mumberg</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karl Ziegelbauer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karl Ziegelbauer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karl++Ziegelbauer">Karl Ziegelbauer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Brands</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Brands</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Brands">Michael Brands</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Franz von Nussbaum</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Franz von Nussbaum</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Franz++von+Nussbaum">Franz von Nussbaum</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Marcus Koppitz</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marcus Koppitz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>M.K.: email, <a href="/cdn-cgi/l/email-protection#204d41524355530e4b4f505049545a6042415945520e434f4d"><span class="__cf_email__" data-cfemail="016c60736274722f6a6e717168757b4163607864732f626e6c">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marcus++Koppitz">Marcus Koppitz</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02035&amp;href=/doi/10.1021%2Facs.jmedchem.9b02035" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 8025–8042</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 27, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 December 2019</li><li><span class="item_label"><b>Published</b> online</span>27 April 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 August 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b02035" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02035</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8025%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DVolker%2BK.%2BSchulze%252C%2BUlrich%2BKlar%252C%2BDirk%2BKosemund%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D15%26contentID%3Dacs.jmedchem.9b02035%26title%3DTreating%2BCancer%2Bby%2BSpindle%2BAssembly%2BCheckpoint%2BAbrogation%253A%2BDiscovery%2Bof%2BTwo%2BClinical%2BCandidates%252C%2BBAY%2B1161909%2Band%2BBAY%2B1217389%252C%2BTargeting%2BMPS1%2BKinase%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8042%26publicationDate%3DAugust%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b02035"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2389</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b02035" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Volker&quot;,&quot;last_name&quot;:&quot;K. Schulze&quot;},{&quot;first_name&quot;:&quot;Ulrich&quot;,&quot;last_name&quot;:&quot;Klar&quot;},{&quot;first_name&quot;:&quot;Dirk&quot;,&quot;last_name&quot;:&quot;Kosemund&quot;},{&quot;first_name&quot;:&quot;Antje&quot;,&quot;last_name&quot;:&quot;M. Wengner&quot;},{&quot;first_name&quot;:&quot;Gerhard&quot;,&quot;last_name&quot;:&quot;Siemeister&quot;},{&quot;first_name&quot;:&quot;Detlef&quot;,&quot;last_name&quot;:&quot;Stöckigt&quot;},{&quot;first_name&quot;:&quot;Roland&quot;,&quot;last_name&quot;:&quot;Neuhaus&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;Lienau&quot;},{&quot;first_name&quot;:&quot;Benjamin&quot;,&quot;last_name&quot;:&quot;Bader&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Prechtl&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;J. Holton&quot;},{&quot;first_name&quot;:&quot;Hans&quot;,&quot;last_name&quot;:&quot;Briem&quot;},{&quot;first_name&quot;:&quot;Tobias&quot;,&quot;last_name&quot;:&quot;Marquardt&quot;},{&quot;first_name&quot;:&quot;Hartmut&quot;,&quot;last_name&quot;:&quot;Schirok&quot;},{&quot;first_name&quot;:&quot;Rolf&quot;,&quot;last_name&quot;:&quot;Jautelat&quot;},{&quot;first_name&quot;:&quot;Rolf&quot;,&quot;last_name&quot;:&quot;Bohlmann&quot;},{&quot;first_name&quot;:&quot;Duy&quot;,&quot;last_name&quot;:&quot;Nguyen&quot;},{&quot;first_name&quot;:&quot;Amaury&quot;,&quot;last_name&quot;:&quot;E. Fernández-Montalván&quot;},{&quot;first_name&quot;:&quot;Ulf&quot;,&quot;last_name&quot;:&quot;Bömer&quot;},{&quot;first_name&quot;:&quot;Uwe&quot;,&quot;last_name&quot;:&quot;Eberspaecher&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Brüning&quot;},{&quot;first_name&quot;:&quot;Olaf&quot;,&quot;last_name&quot;:&quot;Döhr&quot;},{&quot;first_name&quot;:&quot;Marian&quot;,&quot;last_name&quot;:&quot;Raschke&quot;},{&quot;first_name&quot;:&quot;Bertolt&quot;,&quot;last_name&quot;:&quot;Kreft&quot;},{&quot;first_name&quot;:&quot;Dominik&quot;,&quot;last_name&quot;:&quot;Mumberg&quot;},{&quot;first_name&quot;:&quot;Karl&quot;,&quot;last_name&quot;:&quot;Ziegelbauer&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Brands&quot;},{&quot;first_name&quot;:&quot;Franz&quot;,&quot;last_name&quot;:&quot;von Nussbaum&quot;},{&quot;first_name&quot;:&quot;Marcus&quot;,&quot;last_name&quot;:&quot;Koppitz&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;8025-8042&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b02035&quot;},&quot;abstract&quot;:&quot;Inhibition of monopolar spindle 1 (MPS1) kinase represents a novel approach to cancer treatment: instead of arresting the cell cycle in tumor cells, cells are driven into mitosis irrespective of DNA damage and unattached/misattached chromosomes, resulting in aneuploidy and cell death. Starting points for our optimization efforts with the goal to identify MPS1 inhibitors were two HTS hits from the distinct chemical series “triazolopyridines” and “imidazopyrazines”. The major initial issue of the triazolopyridine series was the moderate potency of the HTS hits. The imidazopyrazine series displayed more than 10-fold higher potencies; however, in the early project phase, this series suffered from poor metabolic stability. Here, we outline the evolution of the two hit series to clinical candidates BAY 1161909 and BAY 1217389 and reveal how both clinical candidates bind to the ATP site of MPS1 kinase, while addressing different pockets utilizing different binding interactions, along with their synthesis and preclin&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02035&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02035" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02035&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02035" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02035&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02035" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02035&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02035&amp;href=/doi/10.1021/acs.jmedchem.9b02035" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b02035" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b02035" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b02035%26sid%3Dliteratum%253Aachs%26pmid%3D32338514%26genre%3Darticle%26aulast%3DSchulze%26date%3D2020%26atitle%3DTreating%2BCancer%2Bby%2BSpindle%2BAssembly%2BCheckpoint%2BAbrogation%253A%2BDiscovery%2Bof%2BTwo%2BClinical%2BCandidates%252C%2BBAY%2B1161909%2Band%2BBAY%2B1217389%252C%2BTargeting%2BMPS1%2BKinase%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D15%26spage%3D8025%26epage%3D8042%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/jmcmar.2020.63.issue-15/20200813/jmcmar.2020.63.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0035.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Inhibition of monopolar spindle 1 (MPS1) kinase represents a novel approach to cancer treatment: instead of arresting the cell cycle in tumor cells, cells are driven into mitosis irrespective of DNA damage and unattached/misattached chromosomes, resulting in aneuploidy and cell death. Starting points for our optimization efforts with the goal to identify MPS1 inhibitors were two HTS hits from the distinct chemical series “triazolopyridines” and “imidazopyrazines”. The major initial issue of the triazolopyridine series was the moderate potency of the HTS hits. The imidazopyrazine series displayed more than 10-fold higher potencies; however, in the early project phase, this series suffered from poor metabolic stability. Here, we outline the evolution of the two hit series to clinical candidates BAY 1161909 and BAY 1217389 and reveal how both clinical candidates bind to the ATP site of MPS1 kinase, while addressing different pockets utilizing different binding interactions, along with their synthesis and preclinical characterization in selected <i>in vivo</i> efficacy models.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86175" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86175" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Sustained proliferation is a hallmark of cancer.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The classical approach to fight cancer, therefore, is to slow down or even stop cell proliferation. Prominent examples are medications such as the taxanes and vinca alkaloids which arrest the cell division cycle in mitosis via activation of the spindle assembly checkpoint (SAC). Here, we describe exactly the opposite approach, which is to speed up the proliferation of cancer cells by deactivation of the SAC, leading to a high degree of chromosomal missegregation in cancer cells which ultimately also leads to cell death. The SAC, with the monopolar spindle 1 (MPS1) kinase (also known as TTK) as a key component, is a surveillance and quality control mechanism within the cell cycle which monitors the correct attachment of the spindle apparatus to the kinetochores of the duplicated chromatids, ensuring that each daughter cell receives one of both sister chromatids and consequently an identical copy of the genetic material. As long as even only one single chromosome is not captured by the spindle apparatus, the SAC is active, hindering a premature progression in the cell cycle. Only when the SAC is turned off can the cell cycle progress. A key observation is that MPS1 is the switch to activate or inactivate the SAC. When the spindle is correctly connected to the sister chromatids, MPS1 is lost from the complex, inactivating the kinase, and thus the SAC is switched off and the cell enters the anaphase stage of mitosis.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Inhibition of MPS1 kinase inactivates the SAC, resulting in entry of the cells into mitosis even in the presence of unattached or misattached kinetochores which may lead to massive aneuploidy, multinucleated cells, and eventually cell death by mitotic catastrophe.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Consequently, inhibition of MPS1 kinase represents a novel concept for tackling cancer cells: instead of arresting the cell cycle, MPS1 inhibition drives the cells into mitosis by overriding the SAC, a mode of action also called “SAC breakthrough”.</div><div class="NLM_p">Meanwhile, groups from both academia and industry have embarked on this attractive novel concept for cancer therapy. Early MPS1 inhibitor examples <b>1</b>–<b>3</b> were disclosed by Nerviano,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Myrexis,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and AstraZeneca<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In addition, more recently, organizations such as Cancer Research UK,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Pfizer,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Shionogi,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and the Campbell Family Cancer Research Institute<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> are active in this area.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples of MPS1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47272" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47272" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the search for novel MPS1 inhibitors, we performed a high-throughput screen of the Bayer AG small-molecule compound library. We screened about 2 million compounds in a biochemical HTRF-based MPS1 inhibition assay and obtained 4500 hits for which we determined inhibition curves versus MPS1. For many compounds, the potency was assessed in two biochemical MPS1 assays in the presence of low (10 μM) and high (2 mM) ATP concentration. The higher ATP concentration more realistically reflects the physiological situation in the cell and is thus more relevant for the ranking of compounds, whereas the lower concentration results in higher sensitivity of the assay and was therefore used for the HTS campaign. These MPS1 inhibition assay data, binding efficiency index (BEI),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and lipophilic efficiency (LipE/LLE)<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13−15)</a> were used to prioritize the hit clusters. In addition, we also employed a cellular mechanistic SAC assay indicating interference with the checkpoint, as well as a functional antiproliferation assay panel with different tumor cell lines, for the characterization of our MPS1 inhibitors. Strikingly, many clusters that resulted from project compounds of our previous kinase targets were unexpectedly potent in the functional assays compared to only moderate potency in the biochemical MPS1 assay and were down-prioritized due to anticipated selectivity issues. Instead, we selected two novel compound clusters with a triazolopyridine core (<b>4</b>) and an imidazopyrazine core (<b>5</b>) for further characterization and optimization (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Key Data of HTS Hits <b>4</b> and <b>5</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0012.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The inhibitory capacity of test compounds was assessed in an HTRF-based MPS1 assay with an ATP concentration of 10 μM (low ATP assay).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">SAC assay: the inhibition of the spindle assembly checkpoint by test compounds was assessed in a high content assay by p-histone H3 staining.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">BEI: binding efficiency index (pIC<sub>50</sub>·1000/MW).</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">LipE/LLE: lipophilic efficiency/lipophilic ligand efficiency (pIC<sub>50</sub> – cLogD (pH 7.5)). (Assay descriptions and statistics for biochemical and cellular assay data are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>).</p></div></div><div></div></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Discovery of Triazolopyridine BAY 1161909</h3><div class="NLM_p">The syntheses of the triazolopyridines started with the preparation of the triazolopyridine core <b>7</b>, as outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, by reaction of aminopyridine <b>6</b> with ethoxycarbonyl isothiocyanate, followed by cyclization induced by hydroxylamine.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Suzuki coupling of <b>7</b> with (4-hydroxy-3,5-dimethylphenyl)boronic acid pinacol ester afforded intermediate <b>8</b>. Amide formation with thiophene-2-carboxylic acid gave rise to the HTS hit <b>4</b>. Palladium-catalyzed reaction of <b>8</b> with 1-bromo-2-methoxybenzene yielded arylamination product <b>9</b>. For the synthesis of compound <b>11</b>, Suzuki coupling of the triazolopyridine core <b>7</b> with {4-[(<i>tert</i>-butoxycarbonyl)amino]phenyl}boronic acid and cleavage of the Boc protecting group afforded intermediate <b>10</b>. Subsequent amide formation with (4-fluorophenyl)acetic acid followed by palladium-catalyzed arylamination resulted in <b>11</b>. Several analogues described in this paper were synthesized via similar reaction sequences<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17−19)</a> (for further details, see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Representative Syntheses for the Triazolopyridine Derivatives: Compounds <b>4</b>, <b>9</b>, and <b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethoxycarbonyl isothiocyanate, dioxane, rt, 86%; (b) HONH<sub>2</sub>·HCl, Hünig’s base, EtOH, MeOH, 60 °C, 91%; (c) (4-hydroxy-3,5-dimethylphenyl)boronic acid pinacol ester, PPh<sub>3</sub>, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, 1-propanol, water, K<sub>2</sub>CO<sub>3</sub>, reflux, 45%; (d) thiophene-2-carboxylic acid, PyBOP, Hünig’s base, DMA, rt, 44%; (e) 1-bromo-2-methoxybenzene, Pd<sub>2</sub>(dba)<sub>3</sub>, (<i>R</i>)-(+)-BINAP, NaO<i>t</i>-Bu, toluene, NMP, 110 °C, 27%; (f) {4-[(<i>tert</i>-butoxycarbonyl)amino]phenyl}boronic acid, PPh<sub>3</sub>, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, 1-propanol, water, K<sub>2</sub>CO<sub>3</sub>, reflux, 80%; (g) TFA, DCM, rt, 92%; (h) (4-fluorophenyl)acetic acid, HATU, Hünig’s base, THF, rt, 75%; (i) 2-bromobenzonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, (<i>R</i>)-(+)-BINAP, Cs<sub>2</sub>CO<sub>3</sub>, toluene, NMP, 110 °C, 42%.</p></p></figure><div class="NLM_p">The HTS hit <b>4</b> of the triazolopyridine cluster displayed moderate potency in the low ATP MPS1 assay (IC<sub>50</sub> = 470 nM) and only low activity in the high ATP MPS1 assay (IC<sub>50</sub> = 17 μM) and in the cellular mechanistic SAC assay (IC<sub>50</sub> = 10 μM) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Therefore, potency optimization was the first goal for this cluster. Several amide and urea analogues at the 2-position (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <b>12</b>–<b>14</b>) and also the benzylamine <b>15</b> did not show an improvement. However, installation of an <i>N</i>-aryl substituent delivered a first breakthrough and resulted in significantly increased potency (<b>9</b>, <b>16</b>, <b>17</b>, <b>19</b>). Indeed, <b>9</b>, <b>16</b>, and <b>19</b> were the first compounds in this series with IC<sub>50</sub> values below 1 μM (high ATP MPS1 assay). In particular, the <i>o</i>-cyanophenyl derivative <b>19</b> achieved single-digit nanomolar potency in the low ATP MPS1 assay (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Exploration of the SAR at the 2-Position of Triazolopyridines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0013.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0014.gif" alt="" id="GRAPHIC-d7e746-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The inhibitory capacity of test compounds was assessed in an HTRF-based MPS1 assay with an ATP concentration of 10 μM (low ATP assay) or 2 mM (high ATP assay).</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Not determined. (Assay descriptions and statistics for biochemical assay data are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>.)</p></div></div><div></div></div><div class="NLM_p">Of these analogues, compound <b>9</b> was selected and profiled in more detail (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The IC<sub>50</sub> value in the MPS1 kinase assay at cellular ATP concentration translated nicely into an IC<sub>50</sub> value of 5.8 μM in the cellular mechanistic SAC assay and of 5.9 μM in the antiproliferation assay (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Already at that early time of candidate optimization, lead compound <b>9</b> showed surprisingly high selectivity in the Millipore kinase panel with only 19 of 224 kinases showing >80% inhibition at 10 μM concentration. Assessment of the <i>in vitro</i> metabolic stability of <b>9</b> in rat liver microsomes revealed high stability (i.e., low hepatic extraction) of <i>E</i><sub>H,<i>in vitro</i></sub> (rLM) 21%; however, the compound was unstable upon incubation with rat hepatocytes with <i>E</i><sub>H,<i>in vitro</i></sub> (rHeps) of 96%, indicating instability due to phase 2 metabolic transformation of <b>9</b>. On the basis of these results, we hypothesized that, for example, glucuronidation of the phenol could be the reason for the instability and considered options for its replacement.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Profile of Compound <b>9</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0015.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top"><th class="colsep0 rowsep0" align="center">assay</th><th class="rowsep0" align="center">IC<sub>50</sub>/result</th></tr></thead><tbody><tr valign="top"><td class="colsep0 rowsep0" align="left" valign="bottom">inhibition of MPS1 kinase activity, low ATP<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> [nM]</td><td class="rowsep0" align="left" valign="bottom">26</td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left" valign="bottom">inhibition of MPS1 kinase activity, high ATP<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> [nM]</td><td class="rowsep0" align="left" valign="bottom">900</td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left" valign="bottom">inhibition of SAC<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a> [nM]</td><td class="rowsep0" align="left" valign="bottom">5800</td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left" valign="bottom">inhibition of proliferation (HeLa cell line)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a> [nM]</td><td class="rowsep0" align="left" valign="bottom">5900</td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left" valign="bottom">selectivity in the Millipore kinase panel at 10 mM<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="rowsep0" align="left" valign="bottom">19 of 224 kinases show >80% inhibition</td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left" valign="bottom"><i>in vitro</i> metabolic stability, EH, in vitro [%]<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td><td class="rowsep0" align="left" valign="bottom">rat LM: 21</td></tr><tr valign="top"><td class="colsep0" align="left" valign="bottom"> </td><td align="left" valign="bottom">rat Heps: 96</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The inhibitory capacity of test compounds was assessed in an HTRF-based MPS1 assay with an ATP concentration of 10 μM (low ATP assay) or 2 mM (high ATP assay).</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">SAC assay: the inhibition of the spindle assembly checkpoint by test compounds was assessed in a high content assay by p-histone H3 staining.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Inhibition of proliferation of the HeLa cervix carcinoma cell line by test compounds. (Assay descriptions and statistics for biochemical and cellular assay data are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>.)</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">For the full Millipore panel data; see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">The <i>in vitro</i> metabolic stability was assessed in rat liver microsomes and in rat hepatocytes by determination of the half-life of the test compound (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>). Clearance parameters and <i>E</i><sub>H,<i>in vitro</i></sub> (<i>in vitro</i> metabolic first pass extraction) were calculated from this half-life, representing a measure of hepatic phase 1 and phase 1 + 2 metabolism, respectively.</p></div></div></div><div class="NLM_p">With the goal of further increasing the potency and to design replacements for the phenolic hydroxy group, we attempted cocrystallization experiments with hMPS1 (N515-T806; see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>) and compounds of the triazolopyridine lead series. Cocrystallization was successful with compound <b>16</b>. The X-ray structure revealed that the triazolopyridine core forms hydrogen bonds to Glu<sup>603</sup> and Gly<sup>605</sup> within the hinge region of hMPS1 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). An additional hydrogen bond is formed between the phenolic hydroxy group of <b>16</b> and the Glu<sup>571</sup> side chain.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray costructure of triazolopyridine <b>16</b> cocrystallized with hMPS1. The PDB accession code is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TN9">6TN9</a>. The triazolopyridine core of <b>16</b> interacts with the hinge region of hMPS1, and the phenolic hydroxy group forms a hydrogen bond to Glu<sup>571</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although we aimed to improve the metabolic stability by replacing the phenolic hydroxy group in compound <b>9</b>, <b>16</b>, or <b>19</b>, we nevertheless wanted to retain the hydrogen bond to Glu<sup>571</sup> which was considered important for the potency of these compounds. Therefore, we explored different amides, carbamates, and sulfonamides at the meta- and para-positions of the 6-phenyl group (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). In general, the sulfonamides, amides, and inverted amides at the meta-position, as well as the Boc-protected aniline in the para position, showed reduced potency (<b>20</b>–<b>23</b>). However, several para-substituted <i>N</i>-phenylamides were equally or slightly more potent (<b>24</b>–<b>26</b>) than phenolic compound <b>19</b>. The second breakthrough with respect to biochemical potency was achieved with more elaborate amides in the eastern region; to our surprise, inverting the amide only had little effect on the potency. Accordingly, the <i>N</i>-phenylacetamide <b>27</b> and the inverted amide motif <b>28</b> yielded excellent potency, below 1 nM, in the low ATP MPS1 assay. A further improvement in potency was seen for the (<i>p</i>-fluorophenyl)acetamide <b>11</b>. To distinguish between these compounds, the high ATP MPS1 assay was needed, and even there we came to the limit of detection of the assay, with an IC<sub>50</sub> value of approximately 2 nM obtained for <b>11</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Exploration of the SAR at the 6-Position of Triazolopyridines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0016.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0017.gif" alt="" id="GRAPHIC-d7e1041-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">The inhibitory capacity of test compounds was assessed in an HTRF-based MPS1 assay with an ATP concentration of 10 μM (low ATP assay) or 2 mM (high ATP assay). (Assay descriptions and statistics for biochemical assay data are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>.)</p></div></div><div></div></div><div class="NLM_p">Whereas the metabolic stability of <b>11</b> in rat hepatocytes was improved (rHeps, <i>E</i><sub>H,<i>in vitro</i></sub> = 62%) compared to the phenolic compound <b>9</b>, the <i>in vivo</i> oral exposure was poor and bioavailability (<i>F</i>) in rats was below 10%. In addition, the metabolic stability in human liver microsomes was still low (hLM, <i>E</i><sub>H,<i>in vitro</i></sub> = 87%, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Therefore, we turned our attention back to the <i>N</i>-aryl substituent at the 2-position of the triazolopyridine core with the “magic side chain” (<i>p</i>-fluorophenyl)acetamide or the phenylacetamide in place at the para-position of the 6-phenyl group. Whereas <i>o</i>-methoxyphenyl (<b>29</b>) and <i>p</i>-(morpholinocarbonyl)phenyl (<b>30</b>) only had lower potency than the comparable 2-cyano analogues <b>27</b> and <b>11</b>, the combination of both substituents at the phenyl group (<b>31</b>) led to even higher biochemical and cellular potency than <b>11</b>, and the oral bioavailability in rats was improved to 20%. Replacement of the methoxy group by trifluoroethoxy (<b>32</b>) resulted in further improvement of the potency but also in low metabolic stability, higher molecular weight and lipophilicity (measured log <i>D</i> at pH 7.5 = 3.9), and very low aqueous solubility. Several alternative amides (<b>33</b>–<b>35</b>) had good potency but did not result in improved <i>in vitro</i> or <i>in vivo</i> PK. A major step forward to achieving good potency combined with improved metabolic stability <i>in vitro</i> in rat hepatocytes was attained with the fluoroazetidine-derived amide <b>36</b>, oxazolidinone <b>37</b>, and methylsulfone <b>38</b>, with <b>37</b> and <b>38</b> also showing a much increased oral exposure and an increased oral bioavailability of 52% and 49% <i>in vivo</i> in rats (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Exploration of the SAR at the 2-Position of Triazolopyridines: Substitution at the Aryl</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0018.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0019.gif" alt="" id="GRAPHIC-d7e1169-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">The inhibitory capacity of test compounds was assessed in an HTRF-based MPS1 assay with an ATP concentration of 2 mM (high ATP assay).</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Inhibition of proliferation of the HeLa cervix carcinoma cell line by test compounds. (Assay descriptions and statistics for biochemical and cellular assay data are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>.)</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">The <i>in vitro</i> metabolic stability was assessed in rat and dog hepatocytes and in human liver microsomes by determination of the half-life of test compounds (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>). Clearance parameters and <i>E</i><sub>H,<i>in vitro</i></sub> (<i>in vitro</i> metabolic first pass extraction) were calculated from this half-life, representing a quantitative measure of hepatic metabolic degradation.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Selected <i>in vivo</i> oral PK parameters in rats: dose-normalized exposure referenced to as AUC<sub>norm,po</sub> and bioavailability (<i>F</i>) (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>).</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last">Not determined.</p></div></div><div></div></div><div class="NLM_p">However, these compounds still showed a high hepatic extraction in dog hepatocytes which also translated to a high <i>in vivo</i> clearance in dogs and correlated with the metabolic cleavage of the phenylacetamide in dog hepatocytes (data not shown). To obtain compounds displaying a better metabolic profile in rats and particularly in dogs, we had to staple a methyl group onto the “magic” phenylacetic acid motif. Only the corresponding <i>R</i>-isomers <b>39</b>–<b>41</b> (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) had good potency; <i>S</i>-isomer <b>42</b> and larger α-substituents (<b>43</b>, <b>44</b>) resulted in reduced potency (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Compared to the fluoroazetidine-derived amide <b>39</b> and oxazolidinone <b>40</b>, methylsulfone <b>41</b> showed the best overall profile, further improved kinase selectivity compared to the early lead compound <b>9</b> (<b>41</b> only inhibits two kinases, JNK2 and JNK3, more than 50% at a concentration of 1 μmol/L and no other kinase at 100 nmol/L in the Millipore kinase panel of 230 kinases),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and was selected as our first clinical candidate. Indeed, it was the first MPS1 inhibitor to enter a phase I clinical trial, in May 2014 (NCT02138812).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Further Exploration of the SAR at the 6-Position of Triazolopyridines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0020.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">The inhibitory capacity of test compounds was assessed in an HTRF-based MPS1 assay with an ATP concentration of 2 mM (high ATP assay).</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">SAC assay: the inhibition of the spindle assembly checkpoint by test compounds was assessed in a high content assay by p-histone H3 staining.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Inhibition of proliferation of the HeLa cervix carcinoma cell line by test compounds. (Assay descriptions and statistics for biochemical and cellular assay data are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>.)</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">The <i>in vitro</i> metabolic stability was assessed in rat and dog hepatocytes and in human liver microsomes by determination of the half-life of test compounds (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>). Clearance parameters and <i>E</i><sub>H,<i>in vitro</i></sub> (<i>in vitro</i> metabolic first pass extraction) were calculated from this half-life, representing a quantitative measure of hepatic metabolic degradation.</p></div><div class="footnote" id="t6fn5"><sup><sup>e</sup></sup><p class="last">Selected <i>in vivo</i> PK parameters from iv and po studies: blood clearance (CL<sub>b</sub>), volume of distribution at steady state (<i>V</i><sub>ss</sub>), and half-life (<i>t</i><sub>1/2</sub>) describing the iv disposition and dose-normalized exposure referenced to as AUC<sub>norm,po</sub> and bioavailability (<i>F</i>) describing the oral PK (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>).</p></div><div class="footnote" id="t6fn6"><sup><sup>f</sup></sup><p class="last">Not determined.</p></div><div class="footnote" id="t6fn7"><sup><sup>g</sup></sup><p class="last">Arithmetic mean of <i>n</i> = 4.</p></div><div class="footnote" id="t6fn8"><sup><sup>h</sup></sup><p class="last">Arithmetic mean of <i>n</i> = 3.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Further Exploration of the SAR at the 6-Position of Triazolopyridines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0021.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0022.gif" alt="" id="GRAPHIC-d7e1386-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">The inhibitory capacity of test compounds was assessed in an HTRF-based MPS1 assay with an ATP concentration of 2 mM (high ATP assay).</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">SAC assay: the inhibition of the spindle assembly checkpoint by test compounds was assessed in a high content assay by p-histone H3 staining.</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">Inhibition of proliferation of the HeLa cervix carcinoma cell line by test compounds. (Assay descriptions and statistics for biochemical and cellular assay data are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>.)</p></div></div><div></div></div><div class="NLM_p">Throughout the optimization we also characterized key compounds in binding kinetics studies. These experiments revealed that not only had we improved the potency by switching from the phenolic hydroxy group in the early compound <b>16</b> to the “magic” phenylpropionic acid side chain of the clinical candidate <b>41</b>, but also the target residence time had increased accordingly, by a factor of 1000 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Comparison of early compound <b>16</b> and clinical candidate <b>41</b> by binding kinetics studies, and comparison of their hMPS1 X-ray costructures: (a) SPR multicycle kinetics sensorgram corresponding to the titration of <b>16</b> (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>); (b) SPR single-cycle kinetics sensorgram corresponding to the titration of <b>41</b>; (c) overlay of the structures of hMPS1 in complex with <b>16</b> (gray, PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TN9">6TN9</a>) and with <b>41</b> (blue, PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TNB">6TNB</a>), showing induction of a new pocket by the binding of <b>41</b>; (d) schematic representation of the hydrogen bonding of <b>41</b> in complex with hMPS1; (e) structure of hMPS1 in complex with <b>41</b>. The phenylpropionic acid moiety of <b>41</b> occupies the induced pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">An open question remained as to what additional binding sites of the “magic side chain” would confer these extreme potencies. Docking studies with the X-ray structure obtained from <b>16</b> cocrystallized with hMPS1 did not yield a reasonable explanation which prompted us to also cocrystallize <b>41</b> with the hMPS1 protein. Comparing the X-ray costructures of <b>16</b> and <b>41</b>, we could visualize why the phenylpropionic acid was so “magic”: instead of the hydrogen bond between the phenol and Glu<sup>571</sup>, the phenylpropionic acid side chain is accommodated by conformational changes to the Glu<sup>571</sup> and Tyr<sup>568</sup> side chains that result in a newly formed, specific induced-fit pocket, without a change to a DFG-out motif. Within this pocket, <b>41</b> forms two new hydrogen bonds to Ile<sup>663</sup> and Lys<sup>553</sup> that significantly contribute to tighter binding (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>c–e). The induction of a new binding pocket correlates with increased target residence time and with increased potency of the clinical candidate <b>41</b>.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Discovery of Imidazopyridazine BAY 1217389</h3><div class="NLM_p">For optimization of the imidazopyrazine series, we used the same starting point, commercially available <b>5</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), as researchers from Shionogi.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The optimization proceeded amazingly similarly; hence, our focus here is purely on aspects that have not been covered previously<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> or are required to understand our optimization process. Hit compound <b>5</b> was much more potent than <b>4</b> of the triazolopyridine series but displayed low metabolic stability <i>in vitro</i> and poor PK <i>in vivo</i>. Metabolite identification studies revealed that apart from some amine oxidation and dealkylation in the north, amide bond cleavage in the south is the strongest contributor to compound degradation (data not shown). Our initial optimization efforts were therefore directed toward a metabolic stabilization of these areas. Modifications in the northern amine part revealed that alkyl and benzyl-type moieties are favored and many different residues are tolerated (<b>46</b>, <b>47</b>, <b>49</b>, <b>53</b>) (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). Aryl (<b>48</b>) or polar substituents (<b>45</b>, <b>52</b>) are significantly worse, and other connectivities such as amide (<b>50</b>) or urea (<b>51</b>) are basically inactive. Finally, we selected the trifluoropropyl moiety (<b>53</b>) as optimal residue with respect to potency and also PK profile (data not shown).</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Exploration of the SAR at the 8-Position of Imidazopyrazines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0023.gif" alt="" id="fx8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0024.gif" alt="" id="GRAPHIC-d7e1583-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">The inhibitory capacity of test compounds was assessed in an HTRF-based MPS1 assay with an ATP concentration of 10 μM (low ATP assay) or 2 mM (high ATP assay). (Assay descriptions and statistics for biochemical data are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>.)</p></div></div><div></div></div><div class="NLM_p">Improving metabolic stability in the south at position 3 was much more difficult. Broad variations there revealed a very steep SAR suggesting that the amide motif be retained. Urea derivative <b>54</b> (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) displayed high <i>in vitro</i> stability in rat hepatocytes and good oral bioavailability but suffered from significantly reduced potency. Therefore, extensive work was directed toward identification of suitable amide mimetics. Interestingly, it was possible to identify a few potent amide mimetics (exemplified by <b>55</b> and <b>56</b>); however they also all suffered from low metabolic stability. Consequently, we returned to the highly conserved phenyl <i>N</i>-cyclopropylamide motif and attempted stabilization by the introduction of substituents at the aromatic ring. Ultimately, <i>o</i>-methyl-substituted <b>57</b> was the best compromise: although we had to pay a slight potency penalty, the hepatic extraction <i>in vitro</i> and oral exposure <i>in vivo</i> pointed in the right direction.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Exploration of the SAR at the 3-Position of Imidazopyrazines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0025.gif" alt="" id="fx9" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0026.gif" alt="" id="GRAPHIC-d7e1634-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">The inhibitory capacity of test compounds was assessed in an HTRF-based MPS1 assay with an ATP concentration of 10 μM (low ATP assay) or 2 mM (high ATP assay). (Assay descriptions and statistics for biochemical assay data are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>.)</p></div><div class="footnote" id="t9fn2"><sup><sup>b</sup></sup><p class="last">The <i>in vitro</i> metabolic stability was assessed in rat hepatocytes by determination of the half-life of test compounds (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>). <i>E</i><sub>H,<i>in vitro</i></sub> data were calculated from this half-life, representing a measure of phase 1 + 2 metabolism.</p></div><div class="footnote" id="t9fn3"><sup><sup>c</sup></sup><p class="last">Selected <i>in vivo</i> oral PK parameters in rats: dose-normalized exposure referenced to AUC<sub>norm,po</sub> and bioavailability (<i>F</i>) (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>).</p></div><div class="footnote" id="t9fn4"><sup><sup>d</sup></sup><p class="last">Not determined.</p></div><div class="footnote" id="t9fn5"><sup><sup>e</sup></sup><p class="last">Limit of detection.</p></div></div><div></div></div><div class="NLM_p">A first X-ray structure of compound <b>46</b> cocrystallized with hMPS1 opened a new project avenue as it indicated more available space in the pocket around the 5- and 6-positions of the imidazopyrazine core than anticipated (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) and accordingly allowed the design of new and hopefully improved compounds, in particular with increased potency.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray co-structure of imidazopyrazine <b>46</b> cocrystallized with hMPS1. The PDB accession code is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TNC">6TNC</a>. The imidazopyrazine core of <b>46</b> interacts with the hinge region of hMPS1, and available space in the pocket can be found around positions 5 and 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It quickly became evident that substitution at the 5-position would not lead to improved compounds (cf. <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>, compounds <b>59</b>, <b>60</b>). In contrast, position 6 turned out to be a key position for property and, in particular, potency optimization (<b>61</b>–<b>67</b>). A breakthrough finding was that kinked aryls at position 6 are extremely potent. The nature of the connecting atom is not very important, exemplified by oxygen- and carbon-connected phenyl compounds <b>67</b> and <b>65</b>; however it is required for optimum spacing of the aryl moiety.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Exploration of the SAR at the 5/6-Positions of Imidazopyrazines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0027.gif" alt="" id="fx10" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0028.gif" alt="" id="GRAPHIC-d7e1746-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">The inhibitory capacity of test compounds was assessed in an HTRF-based MPS1 assay with an ATP concentration of 10 μM (low ATP assay) or 2 mM (high ATP assay). (Assay descriptions and statistics for biochemical assay data are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>.)</p></div></div><div></div></div><div class="NLM_p">Next, we searched for a possibly improved hinge binding scaffold. Knowing that N1 and the NH at position 8 of the imidazopyrazine core form the key hinge interaction, we kept those atoms constant in our core variations, which led to five investigated core alternatives (<b>68</b>–<b>76</b>, <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a>). Similar to findings from Shionogi,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> we discovered that the imidazopyridazine scaffold displays exceptional potencies, in particular in the cellular SAC and HeLa antiproliferation assays (compounds <b>75</b> and <b>76</b>). However, the imidazopyridine (<b>70</b>, <b>71</b>) and benzimidazole (<b>73</b>, <b>74</b>) series also constitute good MPS1 inhibitors.</div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Exploration of Different Cores</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0029.gif" alt="" id="fx11" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0030.gif" alt="" id="GRAPHIC-d7e1796-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup><sup>a</sup></sup><p class="last">The inhibitory capacity of test compounds was assessed in an HTRF-based MPS1 assay with an ATP concentration of 10 μM (low ATP assay) or 2 mM (high ATP assay).</p></div><div class="footnote" id="t11fn2"><sup><sup>b</sup></sup><p class="last">SAC assay: the inhibition of the spindle assembly checkpoint by test compounds was assessed in a high content assay by p-histone H3 staining.</p></div><div class="footnote" id="t11fn3"><sup><sup>c</sup></sup><p class="last">Inhibition of proliferation of the HeLa cervix carcinoma cell line by test compounds. (Assay descriptions and statistics for biochemical and cellular assay data are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>.)</p></div></div><div></div></div><div class="NLM_p">With our best MPS1 inhibitors we reached the limit of resolution not only in the standard low ATP biochemical assay but also in the less sensitive high ATP assay. <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b depict the correlation of the MPS1 high ATP IC<sub>50</sub> values versus SAC IC<sub>50</sub> or HeLa antiproliferation IC<sub>50</sub> values of the imidazo series. Compounds bearing the phenyl <i>N</i>-cyclopropylamide motif are displayed in green, others in red. Compounds with affinities below around 1 nM cannot be differentiated in this biochemical assay, indicated by the discontinued linear correlation (blue circle). In contrast, the compounds displayed a linear logarithmic correlation between the less sensitive SAC and antiproliferation assays across all potencies, as shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>c. This demonstrated that the antiproliferative effect indeed is a result of targeting the SAC and not merely a result of nonselective kinase inhibition. Moreover, these two assays allowed identification of highly potent compounds which could not be resolved in the biochemical assay.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Correlation of biochemical and cellular IC<sub>50</sub> values of the imidazo series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For final candidate identification, we then experimented with various “kinked aryl” connectivities to the superior imidazopyridazine core, keeping both our already identified trifluoropropylamine moiety at position 8 and our <i>o</i>-methyl-substituted phenyl <i>N</i>-cyclopropylamide motif at position 3 constant. <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a> lists three advanced compounds with different kinks, which were profiled in depth based on their good overall profile with respect to potency, kinase selectivity,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a><i>in vitro</i> metabolic stability, CYP inhibition profile, hERG inhibition, and Ames mutagenicity (data not shown). The first compound, methylene derivative <b>77</b>, was deprioritized as oral exposure in dogs was very low and bioavailability (<i>F</i>) amounted to just 1.4%. The other two candidates, <b>78</b> and <b>79</b>, were relatively similar with respect to <i>in vitro</i> PK characteristics. We selected BAY 1217389 (<b>79</b>) as our clinical candidate of this series because of lower blood clearance, longer <i>t</i><sub>1/2</sub>, and good oral bioavailability in rats (<i>F</i> = 72%) and dogs (<i>F</i> = 71%).</div><div class="NLM_table-wrap" id="tbl12"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 12. Key Data for Selected Advanced Compounds, Including <b>79</b> (BAY 1217389)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0031.gif" alt="" id="fx12" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0032.gif" alt="" id="GRAPHIC-d7e1912-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t12fn1"><div class="footnote" id="t12fn1"><sup><sup>a</sup></sup><p class="last">The inhibitory capacity of test compounds was assessed in an HTRF-based MPS1 assay with an ATP concentration of 10 μM (low ATP assay) or 2 mM (high ATP assay).</p></div><div class="footnote" id="t12fn2"><sup><sup>b</sup></sup><p class="last">SAC assay: the inhibition of the spindle assembly checkpoint by test compounds was assessed in a high content assay by p-histone H3 staining.</p></div><div class="footnote" id="t12fn3"><sup><sup>c</sup></sup><p class="last">Inhibition of proliferation of the HeLa cervix carcinoma cell line by test compounds. (Assay descriptions and statistics for biochemical and cellular assay data are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>.)</p></div><div class="footnote" id="t12fn4"><sup><sup>d</sup></sup><p class="last">The <i>in vitro</i> metabolic stability (given as metabolic first pass extraction, <i>E</i><sub>H</sub>) was assessed in rat and dog hepatocytes and in human liver microsomes by determination of the half-life of test compounds (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>).</p></div><div class="footnote" id="t12fn5"><sup><sup>e</sup></sup><p class="last">Selected <i>in vivo</i> PK parameters from iv and po studies: blood clearance (CL<sub>b</sub>), volume of distribution at steady state (<i>V</i><sub>ss</sub>), and half-life (<i>t</i><sub>1/2</sub>) describing the iv disposition and dose-normalized exposure referenced to AUC<sub>norm,po</sub> and bioavailability (<i>F</i>) describing the oral PK (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>).</p></div><div class="footnote" id="t12fn6"><sup><sup>f</sup></sup><p class="last">Arithmetic mean of <i>n</i> = 2.</p></div><div class="footnote" id="t12fn7"><sup><sup>g</sup></sup><p class="last">Arithmetic mean of <i>n</i> = 4.</p></div><div class="footnote" id="t12fn8"><sup><sup>h</sup></sup><p class="last">Arithmetic mean of <i>n</i> = 3.</p></div></div><div></div></div><div class="NLM_p">During optimization, it was helpful to be able to vary each of the pharmacophores at positions 3, 6, and 8 in the last step of the synthesis.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> We therefore used the 6,8-disubstituted starting material <b>80</b> only for modifications at position 3 and followed a route in which the third halide function in position 3 was introduced late in the synthesis sequence (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). For the other variations at position 8 or 6, we used the trifunctional key intermediate <b>81</b>. As the <i>N</i>-cyclopropylamide pharmacophore became a fixed residue early on, intermediate <b>81</b> was used for most compounds: on the one hand, it allowed variation of position 8 via 8-methylthio-substituted intermediates; on the other hand, variations at position 6 via an intermediate of type <b>83</b> were possible (cf. <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The route ultimately used for the synthesis of candidate <b>79</b> is depicted in green (see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for details).</div><figure id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Possible Routes and Implemented Route (Green) for the Synthesis of BAY 1217389 (<b>79</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>N</i>-iodosuccinimide, DMF, 60 °C, 86%; (b) 3,3,3-trifluoropropylamine, DMF, 40 °C, 81%; (c) <i>N</i>-cyclopropyl-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide, PdCl<sub>2</sub>(dppf)·DCM, aq Cs<sub>2</sub>CO<sub>3</sub>, THF, 45 °C, 52%; (d) 2,3-difluoro-4-methoxyphenol, NaH, DMSO, 130 °C, 65%.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Comparison of BAY 1217389 with CFI-402257</h3><div class="NLM_p">Recently, a Canadian group embarked on the development of MPS1 inhibitors building on Shionogi’s and our discoveries, eventually leading to CFI-402257 (<b>86</b>) as clinical candidate.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> CFI-402257 carries three typically active pharmacophores, namely, the <i>o</i>-methylphenyl <i>N</i>-cyclopropylamide at position 3, the kinked aryl 3-pyridyloxy at position 6, and an aliphatic hydroxycyclobutylamine at position 8, but grafted on a novel pyrazolopyrimidine scaffold. This prompted us to perform a small in-house study in which we compared the biochemical and cellular potencies of our candidate BAY 1217389 (<b>79</b>), CFI-402257 (<b>86</b>), and the two chimeras <b>84</b> and <b>85</b> in which we grafted the identified three pharmacophores on the respective other core. As expected, the four compounds cannot be differentiated in the biochemical assays due to their outstanding potencies (cf. <a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">Table <a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">13</a></a>). However, on a cellular level, it is possible to differentiate between the compounds. Here, we found that the pharmacophores in the periphery are more important than the core itself, leading to a sequence of decreasing potency from BAY 1217389 (<b>79</b>) to <b>84</b> to <b>85</b> to CFI-402257 (<b>86</b>).</div><div class="NLM_table-wrap" id="tbl13"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 13. Comparison of BAY 1217389 (<b>79</b>), CFI-402257 (<b>86</b>), and the Respective Chimeras <b>84</b> and <b>85</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0033.gif" alt="" id="fx13" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0034.gif" alt="" id="GRAPHIC-d7e2136-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t13fn1"><div class="footnote" id="t13fn1"><sup><sup>a</sup></sup><p class="last">The inhibitory capacity of test compounds was assessed in an HTRF-based MPS1 assay with an ATP concentration of 10 μM (low ATP assay) or 2 mM (high ATP assay).</p></div><div class="footnote" id="t13fn2"><sup><sup>b</sup></sup><p class="last">SAC assay: the inhibition of the spindle assembly checkpoint by test compounds was assessed in a high content assay by p-histone H3 staining.</p></div><div class="footnote" id="t13fn3"><sup><sup>c</sup></sup><p class="last">Inhibition of proliferation of the HT29 colon carcinoma cell line by test compounds. (Assay descriptions and statistics for biochemical and cellular assay data are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>.)</p></div></div><div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Comparison of the Binding Modes of Both Candidates BAY 1161909 and BAY 1217389</h3><div class="NLM_p">Although both compounds BAY 1161909 (<b>41</b>) and BAY 1217389 (<b>79</b>) are hinge binders in the ATP site of MPS1 kinase, they address different interactions in the pocket. This is nicely illustrated by an overlay of the X-ray structures of the two compounds (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) X-ray structure of BAY 1161909 (<b>41</b>, blue, PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TNB">6TNB</a>) and overlay with BAY 1217389 (<b>79</b>, green). (b) X-ray structure of BAY 1217389 (<b>79</b>, green, PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TND">6TND</a>) and overlay with BAY 1161909 (<b>41</b>, blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Key structural motifs of the imidazopyridazine <b>79</b> are the <i>N</i>-cyclopropylamide moiety in the back pocket and the unique kinked aryl substituent which occupies the front pocket. Key feature of the triazolopyridine <b>41</b> (see also <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>e) is the phenylpropionamide that induces a unique pocket deep in the kinase binding site, leading to high potency. Indeed, the overlay of BAY 1217389 (<b>79</b>) with the X-ray costructure of BAY 1161909 (<b>41</b>) with hMPS1 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a) and vice versa (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b) shows that <b>41</b> can only bind to the kinase with an induced pocket, while it would clash with the hMPS1 protein in the very tight part of the pocket around the cyclopropyl group of <b>79</b>.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Pharmacology of Both Candidates BAY 1161909 and BAY 1217389</h3><div class="NLM_p">During our cellular <i>in vitro</i> studies, we discovered a synergistic effect of MPS1 inhibitors in combination with paclitaxel. When HeLa cells were treated with subefficacious doses (0.5 nM) of either paclitaxel or MPS1 inhibitor BAY 1217389 (<b>79</b>), no significant impact on cell division could be observed by microscopy after 2–3 h. In contrast, when both compounds were applied together at the subefficacious concentrations, we detected lagging chromosomes, micronuclei, and multinucleation indicative of mitotic catastrophe, which are the expected signs of an effective interference with the SAC (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>; <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_002.docx" class="ext-link">Figures S1 and S2 (video), Supporting Information</a>).</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Snapshots of proliferating HeLa cells by microscopy upon addition of BAY 1217389 (<b>79</b>) and/or paclitaxel. Arrow indicates prolonged postmitotic bridge, and circle indicates multinucleated daughter cells/mitotic catastrophe.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This prompted us to investigate the antitumor activity of MPS1 inhibitor and paclitaxel combination treatment in tumor xenograft models. One reason for testing MPS1 inhibition in combination was the observation that our compounds only displayed moderate monotherapy efficacy (tumor growth inhibition 50% compared to control) in various mouse tumor models due to limited tolerability (not shown), a phenomenon that has been noted previously.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a></div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> shows the effect of combination treatment with MPS1 inhibitor, using each of our two clinical candidates and paclitaxel, on the growth of human tumor xenografts in immunocompromised mice. The antitumor efficacy of BAY 1217389 (<b>79</b>) in combination with paclitaxel was tested in a patient-derived triple-negative breast cancer model (MAXF 1384) and of BAY 1161909 (<b>41</b>) in combination with paclitaxel in a cell line derived non-small-cell lung cancer model (NCI-H1299). Paclitaxel was dosed intravenously (iv) once per week, while the MPS1 inhibitors were given orally twice daily (b.i.d.) for 2 days followed by 5 days of treatment break, starting concomitantly with paclitaxel administration. We could clearly demonstrate that the addition of MPS1 inhibitor, BAY 1217389 (<b>79</b>) or BAY 1161909 (<b>41</b>), applied at sub-MTD doses to paclitaxel dosed at the MTD significantly improved the antitumor efficacy achieved by paclitaxel alone. A more detailed pharmacological characterization of BAY 1217389 (<b>79</b>) and BAY 1161909 (<b>41</b>) has been published previously.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Synergistic antitumor activity of MPS1 inhibitors in combination with paclitaxel in preclinical tumor xenograft models in mice: (a) BAY 1217389 (<b>79</b>); (b) BAY 1161909 (<b>41</b>). PDX = patient-derived xenograft.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Encouraging data packages with respect to <i>in vitro</i> potency, kinase selectivity, PK profile, and <i>in vivo</i> efficacy as outlined above were accumulated for compounds from both series. The attractiveness of this novel approach for cancer therapy in combination with the option of risk mitigation by selecting two candidates from distinct chemical classes prompted us to enter phase I clinical trials with compound <b>41</b> (NCT02138812) and with compound <b>79</b> (NCT02366949), both in combination with weekly intravenous paclitaxel administration in subjects with advanced malignancies.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83071" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83071" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">With the goal to apply a novel concept to the treatment of cancer using induction of mitotic catastrophe by overriding the spindle assembly checkpoint (SAC), we started a search for small molecule inhibitors of MPS1 kinase, a key activator of the SAC. From the hits of a high-throughput screen of the Bayer AG small-molecule compound library using a biochemical MPS1 inhibition assay, two distinct chemical series “triazolopyridines” and “imidazopyrazines” were selected as starting points for a lead optimization program. Starting with these two distinct chemical series which showed only weak to moderate activity as well as low metabolic stability, X-ray supported optimization led to two highly potent clinical candidates, BAY 1161909 (<b>41</b>) and BAY 1217389 (<b>79</b>), with good <i>in vivo</i> PK properties. Both compounds are ATP-competitive MPS1 inhibitors and yet address differently shaped binding pockets of the kinase utilizing different interactions. Both BAY 1161909 (<b>41</b>) and BAY 1217389 (<b>79</b>) show similar behavior in <i>in vivo</i> efficacy studies, with only modest efficacy as single agent but with both showing synergistic effects in combination with paclitaxel. On the basis of these results, both compounds were selected for clinical trials and were the first MPS1 inhibitors to enter phase I clinical trials.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12037" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12037" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Chemistry. General Methods and Materials</h3><div class="NLM_p last">All reagents and solvents were used as purchased, unless otherwise specified. All final products were at least 95% pure, as determined by UPLC or alternatively by <sup>1</sup>H NMR. <sup>1</sup>H NMR spectra were recorded on Bruker Avance III HD spectrometers operating at 300, 400, or 500 MHz. Chemical shifts (δ) are reported in parts per million (ppm), and coupling constants (<i>J</i>) are given in hertz (Hz). Spin multiplicities are reported as s = singlet, br s = broad singlet, d = doublet, t = triplet, q = quartet, and m = multiplet. HRMS were recorded on a Waters XEVO G2XS with electrospray ionization, coupled to an LC Waters Acquity i-class instrument. Optical rotations were recorded on a JASCO P2000 polarimeter.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> LC–MS Method 1</h3><div class="NLM_p last">System: Waters Acquity UPLC with PDA detector and Waters ZQ mass spectrometer. Column: Acquity BEH C18 1.7 μm, 50 mm × 2.1 mm. Solvent A: water + 0.1% formic acid. Solvent B: acetonitrile. Gradient: 0–1.6 min 99–1% A, 1.6–2.0 min 1% A. Flow: 0.8 mL/min. Temperature: 60 °C. Injection volume: 1.0 μL (0.1–1 mg/mL sample concentration). Detection: PDA scan range 210–400 nm and ESI+ scan range 170–800 <i>m</i>/<i>z</i>.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Synthesis of BAY 1161909 (<b>41</b>) (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>)</h3><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 1-Bromo-2-methoxy-4-(methylsulfonyl)benzene (<b>88</b>). Step 1: 1-Bromo-2-methoxy-4-(methylsulfanyl)benzene (<b>88.1</b>)</h4><div class="NLM_p">To a stirred solution of 1-bromo-4-fluoro-2-methoxybenzene (<b>87</b>; 10.0 g, 48.8 mmol) in DMF (100 mL) was added sodium methanethiolate (4.44 g, 63.4 mmol).<named-content content-type="anchor" rid="sch3" type="simple"></named-content> The mixture was stirred at 65 °C for 2 h, then cooled to 0 °C. MeI (4.55 mL, 73.1 mmol) was added, and the mixture was stirred at rt for 1 h, then further sodium methanethiolate (4.44 g, 63.4 mmol) was added. The mixture was stirred at 65 °C for 1 h, then cooled to 0 °C. MeI (4.55 mL, 73.1 mmol) was added, and the mixture was stirred at rt for 1 h. Water was added, and the mixture was extracted with EtOAc. The organic phase was washed with saturated NaCl solution, dried (Na<sub>2</sub>SO<sub>4</sub>), and the solvent was removed under reduced pressure. Silica gel chromatography (gradient; hexane/0–50% EtOAc) gave <b>88.1</b> (6.2 g) as a 2:1 mixture with the starting material. The mixture was used for the next step without purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 7.44 (d, <i>J</i> = 8.08 Hz, 1H), 6.91 (d, <i>J</i> = 2.27 Hz, 1H), 6.74 (dd, <i>J</i> = 2.02, 8.34 Hz, 1H), 3.82 (s, 3H), 2.46 (s, 3H).</div><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of BAY 1161909 (<b>41</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaSMe, DMF, 65 °C, then MeI; (b) <i>m</i>-CPBA, CHCl<sub>3</sub>, rt; (c) LDA, THF, −78 °C, then MeI; (d) KOH, EtOH, water, 0 °C; (e) enantiomer separation using crystallization of the (1<i>S</i>)-1-phenylethanamine salt from EtOAc; (f) 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, HATU, NaHCO<sub>3</sub>, DMF, DCM, rt; (g) <b>88</b>, first generation XPhos Pd precatalyst, XPhos, K<sub>3</sub>PO<sub>4</sub>, toluene, NMP, reflux; (h) <b>91</b>, Pd(OAc)<sub>2</sub>, SPhos, K<sub>3</sub>PO<sub>4</sub>, KF, toluene, 85 °C, 5 h.</p></p></figure></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Step 2: 1-Bromo-2-methoxy-4-(methylsulfonyl)benzene (<b>88</b>)</h4><div class="NLM_p last">To a stirred solution of <b>88.1</b> (6.2 g, purity 66%, 17.6 mmol) in CHCl<sub>3</sub> (265 mL) was added <i>m</i>-CPBA (17.9 g, purity 77%, 79.8 mmol). The mixture was stirred at rt for 16 h. A half-saturated solution of NaHCO<sub>3</sub> and a half-saturated solution of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> were added with ice-bath cooling, and the mixture was stirred for 30 min, then extracted with DCM. The organic phase was washed with saturated NaCl solution, dried (Na<sub>2</sub>SO<sub>4</sub>), and the solvent was removed under reduced pressure. Silica gel chromatography (gradient; hexane/0–80% EtOAc) gave <b>88</b> (4.32 g). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>8</sub>H<sub>10</sub>BrO<sub>3</sub>S [M + H]<sup>+</sup>, 264.9534; found, 264.9536. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 7.84 (d, <i>J</i> = 8.34 Hz, 1H), 7.50 (d, <i>J</i> = 2.02 Hz, 1H), 7.39 (dd, <i>J</i> = 2.02, 8.08 Hz, 1H), 3.94 (s, 3H), 3.22 (s, 3H).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (2<i>R</i>)-2-(4-Fluorophenyl)propanoic Acid (<b>90</b>). Step 1: <i>rac</i>-Methyl 2-(4-Fluorophenyl)propanoate (<b>90.1</b>)</h4><div class="NLM_p last">To a stirred solution of diisopropylamine (13.0 g, 128 mmol) in THF (160 mL) was added 2.5 M <i>n</i>-BuLi in hexane (51.4 mL, 128 mmol) at −78 °C. The solution was stirred at 0 °C for 15 min. The solution was cooled to −78 °C, and a solution of methyl (4-fluorophenyl)acetate (18.0 g, 107 mmol) dissolved in THF (40 mL) was added. The solution was stirred at −78 °C for 30 min. MeI (10.0 mL, 161 mmol) was added at −78 °C, and the solution was allowed to warm to 0 °C within 1 h. Water was added, and the mixture was extracted with EtOAc. The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>), and the solvent was removed under reduced pressure. Silica gel chromatography (gradient; hexane/0–30% EtOAc) gave <b>90.1</b> (18.9 g). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 7.21–7.40 (m, 2H), 7.05–7.18 (m, 2H), 3.79 (q, <i>J</i> = 7.16 Hz, 1H), 3.55 (s, 3H), 1.34 (d, <i>J</i> = 7.33 Hz, 3H).</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Step 2: <i>rac</i>-2-(4-Fluorophenyl)propanoic Acid (<b>90.2</b>)</h4><div class="NLM_p last">To a stirred solution of <b>90.1</b> (18.9 g, 104 mmol) in EtOH (200 mL) was added a solution of KOH (35 g, 624 mmol) in water (200 mL). The mixture was stirred at 0 °C for 4 h. HCl (4.0 M) was added until pH 5 was reached, and the mixture was extracted with EtOAc. The organic phase was separated, and the solvent was removed under reduced pressure to give <b>90.2</b> (15.64 g). The crude product was used without further purification. LC–MS (method 1): <i>t</i><sub>R</sub> = 0.94 min. MS (ESI−): <i>m</i>/<i>z</i> = 167 [M – H]<sup>−</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 12.30 (br s, 1H), 7.19–7.36 (m, 2H), 7.03–7.17 (m, 2H), 3.66 (q, <i>J</i> = 7.16 Hz, 1H), 1.31 (d, <i>J</i> = 7.16 Hz, 3H).</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Step 3: (2<i>R</i>)-2-(4-Fluorophenyl)propanoic Acid (<b>90</b>)</h4><div class="NLM_p">To a stirred solution of <b>90.2</b> (23.6 g, 140 mmol) in refluxing EtOAc (250 mL) was added a solution of (1<i>S</i>)-1-phenylethanamine (17.35 g, 140 mmol) in EtOAc. The mixture was allowed to cool to rt within 1 h. A white solid was collected by filtration, washed with EtOAc, and dried in vacuo to give 27.5 g of a solid. The solid was recrystallized from refluxing EtOAc (400 mL). The mixture was allowed to cool to rt. A white solid was collected by filtration, washed with EtOAc, and dried in vacuo to give 18.3 g of a solid. The solid was twice recrystallized from refluxing EtOAc (350 mL, 300 mL). A white solid was collected by filtration, washed with EtOAc, and dried in vacuo to give 10.51 g of a solid. The solid was dissolved in water, HCl (2.0 M) was added until pH 5 was reached, and the mixture was extracted with DCM. The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>) and the solvent was removed under reduced pressure to give <b>90</b> (5.6 g). The crude product was used without further purification. LC–MS (method 1): <i>t</i><sub>R</sub> = 0.91 min. MS (ESI−): <i>m</i>/<i>z</i> = 167 [M – H]<sup>−</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 12.28 (br s, 1H), 7.24–7.33 (m, 2H), 7.05–7.16 (m, 2H), 3.66 (q, <i>J</i> = 7.16 Hz, 1H), 1.31 (d, <i>J</i> = 7.16 Hz, 3H). [α]<sup>20</sup><sub>D</sub> −79.3 (<i>c</i> = 0.5 g/100 mL, DMSO). Chiral HPLC was used to determine the enantiomeric ratio (column, Chiralcel OJ-H 150 mm × 4.6 mm; solvent A, hexane; solvent B, 2-propanol + 0.1% formic acid; solvent mixture, 80% A + 20% B; flow, 1.00 mL/min; run time, 30 min. UV 254 nm): <i>t</i><sub>R</sub> = 3.41 min; enantiomeric ratio, 99.8:0.2.</div><div class="NLM_p last">Analogous to the described procedure, the mother liquors and (1<i>R</i>)-1-phenylethanamine were used to prepare (2<i>S</i>)-2-(4-fluorophenyl)propanoic acid.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (2<i>R</i>)-2-(4-Fluorophenyl)-<i>N</i>-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propanamide (<b>91</b>)</h4><div class="NLM_p last">To a stirred solution of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.0 g, 4.56 mmol) in DMF (45 mL) and DCM (90 mL) were added NaHCO<sub>3</sub> (766 mg), <b>90</b> (844 mg, 5.02 mmol), and HATU (2.6 g, 6.85 mmol). The mixture was stirred at rt for 4 h. Water was added, and the mixture was stirred for 30 min. A half-saturated solution of NaHCO<sub>3</sub> was added, and the mixture was extracted with EtOAc. The organic phase was washed with saturated NaCl solution, dried (Na<sub>2</sub>SO<sub>4</sub>), and the solvent was removed under reduced pressure. Silica gel chromatography (gradient; hexane/10–35% EtOAc) gave <b>91</b> (1.53 g). LC–MS (method 1): <i>t</i><sub>R</sub> = 1.37 min. MS (ESI+): <i>m</i>/<i>z</i> = 370 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 10.12 (s, 1H), 7.52–7.60 (m, 4H), 7.34–7.43 (m, 2H), 7.06–7.16 (m, 2H), 3.81 (q, <i>J</i> = 6.91 Hz, 1H), 1.37 (d, <i>J</i> = 6.82 Hz, 3H), 1.23 (s, 12H).</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 6-Chloro[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>92</b>). Step 1: Ethyl [(5-Chloropyridin-2-yl)carbamothioyl]carbamate (<b>92.1</b>)</h4><div class="NLM_p last">Ethoxycarbonyl isothiocyanate (8.98 g, 67.1 mmol) was added to a stirred solution of 2-amino-5-chloropyridine (8.0 g, 61.0 mmol) in dioxane (260 mL). The mixture was stirred at rt for 2 h. The solution was concentrated under reduced pressure to give a solid which was dissolved in DCM/MeOH (100:1). The solution was filtered and concentrated under reduced pressure to give a solid that was recrystallized from EtOAc to give <b>92.1</b> (12.1 g). LC–MS (method 1): <i>t</i><sub>R</sub> = 0.81 min. MS (ESI+): <i>m</i>/<i>z</i> = 260 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 12.16 (br s, 1H), 11.68 (br s, 1H), 8.62 (br s, 1H), 8.42 (d, <i>J</i> = 2.64 Hz, 1H), 7.98 (dd, <i>J</i> = 2.64, 9.04 Hz, 1H), 4.19 (q, <i>J</i> = 7.16 Hz, 2H), 1.22 (t, <i>J</i> = 7.16 Hz, 3H).</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Step 2: 6-Chloro[1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>92</b>)</h4><div class="NLM_p last">Hydroxylammonium chloride (18.8 g, 270.2 mmol) was suspended in MeOH (90 mL) and EtOH (90 mL), and Hünig’s base (21.1 g, 163 mmol) was added at rt. The mixture was heated to 60 °C, <b>92.1</b> (12.1 g, 46.6) was added portionwise, and the mixture was stirred at 60 °C for 2 h. The solvent was removed under reduced pressure, and water (1525 mL) was added. A solid was collected by filtration, washed with water, and dried in vacuo to give <b>92</b> (6.4 g). LC–MS (method 1): <i>t</i><sub>R</sub> = 0.57 min. MS (ESI+): <i>m</i>/<i>z</i> = 169 [M + H]<sup>+</sup>. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>6</sub>H<sub>6</sub>ClN<sub>4</sub> [M + H]<sup>+</sup>, 169.0281; found, 169.0284. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 8.83 (dd, <i>J</i> = 0.75, 2.07 Hz, 1H), 7.39–7.48 (m, 1H), 7.30–7.37 (m, 1H), 6.07 (s, 2H).</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 6-Chloro-<i>N</i>-[2-methoxy-4-(methylsulfonyl)phenyl][1,2,4]triazolo[1,5-<i>a</i>]pyridin-2-amine (<b>93</b>)</h4><div class="NLM_p last">To a stirred suspension of <b>92</b> (5.00 g, 29.7 mmol) in toluene (200 mL) and NMP (12.5 mL) were added <b>88</b> (9.04 g, 34.1 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II)–MTBE adduct (XPhos Pd G1, 735 mg, 890 μmol), XPhos (433 mg, 890 μmol), and powdered potassium phosphate (22.0 g, 104 mmol). The flask was twice degassed and backfilled with argon. The mixture was heated to reflux for 2 h. Amino-phase silica gel chromatography (gradient; hexane/35–80% EtOAc) of the crude mixture gave a solid that was triturated with a mixture of DCM and hexane to give <b>93</b> (7.37 g). LC–MS (method 1): <i>t</i><sub>R</sub> = 1.01 min. MS (ESI+): <i>m</i>/<i>z</i> = 353 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>14</sub>ClN<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 353.0475; found, 353.0465. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 9.20 (t, <i>J</i> = 1.41 Hz, 1H), 8.75 (br s, 1H), 8.43 (d, <i>J</i> = 8.67 Hz, 1H), 7.69 (d, <i>J</i> = 0.94 Hz, 2H), 7.53 (dd, <i>J</i> = 1.88, 8.48 Hz, 1H), 7.44 (d, <i>J</i> = 1.88 Hz, 1H), 3.97 (s, 3H), 3.18 (s, 3H).</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (2<i>R</i>)-2-(4-Fluorophenyl)-<i>N</i>-[4-(2-{[2-methoxy-4-(methylsulfonyl)phenyl]amino}[1,2,4]triazolo[1,5-<i>a</i>]pyridin-6-yl)phenyl]propanamide (BAY 1161909, <b>41</b>)</h4><div class="NLM_p last">To a stirred suspension of <b>91</b> (3.92 g, 10.6 mmol) in toluene (125 mL) were added powdered potassium phosphate (6.02 g, 28.3 mmol) and KF (1.85 g, 31.9 mmol), and the mixture was stirred at rt for 15 min. <b>93</b> (2.50 g, 7.09 mmol), palladium(II) acetate (159 mg, 709 μmol), and SPhos (581 mg, 1.417 mmol) were added. The flask was twice degassed and backfilled with argon, and the mixture was heated to 85 °C for 5 h. EtOAc was added, and the mixture was washed with water. The organic phase was washed with saturated NaCl solution, dried (Na<sub>2</sub>SO<sub>4</sub>), and the solvent was removed under reduced pressure. Amino-phase silica gel chromatography (gradient; hexane/35–100% EtOAc) gave a solid that was triturated with a mixture of DCM and hexane to give <b>41</b> (2.96 g, 75%). LC–MS (method 1): <i>t</i><sub>R</sub> = 1.25 min. MS (ESI+): <i>m</i>/<i>z</i> = 560 [M + H]<sup>+</sup>. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>27</sub>FN<sub>5</sub>O<sub>4</sub>S [M + H]<sup>+</sup>, 560.1768; found, 560.1750. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 10.20 (s, 1H), 9.13 (d, <i>J</i> = 0.95 Hz, 1H), 8.61 (s, 1H), 8.52 (d, <i>J</i> = 8.58 Hz, 1H), 7.95 (dd, <i>J</i> = 1.59, 9.22 Hz, 1H), 7.68–7.78 (m, 5H), 7.55 (dd, <i>J</i> = 1.91, 8.58 Hz, 1H), 7.41–7.49 (m, 3H), 7.12–7.20 (m, 2H), 4.00 (s, 3H), 3.88 (q, <i>J</i> = 6.99 Hz, 1H), 3.19 (s, 3H), 1.44 (d, <i>J</i> = 6.99 Hz, 3H); for the assignment of <sup>1</sup>H NMR (and <sup>13</sup>C NMR) signals, see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>. <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) δ = −116.62–116.50 (m, 1F). [α]<sup>20</sup><sub>D</sub> −82.9 (<i>c</i> = 0.5 g/100 mL, DMSO). Chiral HPLC was used to determine the enantiomeric ratio (column, Chiralcel OD-RH 150 mm × 4.6 mm; solvent A, water + 0.1% formic acid; solvent B, acetonitrile; solvent mixture, 40% A + 60% B; flow, 1.00 mL/min; run time, 30 min. UV 254 nm): <i>t</i><sub>R</sub> = 12.83 min; enantiomeric ratio, <1:>99.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Synthesis of BAY 1217389 (<b>79</b>)</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 6,8-Dibromo-3-iodoimidazo[1,2-<i>b</i>]pyridazine (<b>81</b>)</h4><div class="NLM_p last">A mixture of 6,8-dibromoimidazo[1,2-<i>b</i>]pyridazine (<b>80</b>; 3.64 g, 10.5 mmol), <i>N</i>-iodosuccinimide (2.8 g, 12.4 mmol), and DMF (72.6 mL) was heated at 60 °C for 3 h. Further <i>N</i>-iodosuccinimide (1.4 g, 6.2 mmol) was added, and heating was continued for an additional 4 h. Most of the solvent was removed, water was added, and the mixture was extracted with DCM. The organic phase was washed with water and Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution and dried (Na<sub>2</sub>SO<sub>4</sub>). After filtration and removal of the solvent, the residue was purified by silica gel chromatography (hexane/EtOAc 1:1) to give <b>81</b> (3.64 g, 86%). LC–MS (method 1): <i>t</i><sub>R</sub> = 1.10 min. MS (ESI+): <i>m</i>/<i>z</i> = 404 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ = 7.87 (s, 1H), 7.53 (s, 1H).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 6-Bromo-3-iodo-<i>N</i>-(3,3,3-trifluoropropyl)imidazo[1,2-<i>b</i>]pyridazin-8-amine (<b>82</b>)</h4><div class="NLM_p last">To a solution of <b>81</b> (2.30 g, 5.71 mmol) in DMF (40 mL) was added 3,3,3-trifluoropropan-1-amine (2.0 g, 17.7 mmol), and the mixture was stirred at 40 °C overnight. Water was added, and the mixture was extracted with DCM and MeOH. The organic phase was washed with water and dried (Na<sub>2</sub>SO<sub>4</sub>). After filtration and removal of the solvent, the residue was purified by chromatography to give <b>82</b> (2.0 g, 81%). LC–MS (method 1): <i>t</i><sub>R</sub> = 1.28 min. MS (ESI+): <i>m</i>/<i>z</i> = 435 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 7.94 (t, <i>J</i> = 5.94 Hz, 1H), 7.59 (s, 1H), 6.43 (s, 1H), 3.55 (br s, 2H), 2.54–2.75 (m, 2H).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 4-{6-Bromo-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-<i>b</i>]pyridazin-3-yl}-<i>N</i>-cyclopropyl-2-methylbenzamide (<b>83</b>)</h4><div class="NLM_p last">A mixture of <b>82</b> (1.00 g, 2.3 mmol), <i>N</i>-cyclopropyl-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (976 mg, 3.2 mmol), PdCl<sub>2</sub>(dppf)·DCM (563 mg, 0.69 mmol), 2 M aqueous Cs<sub>2</sub>CO<sub>3</sub> (3.45 mL), and THF (15 mL) was stirred at 45 °C for 12 h. Water was added, and the mixture was extracted with EtOAc and MeOH. The organic layer was washed with brine and dried (Na<sub>2</sub>SO<sub>4</sub>). After filtration and removal of the solvent, the residue was purified by silica gel chromatography (gradient; hexane/10–80% EtOAc) to give <b>83</b> (580 mg, 52%). LC–MS (method 1): <i>t</i><sub>R</sub> = 1.21 min. MS (ESI+): <i>m</i>/<i>z</i> = 482 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 8.27 (d, <i>J</i> = 4.55 Hz, 1H), 7.96 (s, 1H), 7.93–7.95 (m, 1H), 7.91 (dd, <i>J</i> = 1.70, 8.00 Hz, 1H), 7.84 (br s, 1H), 7.37 (d, <i>J</i> = 7.83 Hz, 1H), 6.46 (s, 1H), 3.59 (br s, 2H), 2.80 (spt, <i>J</i> = 3.70 Hz, 1H), 2.60–2.72 (m, 2H), 2.36 (s, 3H), 0.62–0.69 (m, 2H), 0.44–0.56 (m, 2H).</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-Cyclopropyl-4-{6-(2,3-difluoro-4-methoxyphenoxy)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-<i>b</i>]pyridazin-3-yl}-2-methylbenzamide (BAY 1217389, <b>79</b>)</h4><div class="NLM_p last">A solution of 2,3-difluoro-4-methoxyphenol (31.9 g, 199 mmol) in DMSO (450 mL) was treated with 60% NaH (7.96 g, 199 mmol), and the mixture was stirred at rt for 1 h. Then, <b>83</b> (16 g, 33.2 mmol) was added, and the mixture was heated overnight at 130 °C. After cooling, EtOAc (300 mL) was added and the organic phase was washed with water. After concentration of the organic phase, the residue was triturated with EtOH (200 mL) to give <b>79</b> as a solid (12.05 g, 65%). LC–MS (method 1): <i>t</i><sub>R</sub> = 1.33 min. MS (ESI+): <i>m</i>/<i>z</i> = 562 [M + H]<sup>+</sup>. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>25</sub>F<sub>5</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 562.1878; found, 562.1888. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 8.22 (d, <i>J</i> = 4.55 Hz, 1H), 7.94 (s, 1H), 7.75 (t, <i>J</i> = 6.06 Hz, 1H), 7.69 (s, 1H), 7.60 (dd, <i>J</i> = 1.52, 8.08 Hz, 1H), 7.24 (dt, <i>J</i> = 2.15, 8.91 Hz, 1H), 7.16 (d, <i>J</i> = 8.08 Hz, 1H), 7.06–7.13 (m, 1H), 6.19 (s, 1H), 3.89 (s, 3H), 3.62 (q, <i>J</i> = 6.15 Hz, 2H), 2.74–2.82 (m, 1H), 2.62–2.74 (m, 2H), 2.09 (s, 3H), 0.59–0.70 (m, 2H), 0.42–0.51 (m, 2H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 169.8, 161.0, 146.3, 144.1, 143.8, 140.7, 135.6, 135.2, 134.2, 133.4, 129.4, 127.0, 126.9, 122.6, 118.1, 108.1, 81.2, 56.7, 35.5, 31.8, 22.7, 19.2, 5.8.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> X-ray Structures of <b>16</b>, <b>41</b>, <b>46</b>, and <b>79</b> in Complex with hMPS1</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> hMPS1 Protein Production</h4><div class="NLM_p">GST-hMPS1 (N515–T806) with a thrombin cleavage site was expressed in <i>E. coli</i> using BL21(DE3) strain. Purification of hMPS1 (GST tag) was achieved by affinity chromatography using glutathione sepharose (GE Healthcare). Cells from a 20 L <i>E. coli</i> fermentation were lysed in buffer A [20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 10% glycerol, 1 mM DTT, complete with EDTA (Roche, 1 tablet/50 mL buffer)] using a microfluidizer instrument. The lysate was centrifuged at 20 000<i>g</i> and the supernatant batch-bound to 40 mL of glutathione sepharose overnight at 4 °C. After washing three times using buffer B [20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 10% glycerol, 1 mM DTT], the GST-hMPS1 sepharose-bound protein was treated overnight with thrombin (1:2000 dilution w/w) in buffer B (50 mL). The supernatant was concentrated using an Amicon filter (3 kDa cutoff) and further purified by size exclusion chromatography using Superdex 75 in buffer B. Purified protein was concentrated using an Amicon filter (3 kDa cutoff) to 14 mg/mL and flash-frozen in liquid nitrogen and stored at −80 °C for the crystallization process.</div><div class="NLM_p">Prior to crystallization, the protein solution was supplemented with the respective compounds at a final concentration of 1 mM and incubated for 3 h on ice. Samples were then clarified by centrifugation (13 000<i>g</i>, 5 min, 277 K). Complex crystals were grown using the hanging-drop method by mixing 1 μL of protein with 1 μL of the corresponding reservoir solution (<b>16</b>, 1.2 M ammonium sulfate, 100 mM sodium cacodylate, pH 6.54, 25% glycerol; <b>41</b>, 1.2 M ammonium sulfate, 100 mM sodium cacodylate, pH 6.54, 25% glycerol; <b>46</b>, 1.0 M ammonium sulfate, 100 mM MES, pH 6.5, 25% glycerol; <b>79</b>, 10% PEG 3350, 180 mM magnesium formate, 25% glycerol). All crystals were then flash-frozen in liquid nitrogen.</div><div class="NLM_p last">Data were collected under cryogenic conditions on beamline BL14.2 at the BESSY synchrotron facility in Berlin. The structures were solved by molecular replacement using an in-house hMPS1 apo structure as search model. Structures were refined using REFMAC5 within the CCP4 suite.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> REF statistics for the final models are given in <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Table S2, Supporting Information</a>. Coordinates and structure factors have been submitted to the RCSB Protein Data Bank (PDB) and are accessible via the codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TN9">6TN9</a> (<b>16</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TNB">6TNB</a> (<b>41</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TNC">6TNC</a> (<b>46</b>), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TND">6TND</a> (<b>79</b>). During the course of this manuscript preparation the X-ray structures of hMPS1 in complex with <b>41</b> and <b>79</b> were published.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Despite differing construct lengths and crystallization conditions compared to those reported in this contribution, the protein structures and compound binding modes are highly conserved.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47"><a href="/doi/suppl/10.1021/acs.jmedchem.9b02035" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35460" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35460" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b02035?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02035</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Assay descriptions of biochemical and cellular assays and pharmacokinetic and physicochemical assays and <i>in vivo</i> efficacy studies; kinase panel data for compound <b>9</b>; crystallographic data and refinement statistics for compounds <b>16</b>, <b>41</b>, <b>46</b>, and <b>79</b>; chemical synthesis of compounds <b>4</b>, <b>5</b>, <b>7</b>–<b>86</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Live-cell imaging pictures and videos for compound <b>79</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_002.docx" class="ext-link">DOCX</a>)</p></li><li><p class="inline">Molecular formula strings and IC<sub>50</sub> values and statistics for biochemical and cellular assay data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf">jm9b02035_si_001.pdf (1.7 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_002.docx">jm9b02035_si_002.docx (13.04 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_003.csv">jm9b02035_si_003.csv (10.01 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Coordinates and structure factors have been submitted to the RCSB Protein Data Bank (PDB) and are accessible via the codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TN9">6TN9</a> (<b>16</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TNB">6TNB</a> (<b>41</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TNC">6TNC</a> (<b>46</b>), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TND">6TND</a> (<b>79</b>). Authors will release the atomic coordinates upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b02035" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30746" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30746" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Volker K. Schulze</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0158-1789" title="Orcid link">http://orcid.org/0000-0002-0158-1789</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#65130a090e00174b16060d10091f002507041c00174b060a08"><span class="__cf_email__" data-cfemail="5e283132353b2c702d3d362b32243b1e3c3f273b2c703d3133">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marcus Koppitz</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3d505c4f5e484e1356524d4d5449477d5f5c44584f135e5250"><span class="__cf_email__" data-cfemail="1d707c6f7e686e3376726d6d7469675d7f7c64786f337e7270">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ulrich Klar</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dirk Kosemund</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Antje M. Wengner</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gerhard Siemeister</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Detlef Stöckigt</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roland Neuhaus</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip Lienau</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benjamin Bader</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Prechtl</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon J. Holton</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hans Briem</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tobias Marquardt</span> - <span class="hlFld-Affiliation affiliation">Research & Development, Pharmaceuticals, Bayer AG, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hartmut Schirok</span> - <span class="hlFld-Affiliation affiliation">Research & Development, Pharmaceuticals, Bayer AG, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rolf Jautelat</span> - <span class="hlFld-Affiliation affiliation">Research & Development, Pharmaceuticals, Bayer AG, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rolf Bohlmann</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Duy Nguyen</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4534-745X" title="Orcid link">http://orcid.org/0000-0002-4534-745X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amaury E. Fernández-Montalván</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span>; 
    <span>Present Address:
                        A.E.F.: Institut de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9156-0000" title="Orcid link">http://orcid.org/0000-0001-9156-0000</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ulf Bömer</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Uwe Eberspaecher</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Brüning</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Olaf Döhr</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marian Raschke</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bertolt Kreft</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dominik Mumberg</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karl Ziegelbauer</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Brands</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Franz von Nussbaum</span> - <span class="hlFld-Affiliation affiliation">Research & Development,
Pharmaceuticals, Bayer AG, 13353 Berlin, Germany</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>V.K.S. and M.K. contributed equally. The manuscript was written through contributions from all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): V.K.S., U.K., D.K., A.M.W., G.S., D.S., R.N., P.L., B.B., S.P., S.J.H., H.B., T.M., H.S., R.J., R.B., D.N., A.E.F., U.B., U.E., M.B., O.D., M.R., B.K., D.M., K.Z., M.B., F.v.N., and M.K. are/were employees and stockholders of Bayer AG.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e3591-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41611" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41611" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The expert technical assistance of A. Glowczewski, I. Herms, K. Kauffeldt, S. Kubicka, F. Kuczynski, A. van Lingen, C. Pakebusch, G. Piechowiak, A. Pletsch, G. Reinhardt, B. Röhr, C. Schlicht, D. Schmidt, S. Schulze, C. Wegner, and H. Zimmermann is gratefully acknowledged. We thank K. Greenfield for support in writing the manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">MPS1</td><td class="NLM_def"><p class="first last">monopolar spindle 1</p></td></tr><tr><td class="NLM_term">SAC</td><td class="NLM_def"><p class="first last">spindle assembly checkpoint</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogeneous time-resolved fluorescence</p></td></tr><tr><td class="NLM_term">SPR</td><td class="NLM_def"><p class="first last">surface plasmon resonance</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">XPhos Pd G1</td><td class="NLM_def"><p class="first last">first generation XPhos Pd precatalyst chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II)–MTBE adduct</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term">log <i>D</i> (pH 7.5)</td><td class="NLM_def"><p class="first last">distribution coefficient between octanol and water at pH 7.5</p></td></tr><tr><td class="NLM_term">BEI</td><td class="NLM_def"><p class="first last">binding efficiency index (pIC<sub>50</sub>·1000/MW)</p></td></tr><tr><td class="NLM_term">LipE/LLE</td><td class="NLM_def"><p class="first last">lipophilic efficiency/lipophilic ligand efficiency (pIC<sub>50</sub> – cLogD (pH 7.5)</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22687" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22687" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 25 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of Cancer: The Next Generation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+Cancer%3A+The+Next+Generation&doi=10.1016%2Fj.cell.2011.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0lgXCBz-vOUlJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520Cancer%253A%2520The%2520Next%2520Generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674%26doi%3D10.1016%2Fj.cell.2011.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pachis, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kops, G. J. P. L.</span></span> <span> </span><span class="NLM_article-title">Leader of the SAC: Molecular Mechanisms of Mps1/TTK Regulation in Mitosis</span>. <i>Open Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">180109</span>, <span class="refDoi"> DOI: 10.1098/rsob.180109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1098%2Frsob.180109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=30111590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVamurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=180109&author=S.+T.+Pachisauthor=G.+J.+P.+L.+Kops&title=Leader+of+the+SAC%3A+Molecular+Mechanisms+of+Mps1%2FTTK+Regulation+in+Mitosis&doi=10.1098%2Frsob.180109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Leader of the SAC: molecular mechanisms of Mps1/TTK regulation in mitosis</span></div><div class="casAuthors">Pachis, Spyridon T.; Kops, Geert J. P. L.</div><div class="citationInfo"><span class="NLM_cas:title">Open Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">180109/1-180109/10</span>CODEN:
                <span class="NLM_cas:coden">OBPICQ</span>;
        ISSN:<span class="NLM_cas:issn">2046-2441</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">A review.  Discovered in 1991 in a screen for genes involved in spindle pole body duplication, the monopolar spindle 1 (Mps1) kinase has since claimed a central role in processes that ensure error-free chromosome segregation.  As a result, Mps1 kinase activity has become an attractive candidate for pharmaceutical companies in the search for compds. that target essential cellular processes to eliminate, for example, tumor cells or pathogens.  Research in recent decades has offered many insights into the mol. function of Mps1 and its regulation.  In this review, we integrate the latest knowledge regarding the regulation of Mps1 activity and its spatio-temporal distribution, highlight gaps in our understanding of these processes and propose future research avenues to address them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTP5y-J8bKWrVg90H21EOLACvtfcHk0lh7FNHI1CXR3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVamurY%253D&md5=ac59e9362441cf9877c51f7d19f0d5ce</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1098%2Frsob.180109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frsob.180109%26sid%3Dliteratum%253Aachs%26aulast%3DPachis%26aufirst%3DS.%2BT.%26aulast%3DKops%26aufirst%3DG.%2BJ.%2BP.%2BL.%26atitle%3DLeader%2520of%2520the%2520SAC%253A%2520Molecular%2520Mechanisms%2520of%2520Mps1%252FTTK%2520Regulation%2520in%2520Mitosis%26jtitle%3DOpen%2520Biol.%26date%3D2018%26volume%3D8%26spage%3D180109%26doi%3D10.1098%2Frsob.180109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kops, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medema, R. H.</span></span> <span> </span><span class="NLM_article-title">Targeting the Mitotic Checkpoint to Kill Tumor Cells</span>. <i>Horm. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1007/s12672-010-0059-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1007%2Fs12672-010-0059-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=21475725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnot1Wkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=113-116&author=A.+Janssenauthor=G.+J.+Kopsauthor=R.+H.+Medema&title=Targeting+the+Mitotic+Checkpoint+to+Kill+Tumor+Cells&doi=10.1007%2Fs12672-010-0059-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the mitotic checkpoint to kill tumor cells</span></div><div class="casAuthors">Janssen Aniek; Kops Geert J; Medema Rene H</div><div class="citationInfo"><span class="NLM_cas:title">Hormones & cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">One of the most common hallmarks of cancer cells is aneuploidy or an abnormal number of chromosomes.  This abnormal chromosome content is a consequence of chromosome missegregation during mitosis, a defect that is seen more frequently in tumor cell divisions as in normal cell divisions.  In fact, a large fraction of human tumors display a chromosome instable phenotype, meaning that they very frequently missegregate chromosomes.  This can cause variegated aneuploidy within the tumor tissue.  It has been argued that this hallmark of cancer could be exploited in anti-cancer therapies.  Here we test this hypothesis by inactivation of the mitotic checkpoint through RNAi-mediated depletion of an essential checkpoint component, Mps1.  The mitotic checkpoint delays segregation of chromosomes during mitosis until all chromosomes are properly attached to the mitotic spindle.  Its inactivation will therefore lead to increased segregation errors.  Indeed, we show that this can lead to increased cell death in tumor cells.  We demonstrate that increased cell death is associated with a dramatic increase in segregation errors.  This suggests that inhibition of the mitotic checkpoint might represent a useful anti-cancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTx5ZlxKChceNts4TFFB11gfW6udTcc2eYv_gMZWSLF_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnot1Wkug%253D%253D&md5=7ea1be16c9e26670ce447b0caca260c3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs12672-010-0059-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12672-010-0059-x%26sid%3Dliteratum%253Aachs%26aulast%3DJanssen%26aufirst%3DA.%26aulast%3DKops%26aufirst%3DG.%2BJ.%26aulast%3DMedema%26aufirst%3DR.%2BH.%26atitle%3DTargeting%2520the%2520Mitotic%2520Checkpoint%2520to%2520Kill%2520Tumor%2520Cells%26jtitle%3DHorm.%2520Cancer%26date%3D2011%26volume%3D2%26spage%3D113%26epage%3D116%26doi%3D10.1007%2Fs12672-010-0059-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jemaà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kepp, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senovilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boemer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prechtl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrieu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castedo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Characterization of Novel MPS1 Inhibitors with Preclinical Anticancer Activity</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1532</span>– <span class="NLM_lpage">1545</span>, <span class="refDoi"> DOI: 10.1038/cdd.2013.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1038%2Fcdd.2013.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=23933817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2gurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1532-1545&author=M.+Jema%C3%A0author=L.+Galluzziauthor=O.+Keppauthor=L.+Senovillaauthor=M.+Brandsauthor=U.+Boemerauthor=M.+Koppitzauthor=P.+Lienauauthor=S.+Prechtlauthor=V.+Schulzeauthor=G.+Siemeisterauthor=A.+M.+Wengnerauthor=D.+Mumbergauthor=K.+Ziegelbauerauthor=A.+Abrieuauthor=M.+Castedoauthor=I.+Vitaleauthor=G.+Kroemer&title=Characterization+of+Novel+MPS1+Inhibitors+with+Preclinical+Anticancer+Activity&doi=10.1038%2Fcdd.2013.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of novel MPS1 inhibitors with preclinical anticancer activity</span></div><div class="casAuthors">Jemaa, M.; Galluzzi, L.; Kepp, O.; Senovilla, L.; Brands, M.; Boemer, U.; Koppitz, M.; Lienau, P.; Prechtl, S.; Schulze, V.; Siemeister, G.; Wengner, A. M.; Mumberg, D.; Ziegelbauer, K.; Abrieu, A.; Castedo, M.; Vitale, I.; Kroemer, G.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1532-1545</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Monopolar spindle 1 (MPS1), a mitotic kinase that is overexpressed in several human cancers, contributes to the alignment of chromosomes to the metaphase plate as well as to the execution of the spindle assembly checkpoint (SAC).  Here, we report the identification and functional characterization of three novel inhibitors of MPS1 of two independent structural classes, N-(4-{2-[(2-cyanophenyl)amino][1,2,4]triazolo[1,5-a]pyridin-6-yl}phenyl)-2-phenylacetamide (Mps-BAY1) (a triazolopyridine), N-cyclopropyl-4-{8-[(2-methylpropyl)amino]-6-(quinolin-5-yl)imidazo[1,2-a]pyrazin-3-yl}benzamide (Mps-BAY2a) and N-cyclopropyl-4-{8-(isobutylamino)imidazo[1,2-a]pyrazin-3-yl}benzamide (Mps-BAY2b) (two imidazopyrazines).  By selectively inactivating MPS1, these small inhibitors can arrest the proliferation of cancer cells, causing their polyploidization and/or their demise.  Cancer cells treated with Mps-BAY1 or Mps-BAY2a manifested multiple signs of mitotic perturbation including inefficient chromosomal congression during metaphase, unscheduled SAC inactivation and severe anaphase defects.  Videomicroscopic cell fate profiling of histone 2B-green fluorescent protein-expressing cells revealed the capacity of MPS1 inhibitors to subvert the correct timing of mitosis as they induce a premature anaphase entry in the context of misaligned metaphase plates.  Hence, in the presence of MPS1 inhibitors, cells either divided in a bipolar (but often asym.) manner or entered one or more rounds of abortive mitoses, generating gross aneuploidy and polyploidy, resp.  In both cases, cells ultimately succumbed to the mitotic catastrophe-induced activation of the mitochondrial pathway of apoptosis.  Of note, low doses of MPS1 inhibitors and paclitaxel (a microtubular poison) synergized at increasing the frequency of chromosome misalignments and missegregations in the context of SAC inactivation.  This resulted in massive polyploidization followed by the activation of mitotic catastrophe.  A synergistic interaction between paclitaxel and MPS1 inhibitors could also be demonstrated in vivo, as the combination of these agents efficiently reduced the growth of tumor xenografts and exerted superior antineoplastic effects compared with either compd. employed alone.  Altogether, these results suggest that MPS1 inhibitors may exert robust anticancer activity, either as standalone therapeutic interventions or combined with microtubule-targeting chems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHoriIGxHO_rVg90H21EOLACvtfcHk0lh7FNHI1CXR3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2gurjI&md5=867fb902b15b6df0f7049b069bd47a4c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2013.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2013.105%26sid%3Dliteratum%253Aachs%26aulast%3DJema%25C3%25A0%26aufirst%3DM.%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DKepp%26aufirst%3DO.%26aulast%3DSenovilla%26aufirst%3DL.%26aulast%3DBrands%26aufirst%3DM.%26aulast%3DBoemer%26aufirst%3DU.%26aulast%3DKoppitz%26aufirst%3DM.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DPrechtl%26aufirst%3DS.%26aulast%3DSchulze%26aufirst%3DV.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DAbrieu%26aufirst%3DA.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DCharacterization%2520of%2520Novel%2520MPS1%2520Inhibitors%2520with%2520Preclinical%2520Anticancer%2520Activity%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2013%26volume%3D20%26spage%3D1532%26epage%3D1545%26doi%3D10.1038%2Fcdd.2013.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldarelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennecozzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sola, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappella, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Re Depaolini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cucchi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colotta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moll, J.</span></span> <span> </span><span class="NLM_article-title">Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">10255</span>– <span class="NLM_lpage">10264</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1158%2F0008-5472.CAN-10-2101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=21159646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGrt7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=10255-10264&author=R.+Colomboauthor=M.+Caldarelliauthor=M.+Mennecozziauthor=M.+L.+Giorginiauthor=F.+Solaauthor=P.+Cappellaauthor=C.+Perreraauthor=S.+Re+Depaoliniauthor=L.+Rusconiauthor=U.+Cucchiauthor=N.+Avanziauthor=J.+A.+Bertrandauthor=R.+T.+Bossiauthor=E.+Pesentiauthor=A.+Galvaniauthor=A.+Isacchiauthor=F.+Colottaauthor=D.+Donatiauthor=J.+Moll&title=Targeting+the+Mitotic+Checkpoint+for+Cancer+Therapy+with+NMS-P715%2C+an+Inhibitor+of+MPS1+Kinase&doi=10.1158%2F0008-5472.CAN-10-2101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase</span></div><div class="casAuthors">Colombo, Riccardo; Caldarelli, Marina; Mennecozzi, Milena; Giorgini, Maria Laura; Sola, Francesco; Cappella, Paolo; Perrera, Claudia; Depaolini, Stefania Re; Rusconi, Luisa; Cucchi, Ulisse; Avanzi, Nilla; Bertrand, Jay Aaron; Bossi, Roberto Tiberio; Pesenti, Enrico; Galvani, Arturo; Isacchi, Antonella; Colotta, Francesco; Donati, Daniele; Moll, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10255-10264</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">MPS1 kinase is a key regulator of the spindle assembly checkpoint (SAC), a mitotic mechanism specifically required for proper chromosomal alignment and segregation.  It has been found aberrantly overexpressed in a wide range of human tumors and is necessary for tumoral cell proliferation.  Here the authors report the identification and characterization of NMS-P715, a selective and orally bioavailable MPS1 small-mol. inhibitor, which selectively reduces cancer cell proliferation, leaving normal cells almost unaffected.  NMS-P715 accelerates mitosis and affects kinetochore components localization causing massive aneuploidy and cell death in a variety of tumoral cell lines and inhibits tumor growth in preclin. cancer models.  Inhibiting the SAC could represent a promising new approach to selectively target cancer cells.  Cancer Res; 70(24); 10255-64.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJeGyiQf0_uLVg90H21EOLACvtfcHk0ljKRDo-KRTsEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGrt7bK&md5=6478b34886d1d2f2a364d142bbd388fe</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2101%26sid%3Dliteratum%253Aachs%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DCaldarelli%26aufirst%3DM.%26aulast%3DMennecozzi%26aufirst%3DM.%26aulast%3DGiorgini%26aufirst%3DM.%2BL.%26aulast%3DSola%26aufirst%3DF.%26aulast%3DCappella%26aufirst%3DP.%26aulast%3DPerrera%26aufirst%3DC.%26aulast%3DRe%2BDepaolini%26aufirst%3DS.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DCucchi%26aufirst%3DU.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DColotta%26aufirst%3DF.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DMoll%26aufirst%3DJ.%26atitle%3DTargeting%2520the%2520Mitotic%2520Checkpoint%2520for%2520Cancer%2520Therapy%2520with%2520NMS-P715%252C%2520an%2520Inhibitor%2520of%2520MPS1%2520Kinase%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D10255%26epage%3D10264%26doi%3D10.1158%2F0008-5472.CAN-10-2101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tardif, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassiano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimbora, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinnon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douce, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorweiler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostanin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papac, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baichwal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAlexander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willardsen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wettstein, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B. L.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Cellular and Antitumor Effects of MPI-0479605, a Small-Molecule Inhibitor of the Mitotic Kinase Mps1</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2267</span>– <span class="NLM_lpage">2275</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1158%2F1535-7163.MCT-11-0453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=21980130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2267-2275&author=K.+D.+Tardifauthor=A.+Rogersauthor=J.+Cassianoauthor=B.+L.+Rothauthor=D.+M.+Cimboraauthor=R.+McKinnonauthor=A.+Petersonauthor=T.+B.+Douceauthor=R.+Robinsonauthor=I.+Dorweilerauthor=T.+Davisauthor=M.+A.+Hessauthor=K.+Ostaninauthor=D.+I.+Papacauthor=V.+Baichwalauthor=I.+McAlexanderauthor=J.+A.+Willardsenauthor=M.+Saundersauthor=H.+Christopheauthor=D.+V.+Kumarauthor=D.+A.+Wettsteinauthor=R.+O.+Carlsonauthor=B.+L.+Williams&title=Characterization+of+the+Cellular+and+Antitumor+Effects+of+MPI-0479605%2C+a+Small-Molecule+Inhibitor+of+the+Mitotic+Kinase+Mps1&doi=10.1158%2F1535-7163.MCT-11-0453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Cellular and Antitumor Effects of MPI-0479605, a Small-Molecule Inhibitor of the Mitotic Kinase Mps1</span></div><div class="casAuthors">Tardif, Keith D.; Rogers, Aaron; Cassiano, Jared; Roth, Bruce L.; Cimbora, Daniel M.; McKinnon, Rena; Peterson, Ashley; Douce, Thomas B.; Robinson, Rosann; Dorweiler, Irene; Davis, Thaylon; Hess, Mark A.; Ostanin, Kirill; Papac, Damon I.; Baichwal, Vijay; McAlexander, Ian; Willardsen, J. Adam; Saunders, Michael; Christophe, Hoarau; Kumar, D. Vijay; Wettstein, Daniel A.; Carlson, Robert O.; Williams, Brandi L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2267-2275</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mps1 is a dual specificity protein kinase that is essential for the bipolar attachment of chromosomes to the mitotic spindle and for maintaining the spindle assembly checkpoint until all chromosomes are properly attached.  Mps1 is expressed at high levels during mitosis and is abundantly expressed in cancer cells.  Disruption of Mps1 function induces aneuploidy and cell death.  We report the identification of MPI-0479605, a potent and selective ATP competitive inhibitor of Mps1.  Cells treated with MPI-0479605 undergo aberrant mitosis, resulting in aneuploidy and formation of micronuclei.  In cells with wild-type p53, this promotes the induction of a postmitotic checkpoint characterized by the ATM- and RAD3-related-dependent activation of the p53-p21 pathway.  In both wild-type and p53 mutant cells lines, there is a growth arrest and inhibition of DNA synthesis.  Subsequently, cells undergo mitotic catastrophe and/or an apoptotic response.  In xenograft models, MPI-0479605 inhibits tumor growth, suggesting that drugs targeting Mps1 may have utility as novel cancer therapeutics.  Mol Cancer Ther; 10(12); 2267-75.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMIODujnZWCLVg90H21EOLACvtfcHk0ljKRDo-KRTsEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnO&md5=e243764443e9dfda40fc84a329d776c2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0453%26sid%3Dliteratum%253Aachs%26aulast%3DTardif%26aufirst%3DK.%2BD.%26aulast%3DRogers%26aufirst%3DA.%26aulast%3DCassiano%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DCimbora%26aufirst%3DD.%2BM.%26aulast%3DMcKinnon%26aufirst%3DR.%26aulast%3DPeterson%26aufirst%3DA.%26aulast%3DDouce%26aufirst%3DT.%2BB.%26aulast%3DRobinson%26aufirst%3DR.%26aulast%3DDorweiler%26aufirst%3DI.%26aulast%3DDavis%26aufirst%3DT.%26aulast%3DHess%26aufirst%3DM.%2BA.%26aulast%3DOstanin%26aufirst%3DK.%26aulast%3DPapac%26aufirst%3DD.%2BI.%26aulast%3DBaichwal%26aufirst%3DV.%26aulast%3DMcAlexander%26aufirst%3DI.%26aulast%3DWillardsen%26aufirst%3DJ.%2BA.%26aulast%3DSaunders%26aufirst%3DM.%26aulast%3DChristophe%26aufirst%3DH.%26aulast%3DKumar%26aufirst%3DD.%2BV.%26aulast%3DWettstein%26aufirst%3DD.%2BA.%26aulast%3DCarlson%26aufirst%3DR.%2BO.%26aulast%3DWilliams%26aufirst%3DB.%2BL.%26atitle%3DCharacterization%2520of%2520the%2520Cellular%2520and%2520Antitumor%2520Effects%2520of%2520MPI-0479605%252C%2520a%2520Small-Molecule%2520Inhibitor%2520of%2520the%2520Mitotic%2520Kinase%2520Mps1%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2267%26epage%3D2275%26doi%3D10.1158%2F1535-7163.MCT-11-0453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tighe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santaguida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musacchio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. S.</span></span> <span> </span><span class="NLM_article-title">Sustained Mps1 Activity is Required in Mitosis to Recruit O-Mad2 to the Mad1–C-Mad2 Core Complex</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1083/jcb.201002133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1083%2Fjcb.201002133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=20624899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVOht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2010&pages=25-34&author=L.+Hewittauthor=A.+Tigheauthor=S.+Santaguidaauthor=A.+M.+Whiteauthor=C.+D.+Jonesauthor=A.+Musacchioauthor=S.+Greenauthor=S.+S.+Taylor&title=Sustained+Mps1+Activity+is+Required+in+Mitosis+to+Recruit+O-Mad2+to+the+Mad1%E2%80%93C-Mad2+Core+Complex&doi=10.1083%2Fjcb.201002133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex</span></div><div class="casAuthors">Hewitt, Laura; Tighe, Anthony; Santaguida, Stefano; White, Anne M.; Jones, Clifford D.; Musacchio, Andrea; Green, Stephen; Taylor, Stephen S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-34</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Mps1 is an essential component of the spindle assembly checkpoint.  In this study, we describe a novel Mps1 inhibitor, AZ3146, and use it to probe the role of Mps1's catalytic activity during mitosis.  When Mps1 is inhibited before mitotic entry, subsequent recruitment of Mad1 and Mad2 to kinetochores is abolished.  However, if Mps1 is inhibited after mitotic entry, the Mad1-C-Mad2 core complex remains kinetochore bound, but O-Mad2 is not recruited to the core.  Although inhibiting Mps1 also interferes with chromosome alignment, we see no obvious effect on aurora B activity.  In contrast, kinetochore recruitment of centromere protein E (CENP-E), a kinesin-related motor protein, is severely impaired.  Strikingly, inhibition of Mps1 significantly increases its own abundance at kinetochores.  Furthermore, we show that Mps1 can dimerize and transphosphorylate in cells.  We propose a model whereby Mps1 transphosphorylation results in its release from kinetochores, thus facilitating recruitment of O-Mad2 and CENP-E and thereby simultaneously promoting checkpoint signaling and chromosome congression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr40BfrYS2Vu7Vg90H21EOLACvtfcHk0lih2WOJmN19Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVOht7Y%253D&md5=2b95cfba4b228bada877bdb6dc95be1f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201002133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201002133%26sid%3Dliteratum%253Aachs%26aulast%3DHewitt%26aufirst%3DL.%26aulast%3DTighe%26aufirst%3DA.%26aulast%3DSantaguida%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DA.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DMusacchio%26aufirst%3DA.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26atitle%3DSustained%2520Mps1%2520Activity%2520is%2520Required%2520in%2520Mitosis%2520to%2520Recruit%2520O-Mad2%2520to%2520the%2520Mad1%25E2%2580%2593C-Mad2%2520Core%2520Complex%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2010%26volume%3D190%26spage%3D25%26epage%3D34%26doi%3D10.1083%2Fjcb.201002133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Innocenti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westwood, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faisal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, G. W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Haven Brandon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Fee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saville, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matijssen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Montfort, R. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linardopoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoelder, S.</span></span> <span> </span><span class="NLM_article-title">Rapid Discovery of Pyrido[3,4-<i>d</i>]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3671</span>– <span class="NLM_lpage">3688</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01811</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01811" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsF2qsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3671-3688&author=P.+Innocentiauthor=H.+L.+Woodwardauthor=S.+Solankiauthor=S.+Naudauthor=I.+M.+Westwoodauthor=N.+Croninauthor=A.+Hayesauthor=J.+Robertsauthor=A.+T.+Henleyauthor=R.+Bakerauthor=A.+Faisalauthor=G.+W.-Y.+Makauthor=G.+Boxauthor=M.+Valentiauthor=A.+De+Haven+Brandonauthor=L.+O%E2%80%99Feeauthor=H.+Savilleauthor=J.+Schmittauthor=B.+Matijssenauthor=R.+Burkeauthor=R.+L.+M.+van+Montfortauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=S.+Linardopoulosauthor=J.+Blaggauthor=S.+Hoelder&title=Rapid+Discovery+of+Pyrido%5B3%2C4-d%5Dpyrimidine+Inhibitors+of+Monopolar+Spindle+Kinase+1+%28MPS1%29+Using+a+Structure-Based+Hybridization+Approach&doi=10.1021%2Facs.jmedchem.5b01811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach</span></div><div class="casAuthors">Innocenti, Paolo; Woodward, Hannah L.; Solanki, Savade; Naud, Sebastien; Westwood, Isaac M.; Cronin, Nora; Hayes, Angela; Roberts, Jennie; Henley, Alan T.; Baker, Ross; Faisal, Amir; Mak, Grace Wing-Yan; Box, Gary; Valenti, Melanie; De Haven Brandon, Alexis; O'Fee, Lisa; Saville, Harry; Schmitt, Jessica; Matijssen, Berry; Burke, Rosemary; van Montfort, Rob L. M.; Raynaud, Florence I.; Eccles, Suzanne A.; Linardopoulos, Spiros; Blagg, Julian; Hoelder, Swen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3671-3688</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monopolar spindle 1 (MPS1) plays a central role in the transition of cells from metaphase to anaphase and is one of the main components of the spindle assembly checkpoint.  Chromosomally unstable cancer cells rely heavily on MPS1 to cope with the stress arising from abnormal nos. of chromosomes and centrosomes and are thus more sensitive to MPS1 inhibition than normal cells.  We report the discovery and optimization of a series of new pyrido[3,4-d]pyrimidine based inhibitors via a structure-based hybridization approach from our previously reported inhibitor CCT251455 and a modestly potent screening hit.  Compds. in this novel series display excellent potency and selectivity for MPS1, which translates into biomarker modulation in an in vivo human tumor xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr42v6loNvM1bVg90H21EOLACvtfcHk0lih2WOJmN19Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsF2qsro%253D&md5=dd858ed11744e0b036061baf5e2c181a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01811%26sid%3Dliteratum%253Aachs%26aulast%3DInnocenti%26aufirst%3DP.%26aulast%3DWoodward%26aufirst%3DH.%2BL.%26aulast%3DSolanki%26aufirst%3DS.%26aulast%3DNaud%26aufirst%3DS.%26aulast%3DWestwood%26aufirst%3DI.%2BM.%26aulast%3DCronin%26aufirst%3DN.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DJ.%26aulast%3DHenley%26aufirst%3DA.%2BT.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DMak%26aufirst%3DG.%2BW.-Y.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DDe%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Fee%26aufirst%3DL.%26aulast%3DSaville%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DMatijssen%26aufirst%3DB.%26aulast%3DBurke%26aufirst%3DR.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%2BM.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DLinardopoulos%26aufirst%3DS.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DRapid%2520Discovery%2520of%2520Pyrido%255B3%252C4-d%255Dpyrimidine%2520Inhibitors%2520of%2520Monopolar%2520Spindle%2520Kinase%25201%2520%2528MPS1%2529%2520Using%2520a%2520Structure-Based%2520Hybridization%2520Approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3671%26epage%3D3688%26doi%3D10.1021%2Facs.jmedchem.5b01811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rymer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanochko, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trajkovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappin, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span> <span> </span><span class="NLM_article-title">Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e0138616</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0138616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1371%2Fjournal.pone.0138616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=26398286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ymsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0138616&author=R.+Martinezauthor=A.+Blasinaauthor=J.+F.+Hallinauthor=W.+Huauthor=I.+Rymerauthor=J.+Fanauthor=R.+L.+Hoffmanauthor=S.+Murphyauthor=M.+Marxauthor=G.+Yanochkoauthor=D.+Trajkovicauthor=D.+Dinhauthor=S.+Timofeevskiauthor=Z.+Zhuauthor=P.+Sunauthor=P.+B.+Lappinauthor=B.+W.+Murray&title=Mitotic+Checkpoint+Kinase+Mps1+Has+a+Role+in+Normal+Physiology+which+Impacts+Clinical+Utility&doi=10.1371%2Fjournal.pone.0138616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mitotic checkpoint kinase Mps1 has a role in normal physiology which impacts clinical utility</span></div><div class="casAuthors">Martinez, Ricardo; Blasina, Alessandra; Hallin, Jill F.; Hu, Wenyue; Rymer, Isha; Fan, Jeffery; Hoffman, Robert L.; Murphy, Sean; Marx, Matthew; Yanochko, Gina; Trajkovic, Dusko; Dinh, Dac; Timofeevski, Sergei; Zhu, Zhou; Sun, Peiquing; Lappin, Patrick B.; Murray, Brion W.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0138616/1-e0138616/23</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Cell cycle checkpoint intervention is an effective therapeutic strategy for cancer when applied to patients predisposed to respond and the treatment is well-tolerated.  A crit. cell cycle process that could be targeted is the mitotic checkpoint (spindle assembly checkpoint) which governs the metaphase-to-anaphase transition and insures proper chromosomal segregation.  The mitotic checkpoint kinase Mps1 was selected to explore whether enhancement in genomic instability is a viable therapeutic strategy.  The basal-a subset of triple-neg. breast cancer was chosen as a model system because it has a higher incidence of chromosomal instability and Mps1 expression is up-regulated.  Depletion of Mps1 reduces tumor cell viability relative to normal cells.  Highly selective, extremely potent Mps1 kinase inhibitors were created to investigate the roles of Mps1 catalytic activity in tumor cells and normal physiol. (PF-7006, PF-3837; Ki<0.5 nM; cellular IC50 2-6 nM).  Treatment of tumor cells in vitro with PF-7006 modulates expected Mps1-dependent biol. as demonstrated by mol. and phenotypic measures (reduced pHH3-Ser10 levels, shorter duration of mitosis, micro-nucleation, and apoptosis).  Tumor-bearing mice treated with PF-7006 exhibit tumor growth inhibition concomitant with pharmacodynamic modulation of a downstream biomarker (pHH3-Ser10).  Unfortunately, efficacy only occurs at drug exposures that cause dose-limiting body wt. loss, gastrointestinal toxicities, and neutropenia.  Mps1 inhibitor toxicities may be mitigated by inducing G1 cell cycle arrest in Rb1-competent cells with the cyclin-dependent kinase-4/6 inhibitor palbociclib.  Using an isogenic cellular model system, PF-7006 is shown to be selectively cytotoxic to Rb1-deficient cells relative to Rb1-competent cells (also a measure of kinase selectivity).  Human bone marrow cells pretreated with palbociclib have decreased PF-7006-dependent apoptosis relative to cells without palbociclib pretreatment.  Collectively, this study raises a concern that single agent therapies inhibiting Mps1 will not be well-tolerated clin. but may be when combined with a selective CDK4/6 drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc-9LR3Gfty7Vg90H21EOLACvtfcHk0ljtqv6RM3iIlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ymsLo%253D&md5=68fc918b70df2cd020be0c4fec209c12</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0138616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0138616%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DBlasina%26aufirst%3DA.%26aulast%3DHallin%26aufirst%3DJ.%2BF.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DRymer%26aufirst%3DI.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DMurphy%26aufirst%3DS.%26aulast%3DMarx%26aufirst%3DM.%26aulast%3DYanochko%26aufirst%3DG.%26aulast%3DTrajkovic%26aufirst%3DD.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DLappin%26aufirst%3DP.%2BB.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DMitotic%2520Checkpoint%2520Kinase%2520Mps1%2520Has%2520a%2520Role%2520in%2520Normal%2520Physiology%2520which%2520Impacts%2520Clinical%2520Utility%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0138616%26doi%3D10.1371%2Fjournal.pone.0138616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ide, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daigo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagashira, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanazawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishioka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Imidazo[1,2-<i>b</i>]pyridazine Derivatives: Selective and Orally Available Mps1 (TTK) Kinase Inhibitors Exhibiting Remarkable Antiproliferative Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1760</span>– <span class="NLM_lpage">1775</span>, <span class="refDoi"> DOI: 10.1021/jm501599u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501599u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2it7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1760-1775&author=K.+Kusakabeauthor=N.+Ideauthor=Y.+Daigoauthor=T.+Itohauthor=T.+Yamamotoauthor=H.+Hashizumeauthor=K.+Nozuauthor=H.+Yoshidaauthor=G.+Tadanoauthor=S.+Tagashiraauthor=K.+Higashinoauthor=Y.+Okanoauthor=Y.+Satoauthor=M.+Inoueauthor=M.+Iguchiauthor=T.+Kanazawaauthor=Y.+Ishiokaauthor=K.+Dohiauthor=Y.+Kidoauthor=S.+Sakamotoauthor=S.+Andoauthor=M.+Maedaauthor=M.+Higakiauthor=Y.+Babaauthor=Y.+Nakamura&title=Discovery+of+Imidazo%5B1%2C2-b%5Dpyridazine+Derivatives%3A+Selective+and+Orally+Available+Mps1+%28TTK%29+Kinase+Inhibitors+Exhibiting+Remarkable+Antiproliferative+Activity&doi=10.1021%2Fjm501599u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Imidazo[1,2-b]pyridazine Derivatives: Selective and Orally Available Mps1 (TTK) Kinase Inhibitors Exhibiting Remarkable Antiproliferative Activity</span></div><div class="casAuthors">Kusakabe, Ken-ichi; Ide, Nobuyuki; Daigo, Yataro; Itoh, Takeshi; Yamamoto, Takahiko; Hashizume, Hiroshi; Nozu, Kohei; Yoshida, Hiroshi; Tadano, Genta; Tagashira, Sachie; Higashino, Kenichi; Okano, Yousuke; Sato, Yuji; Inoue, Makiko; Iguchi, Motofumi; Kanazawa, Takayuki; Ishioka, Yukichi; Dohi, Keiji; Kido, Yasuto; Sakamoto, Shingo; Ando, Shigeru; Maeda, Masahiro; Higaki, Masayo; Baba, Yoshiyasu; Nakamura, Yusuke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1760-1775</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monopolar spindle 1 (Mps1) is an attractive oncol. target due to its high expression level in cancer cells as well as the correlation of its expression levels with histol. grades of cancers.  An imidazo[1,2-a]pyrazine 10a was identified during an HTS campaign.  Although 10a exhibited good biochem. activity, its moderate cellular as well as antiproliferative activities needed to be improved.  The cocrystal structure of an analog of 10a guided our lead optimization to introduce substituents at the 6-position of the scaffold, giving the 6-aryl substituted 21b which had improved cellular activity but no oral bioavailability in rat.  Property-based optimization at the 6-position and a scaffold change led to the discovery of the imidazo[1,2-b]pyridazine-based 27f, an extremely potent (cellular Mps1 IC50 = 0.70 nM, A549 IC50 = 6.0 nM), selective Mps1 inhibitor over 192 kinases, which could be orally administered and was active in vivo.  This 27f demonstrated remarkable antiproliferative activity in the nanomolar range against various tissue cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8D9nRl5vWabVg90H21EOLACvtfcHk0ljtqv6RM3iIlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2it7g%253D&md5=bee62a50247a363dc3e35fcdeac6a64f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm501599u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501599u%26sid%3Dliteratum%253Aachs%26aulast%3DKusakabe%26aufirst%3DK.%26aulast%3DIde%26aufirst%3DN.%26aulast%3DDaigo%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DNozu%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DTadano%26aufirst%3DG.%26aulast%3DTagashira%26aufirst%3DS.%26aulast%3DHigashino%26aufirst%3DK.%26aulast%3DOkano%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DIguchi%26aufirst%3DM.%26aulast%3DKanazawa%26aufirst%3DT.%26aulast%3DIshioka%26aufirst%3DY.%26aulast%3DDohi%26aufirst%3DK.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DSakamoto%26aufirst%3DS.%26aulast%3DAndo%26aufirst%3DS.%26aulast%3DMaeda%26aufirst%3DM.%26aulast%3DHigaki%26aufirst%3DM.%26aulast%3DBaba%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Imidazo%255B1%252C2-b%255Dpyridazine%2520Derivatives%253A%2520Selective%2520and%2520Orally%2520Available%2520Mps1%2520%2528TTK%2529%2520Kinase%2520Inhibitors%2520Exhibiting%2520Remarkable%2520Antiproliferative%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1760%26epage%3D1775%26doi%3D10.1021%2Fjm501599u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brokx, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beletskaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awrey, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiarash, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madeira, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, H. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-(4-Aminopyrazolo[1,5-<i>a</i>][1,3,5]triazin-8-yl)benzamides as Novel, Highly Potent and Selective, Orally Bioavailable Inhibitors of Tyrosine Threonine Kinase, TTK</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3562</span>– <span class="NLM_lpage">3566</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1016%2Fj.bmcl.2016.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=27335255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKgtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3562-3566&author=R.+Lauferauthor=S.-W.+Liauthor=Y.+Liuauthor=G.+Ngauthor=Y.+Langauthor=M.+Feherauthor=R.+Brokxauthor=I.+Beletskayaauthor=R.+Hodgsonauthor=G.+Maoauthor=O.+Plotnikovaauthor=D.+E.+Awreyauthor=J.+M.+Masonauthor=X.+Weiauthor=D.+C.-C.+Linauthor=Y.+Cheauthor=R.+Kiarashauthor=B.+Madeiraauthor=G.+C.+Fletcherauthor=T.+W.+Makauthor=M.+R.+Brayauthor=H.+W.+Pauls&title=Discovery+of+4-%284-Aminopyrazolo%5B1%2C5-a%5D%5B1%2C3%2C5%5Dtriazin-8-yl%29benzamides+as+Novel%2C+Highly+Potent+and+Selective%2C+Orally+Bioavailable+Inhibitors+of+Tyrosine+Threonine+Kinase%2C+TTK&doi=10.1016%2Fj.bmcl.2016.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK</span></div><div class="casAuthors">Laufer, Radoslaw; Li, Sze-Wan; Liu, Yong; Ng, Grace; Lang, Yunhui; Feher, Miklos; Brokx, Richard; Beletskaya, Irina; Hodgson, Richard; Mao, Guodong; Plotnikova, Olga; Awrey, Donald E.; Mason, Jacqueline M.; Wei, Xin; Lin, Dan Chi-Chia; Che, Yi; Kiarash, Reza; Madeira, Brian; Fletcher, Graham C.; Mak, Tak W.; Bray, Mark R.; Pauls, Henry W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3562-3566</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">TTK/Mps1 is a key kinase controlling progression of cell division via participation in the mitotic spindle assembly checkpoint and is overexpressed in a no. of human cancers.  Herein the authors report the discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as a potent, novel class of TTK inhibitors.  The series was identified by bioisosteric replacement of the related imidazopyrazine and imidazopyridazine scaffolds.  Optimization led to the identification of compds. with excellent potency (Ki = 0.8 nM) and exceptional kinase selectivity.  The SAR indicates a strong dependence of activity on the presence of the N-cyclopropyl-2-methylbenzamide moiety delineating the geometry for 11/2 type kinase inhibitor.  Mol. modeling indicates the extensive and optimal contacts, mediated through H-bonds and hydrophobic interactions, are responsible for the selectivity and potency of the inhibitors.  The compds. demonstrate a strong anti-proliferative activity in a panel of human cancer cell lines (HCT116 GIC50 <15 nM) and good rodent pharmacokinetics (oral %F 97%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTb2Z2xtkAWLVg90H21EOLACvtfcHk0liG8ff-uIpV6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKgtLnL&md5=d107d562ed4407d05bfbba57abcd6b98</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DS.-W.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DNg%26aufirst%3DG.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DBrokx%26aufirst%3DR.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DMao%26aufirst%3DG.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DD.%2BC.-C.%26aulast%3DChe%26aufirst%3DY.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DMadeira%26aufirst%3DB.%26aulast%3DFletcher%26aufirst%3DG.%2BC.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DBray%26aufirst%3DM.%2BR.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DDiscovery%2520of%25204-%25284-Aminopyrazolo%255B1%252C5-a%255D%255B1%252C3%252C5%255Dtriazin-8-yl%2529benzamides%2520as%2520Novel%252C%2520Highly%2520Potent%2520and%2520Selective%252C%2520Orally%2520Bioavailable%2520Inhibitors%2520of%2520Tyrosine%2520Threonine%2520Kinase%252C%2520TTK%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3562%26epage%3D3566%26doi%3D10.1016%2Fj.bmcl.2016.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abad-Zapatero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, J. T.</span></span> <span> </span><span class="NLM_article-title">Ligand Efficiency Indices as Guideposts for Drug Discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(05)03386-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1016%2FS1359-6446%2805%2903386-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=15809192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A280%3ADC%252BD2M7nsF2iug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=464-469&author=C.+Abad-Zapateroauthor=J.+T.+Metz&title=Ligand+Efficiency+Indices+as+Guideposts+for+Drug+Discovery&doi=10.1016%2FS1359-6446%2805%2903386-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency indices as guideposts for drug discovery</span></div><div class="casAuthors">Abad-Zapatero Cele; Metz James T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">464-9</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHqVfZXUq224qdXsLcGTEUfW6udTcc2ea9827YY5xfyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7nsF2iug%253D%253D&md5=1720f263a306122c86a57463e5a39287</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903386-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903386-6%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26aulast%3DMetz%26aufirst%3DJ.%2BT.%26atitle%3DLigand%2520Efficiency%2520Indices%2520as%2520Guideposts%2520for%2520Drug%2520Discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D464%26epage%3D469%26doi%3D10.1016%2FS1359-6446%2805%2903386-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">Setting Expectations in Molecular Optimizations: Strengths and Limitations of Commonly used Composite Parameters</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5980</span>– <span class="NLM_lpage">5991</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1016%2Fj.bmcl.2013.08.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=24018190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSrs7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5980-5991&author=M.+D.+Shultz&title=Setting+Expectations+in+Molecular+Optimizations%3A+Strengths+and+Limitations+of+Commonly+used+Composite+Parameters&doi=10.1016%2Fj.bmcl.2013.08.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5980-5991</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Over the past 15 years there have been extensive efforts to understand and reduce the high attrition rates of drug candidates with an increased focus on physicochem. properties.  The fruits of this labor have been the generation of numerous efficiency indexes, metric-based rules and visualization tools to help guide medicinal chemists in the design of new compds. with more favorable properties.  This deluge of information may have had the unintended consequence of further obfuscating mol. optimizations by the inability of these scoring functions, rules and guides to reach a consensus on when a particular transformation is identified as beneficial.  In this manuscript, several composite parameters, or efficiency indexes, are examd. utilizing theor. and exptl. matched mol. pair analyses in order to understand the basis for how each will perform under varying scenarios of mol. optimizations.  In contrast to empirically derived composite parameters based on heavy atom count, lipophilic efficiency (LipE) sets consistent expectations regardless of mol. wt. or relative potency and can be used to generate consistent expectations for any matched mol. pair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJeTISXSJyLbVg90H21EOLACvtfcHk0liG8ff-uIpV6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSrs7rI&md5=3b766e26254f482b75b8973888c13aec</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.029%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DSetting%2520Expectations%2520in%2520Molecular%2520Optimizations%253A%2520Strengths%2520and%2520Limitations%2520of%2520Commonly%2520used%2520Composite%2520Parameters%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5980%26epage%3D5991%26doi%3D10.1016%2Fj.bmcl.2013.08.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">The Thermodynamic Basis for the Use of Lipophilic Efficiency (LipE) in Enthalpic Optimizations</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5992</span>– <span class="NLM_lpage">6000</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1016%2Fj.bmcl.2013.08.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=24054120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOns73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5992-6000&author=M.+D.+Shultz&title=The+Thermodynamic+Basis+for+the+Use+of+Lipophilic+Efficiency+%28LipE%29+in+Enthalpic+Optimizations&doi=10.1016%2Fj.bmcl.2013.08.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5992-6000</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Approaches to improve the efficiency of mol. optimizations have received great attention and numerous efficiency metrics have been introduced to assist in this effort.  Optimization of properties is equally important to optimization of potency and therefore these metrics contain potency vs. property calcns.  Widespread use of a metric does not guarantee its accuracy and a further understanding of which, if any, metric increases the probability of success was sought.  An anal. of LE, LELP and LipE based on theor. and exptl. data was performed demonstrating that LipE most strongly correlates with compd. quality as defined by enthalpy-driven binding.  The basis for the prioritization of LipE over other metrics in enthalpic optimizations is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobuMO74LdKnbVg90H21EOLACvtfcHk0lhx3XWkwAoSXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOns73P&md5=23d948d1135eeefdfebc60846f28ec2b</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.030%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DThe%2520Thermodynamic%2520Basis%2520for%2520the%2520Use%2520of%2520Lipophilic%2520Efficiency%2520%2528LipE%2529%2520in%2520Enthalpic%2520Optimizations%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5992%26epage%3D6000%26doi%3D10.1016%2Fj.bmcl.2013.08.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The Influence of Drug-like Concepts on Decision-making in Medicinal Chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+Influence+of+Drug-like+Concepts+on+Decision-making+in+Medicinal+Chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lhx3XWkwAoSXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520Influence%2520of%2520Drug-like%2520Concepts%2520on%2520Decision-making%2520in%2520Medicinal%2520Chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verček, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogorevc, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanovnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tišler, M.</span></span> <span> </span><span class="NLM_article-title">Cyanoamino Compounds in Synthesis. Syntheses of Some Heterocycles</span>. <i>Monatsh. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.1007/BF01134190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1007%2FBF01134190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADyaL2cXltFGitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1983&pages=789-798&author=B.+Ver%C4%8Dekauthor=B.+Ogorevcauthor=B.+Stanovnikauthor=M.+Ti%C5%A1ler&title=Cyanoamino+Compounds+in+Synthesis.+Syntheses+of+Some+Heterocycles&doi=10.1007%2FBF01134190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cyanoamino compounds in synthesis.  Syntheses of some heterocycles</span></div><div class="casAuthors">Vercek, Bojan; Ogorevc, Bozidar; Stanovnik, Branko; Tisler, Miha</div><div class="citationInfo"><span class="NLM_cas:title">Monatshefte fuer Chemie</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">789-98</span>CODEN:
                <span class="NLM_cas:coden">MOCMB7</span>;
        ISSN:<span class="NLM_cas:issn">0026-9247</span>.
    </div><div class="casAbstract">Transformations of some heterocyclic cyanoamino compds. leading to various heterocyclic systems are described.  s-Triazolo[1,5-a]azines, e.g. I, II, and III, are obtained either in a direct synthetic approach or via the substituted aminotetrazoles, substituted 3-amino-5-oxo-1,2,4-oxadiazolines, and from N-ethoxycarbonyl N'-heteroaryl thioureas or N-heteroaryl N'-hydroxyguanidine.  Thus, 2-(cyanoamino)pyridine cyclized with Me3SiN3 to give the tetrazole IV, which was cyclized with polyphosphoric acid to give I.  The cyanoamino group reacts also with o-difunctional benzenes to give the corresponding substituted derivs. of benzimidazole, benzoxazole or benzothiazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovqVshQOSm87Vg90H21EOLACvtfcHk0lhx3XWkwAoSXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXltFGitQ%253D%253D&md5=32d36961bd0e42a34b73bbed4268a553</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2FBF01134190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01134190%26sid%3Dliteratum%253Aachs%26aulast%3DVer%25C4%258Dek%26aufirst%3DB.%26aulast%3DOgorevc%26aufirst%3DB.%26aulast%3DStanovnik%26aufirst%3DB.%26aulast%3DTi%25C5%25A1ler%26aufirst%3DM.%26atitle%3DCyanoamino%2520Compounds%2520in%2520Synthesis.%2520Syntheses%2520of%2520Some%2520Heterocycles%26jtitle%3DMonatsh.%2520Chem.%26date%3D1983%26volume%3D114%26spage%3D789%26epage%3D798%26doi%3D10.1007%2FBF01134190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, V.</span>; <span class="NLM_string-name">Koppitz, M.</span>; <span class="NLM_string-name">Kosemund, D.</span>; <span class="NLM_string-name">Schirok, H.</span>; <span class="NLM_string-name">Bader, B.</span>; <span class="NLM_string-name">Lienau, P.</span>; <span class="NLM_string-name">Wengner, A.</span>; <span class="NLM_string-name">Briem, H.</span>; <span class="NLM_string-name">Holton, S.</span>; <span class="NLM_string-name">Siemeister, G.</span>; <span class="NLM_string-name">Prechtl, S.</span>; <span class="NLM_string-name">Bömer, U.</span></span> <span> </span><span class="NLM_article-title">Triazolopyridines</span>. PCT Int. Appl. <span class="NLM_patent">WO 2011063908 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=V.+Schulze&author=M.+Koppitz&author=D.+Kosemund&author=H.+Schirok&author=B.+Bader&author=P.+Lienau&author=A.+Wengner&author=H.+Briem&author=S.+Holton&author=G.+Siemeister&author=S.+Prechtl&author=U.+B%C3%B6mer&title=Triazolopyridines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchulze%26aufirst%3DV.%26atitle%3DTriazolopyridines%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, V.</span>; <span class="NLM_string-name">Kosemund, D.</span>; <span class="NLM_string-name">Schirok, H.</span>; <span class="NLM_string-name">Bader, B.</span>; <span class="NLM_string-name">Lienau, P.</span>; <span class="NLM_string-name">Wengner, A. M.</span>; <span class="NLM_string-name">Briem, H.</span>; <span class="NLM_string-name">Holton, S.</span>; <span class="NLM_string-name">Siemeister, G.</span>; <span class="NLM_string-name">Prechtl, S.</span>; <span class="NLM_string-name">Koppitz, M.</span>; <span class="NLM_string-name">Stöckigt, D.</span>; <span class="NLM_string-name">Prien, O.</span></span> <span> </span><span class="NLM_article-title">Substituted Triazolopyridines</span>. PCT Int. Appl. <span class="NLM_patent">WO 2011157688 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=V.+Schulze&author=D.+Kosemund&author=H.+Schirok&author=B.+Bader&author=P.+Lienau&author=A.+M.+Wengner&author=H.+Briem&author=S.+Holton&author=G.+Siemeister&author=S.+Prechtl&author=M.+Koppitz&author=D.+St%C3%B6ckigt&author=O.+Prien&title=Substituted+Triazolopyridines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchulze%26aufirst%3DV.%26atitle%3DSubstituted%2520Triazolopyridines%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, V.</span>; <span class="NLM_string-name">Kosemund, D.</span>; <span class="NLM_string-name">Wengner, A. M.</span>; <span class="NLM_string-name">Siemeister, G.</span>; <span class="NLM_string-name">Stöckigt, D.</span>; <span class="NLM_string-name">Bruening, M.</span></span> <span> </span><span class="NLM_article-title">Substituted Triazolopyridines and Their Use as TTK Inhibitors</span>. PCT Int. Appl. <span class="NLM_patent">WO 2013087579 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=V.+Schulze&author=D.+Kosemund&author=A.+M.+Wengner&author=G.+Siemeister&author=D.+St%C3%B6ckigt&author=M.+Bruening&title=Substituted+Triazolopyridines+and+Their+Use+as+TTK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchulze%26aufirst%3DV.%26atitle%3DSubstituted%2520Triazolopyridines%2520and%2520Their%2520Use%2520as%2520TTK%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosemund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoeckigt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhaus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prechtl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raschke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisk, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Ahsen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreft, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Nussbaum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span> <span> </span><span class="NLM_article-title">Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1158%2F1535-7163.MCT-15-0500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=26832791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVSqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=583-592&author=A.+M.+Wengnerauthor=G.+Siemeisterauthor=M.+Koppitzauthor=V.+Schulzeauthor=D.+Kosemundauthor=U.+Klarauthor=D.+Stoeckigtauthor=R.+Neuhausauthor=P.+Lienauauthor=B.+Baderauthor=S.+Prechtlauthor=M.+Raschkeauthor=A.-L.+Friskauthor=O.+von+Ahsenauthor=M.+Michelsauthor=B.+Kreftauthor=F.+von+Nussbaumauthor=M.+Brandsauthor=D.+Mumbergauthor=K.+Ziegelbauer&title=Novel+Mps1+Kinase+Inhibitors+with+Potent+Antitumor+Activity&doi=10.1158%2F1535-7163.MCT-15-0500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity</span></div><div class="casAuthors">Wengner, Antje M.; Siemeister, Gerhard; Koppitz, Marcus; Schulze, Volker; Kosemund, Dirk; Klar, Ulrich; Stoeckigt, Detlef; Neuhaus, Roland; Lienau, Philip; Bader, Benjamin; Prechtl, Stefan; Raschke, Marian; Frisk, Anna-Lena; von Ahsen, Oliver; Michels, Martin; Kreft, Bertolt; von Nussbaum, Franz; Brands, Michael; Mumberg, Dominik; Ziegelbauer, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">583-592</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Monopolar spindle 1 (Mps1) has been shown to function as the key kinase that activates the spindle assembly checkpoint (SAC) to secure proper distribution of chromosomes to daughter cells.  Here, we report the structure and functional characterization of two novel selective Mps1 inhibitors, BAY 1161909 and BAY 1217389, derived from structurally distinct chem. classes.  BAY 1161909 and BAY 1217389 inhibited Mps1 kinase activity with IC50 values below 10 nmol/L while showing an excellent selectivity profile.  In cellular mechanistic assays, both Mps1 inhibitors abrogated nocodazole-induced SAC activity and induced premature exit from mitosis ("mitotic breakthrough"), resulting in multinuclearity and tumor cell death.  Both compds. efficiently inhibited tumor cell proliferation in vitro (IC50 nmol/L range).  In vivo, BAY 1161909 and BAY 1217389 achieved moderate efficacy in monotherapy in tumor xenograft studies.  However, in line with its unique mode of action, when combined with paclitaxel, low doses of Mps1 inhibitor reduced paclitaxel-induced mitotic arrest by the weakening of SAC activity.  As a result, combination therapy strongly improved efficacy over paclitaxel or Mps1 inhibitor monotreatment at the resp. MTDs in a broad range of xenograft models, including those showing acquired or intrinsic paclitaxel resistance.  Both Mps1 inhibitors showed good tolerability without adding toxicity to paclitaxel monotherapy.  These preclin. findings validate the innovative concept of SAC abrogation for cancer therapy and justify clin. proof-of-concept studies evaluating the Mps1 inhibitors BAY 1161909 and BAY 1217389 in combination with antimitotic cancer drugs to enhance their efficacy and potentially overcome resistance.  Mol Cancer Ther; 15(4); 583-92. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGZQmIvWHFcLVg90H21EOLACvtfcHk0lj9NmC4mgRL6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVSqt7g%253D&md5=f2b5cf0daf178088479be4be2aefa6b7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0500%26sid%3Dliteratum%253Aachs%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DKoppitz%26aufirst%3DM.%26aulast%3DSchulze%26aufirst%3DV.%26aulast%3DKosemund%26aufirst%3DD.%26aulast%3DKlar%26aufirst%3DU.%26aulast%3DStoeckigt%26aufirst%3DD.%26aulast%3DNeuhaus%26aufirst%3DR.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DBader%26aufirst%3DB.%26aulast%3DPrechtl%26aufirst%3DS.%26aulast%3DRaschke%26aufirst%3DM.%26aulast%3DFrisk%26aufirst%3DA.-L.%26aulast%3Dvon%2BAhsen%26aufirst%3DO.%26aulast%3DMichels%26aufirst%3DM.%26aulast%3DKreft%26aufirst%3DB.%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DBrands%26aufirst%3DM.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26atitle%3DNovel%2520Mps1%2520Kinase%2520Inhibitors%2520with%2520Potent%2520Antitumor%2520Activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D583%26epage%3D592%26doi%3D10.1158%2F1535-7163.MCT-15-0500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klar, U.</span>; <span class="NLM_string-name">Koppitz, M.</span>; <span class="NLM_string-name">Jautelat, R.</span>; <span class="NLM_string-name">Kosemund, D.</span>; <span class="NLM_string-name">Bohlmann, R.</span>; <span class="NLM_string-name">Lienau, P.</span>; <span class="NLM_string-name">Siemeister, G.</span>; <span class="NLM_string-name">Wengner, A. M.</span></span> <span> </span><span class="NLM_article-title">Substituted Imidazopyridazines</span>. PCT Int. Appl. <span class="NLM_patent">WO 2012032031 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=U.+Klar&author=M.+Koppitz&author=R.+Jautelat&author=D.+Kosemund&author=R.+Bohlmann&author=P.+Lienau&author=G.+Siemeister&author=A.+M.+Wengner&title=Substituted+Imidazopyridazines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKlar%26aufirst%3DU.%26atitle%3DSubstituted%2520Imidazopyridazines%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brokx, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beletskaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awrey, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirgadze, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiarash, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, H. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of Pyrazolo[1,5-<i>a</i>]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">675</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00485</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00485" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC28Xntl2isLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=671-675&author=Y.+Liuauthor=R.+Lauferauthor=N.+K.+Patelauthor=G.+Ngauthor=P.+B.+Sampsonauthor=S.-W.+Liauthor=Y.+Langauthor=M.+Feherauthor=R.+Brokxauthor=I.+Beletskayaauthor=R.+Hodgsonauthor=O.+Plotnikovaauthor=D.+E.+Awreyauthor=W.+Qiuauthor=N.+Y.+Chirgadzeauthor=J.+M.+Masonauthor=X.+Weiauthor=D.+C.-C.+Linauthor=Y.+Cheauthor=R.+Kiarashauthor=G.+C.+Fletcherauthor=T.+W.+Makauthor=M.+R.+Brayauthor=H.+W.+Pauls&title=Discovery+of+Pyrazolo%5B1%2C5-a%5Dpyrimidine+TTK+Inhibitors%3A+CFI-402257+is+a+Potent%2C+Selective%2C+Bioavailable+Anticancer+Agent&doi=10.1021%2Facsmedchemlett.5b00485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent</span></div><div class="casAuthors">Liu, Yong; Laufer, Radoslaw; Patel, Narendra Kumar; Ng, Grace; Sampson, Peter B.; Li, Sze-Wan; Lang, Yunhui; Feher, Miklos; Brokx, Richard; Beletskaya, Irina; Hodgson, Richard; Plotnikova, Olga; Awrey, Donald E.; Qiu, Wei; Chirgadze, Nickolay Y.; Mason, Jacqueline M.; Wei, Xin; Lin, Dan Chi-Chia; Che, Yi; Kiarash, Reza; Fletcher, Graham C.; Mak, Tak W.; Bray, Mark R.; Pauls, Henry W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">671-675</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This work describes a scaffold hopping exercise that begins with known imidazo[1,2-a]pyrazines, briefly explores pyrazolo[1,5-a][1,3,5]triazines, and ultimately yields pyrazolo[1,5-a]pyrimidines as a novel class of potent TTK inhibitors.  An X-ray structure of a representative compd. is consistent with 11/2 type inhibition and provides structural insight to aid subsequent optimization of in vitro activity and physicochem. and pharmacokinetic properties.  Incorporation of polar moieties in the hydrophobic and solvent accessible regions modulates physicochem. properties while maintaining potency.  Compds. with enhanced oral exposure were identified for xenograft studies.  The work culminates in the identification of a potent (TTK Ki = 0.1 nM), highly selective, orally bioavailable anticancer agent (CFI-402257) for IND enabling studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8YPAge-MdqLVg90H21EOLACvtfcHk0lj9NmC4mgRL6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xntl2isLo%253D&md5=3eb4e1971e0c0a73e6eee657ac9d6fe0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00485%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DN.%2BK.%26aulast%3DNg%26aufirst%3DG.%26aulast%3DSampson%26aufirst%3DP.%2BB.%26aulast%3DLi%26aufirst%3DS.-W.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DBrokx%26aufirst%3DR.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DChirgadze%26aufirst%3DN.%2BY.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DD.%2BC.-C.%26aulast%3DChe%26aufirst%3DY.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DFletcher%26aufirst%3DG.%2BC.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DBray%26aufirst%3DM.%2BR.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DDiscovery%2520of%2520Pyrazolo%255B1%252C5-a%255Dpyrimidine%2520TTK%2520Inhibitors%253A%2520CFI-402257%2520is%2520a%2520Potent%252C%2520Selective%252C%2520Bioavailable%2520Anticancer%2520Agent%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D671%26epage%3D675%26doi%3D10.1021%2Facsmedchemlett.5b00485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiarash, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brokx, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beletskaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span> <span> </span><span class="NLM_article-title">Functional Characterization of CFI-402257, a Potent and Selective Mps1/TTK Kinase Inhibitor, for the Treatment of Cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">3127</span>– <span class="NLM_lpage">3132</span>, <span class="refDoi"> DOI: 10.1073/pnas.1700234114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1073%2Fpnas.1700234114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=28270606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvVyjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=3127-3132&author=J.+M.+Masonauthor=X.+Weiauthor=G.+C.+Fletcherauthor=R.+Kiarashauthor=R.+Brokxauthor=R.+Hodgsonauthor=I.+Beletskayaauthor=M.+R.+Brayauthor=T.+W.+Mak&title=Functional+Characterization+of+CFI-402257%2C+a+Potent+and+Selective+Mps1%2FTTK+Kinase+Inhibitor%2C+for+the+Treatment+of+Cancer&doi=10.1073%2Fpnas.1700234114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer</span></div><div class="casAuthors">Mason, Jacqueline M.; Wei, Xin; Fletcher, Graham C.; Kiarash, Reza; Brokx, Richard; Hodgson, Richard; Beletskaya, Irina; Bray, Mark R.; Mak, Tak W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3127-3132</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Loss of cell-cycle control is a hallmark of human cancer.  Cell-cycle checkpoints are essential for maintaining genome integrity and balanced growth and division.  They are specifically deregulated in cancer cells and contain regulators that represent potential therapeutic targets.  Monopolar spindle 1 (Mps1; also known as TTK protein kinase) is a core component of the spindle assembly checkpoint (SAC), a genome-surveillance mechanism that is important for cell survival, and has emerged as a candidate target for anticancer therapy.  Here, the authors report the cellular and antitumor effects of CFI-402257, a potent (Mps1 Ki = 0.09±0.02 nM; cellular Mps1 EC50 = 6.5±0.5 nM), highly selective, and orally active small-mol. inhibitor of Mps1 that was identified through a drug-discovery program.  Human cancer cells treated with CFI-402257 exhibit effects consistent with Mps1 kinase inhibition, specifically SAC inactivation, leading to chromosome missegregation, aneuploidy, and ultimately cell death.  Oral administration of CFI-402257 in monotherapy or in combination with an anti-programmed cell death 1 (PD-1) antibody in mouse models of human cancer results in inhibition of tumor growth at doses that are well-tolerated.  The authors' findings provide a rationale for the clin. evaluation of CFI-402257 in patients with solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFQJ3eg_c-qLVg90H21EOLACvtfcHk0lhx0JLa6Ulmhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvVyjsL8%253D&md5=bb9742c8d07314e7d3c322bef71ef0ff</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1700234114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1700234114%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DFletcher%26aufirst%3DG.%2BC.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DBrokx%26aufirst%3DR.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DBray%26aufirst%3DM.%2BR.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DFunctional%2520Characterization%2520of%2520CFI-402257%252C%2520a%2520Potent%2520and%2520Selective%2520Mps1%252FTTK%2520Kinase%2520Inhibitor%252C%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D3127%26epage%3D3132%26doi%3D10.1073%2Fpnas.1700234114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krissinel, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span> <span> </span><span class="NLM_article-title">Overview of the CCP4 Suite and Current Developments</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=21460441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+Suite+and+Current+Developments&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0lhx0JLa6Ulmhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520Suite%2520and%2520Current%2520Developments%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uitdehaag, J. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Man, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemsen-Seegers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinsen, M. B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libouban, M. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterrenburg, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">deWit, J. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vetter, J. R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Roos, J. A. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G. J. R.</span></span> <span> </span><span class="NLM_article-title">Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>429</i></span>,  <span class="NLM_fpage">2211</span>– <span class="NLM_lpage">2230</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2017.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1016%2Fj.jmb.2017.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=28539250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1Wiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=429&publication_year=2017&pages=2211-2230&author=J.+C.+M.+Uitdehaagauthor=J.+de+Manauthor=N.+Willemsen-Seegersauthor=M.+B.+W.+Prinsenauthor=M.+A.+A.+Liboubanauthor=J.+G.+Sterrenburgauthor=J.+J.+P.+deWitauthor=J.+R.+F.+de+Vetterauthor=J.+A.+D.+M.+de+Roosauthor=R.+C.+Buijsmanauthor=G.+J.+R.+Zaman&title=Target+Residence+Time-Guided+Optimization+on+TTK+Kinase+Results+in+Inhibitors+with+Potent+Anti-Proliferative+Activity&doi=10.1016%2Fj.jmb.2017.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity</span></div><div class="casAuthors">Uitdehaag, Joost C. M.; de Man, Jos; Willemsen-Seegers, Nicole; Prinsen, Martine B. W.; Libouban, Marion A. A.; Sterrenburg, Jan Gerard; de Wit, Joeri J. P.; de Vetter, Judith R. F.; de Roos, Jeroen A. D. M.; Buijsman, Rogier C.; Zaman, Guido J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">429</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2211-2230</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The protein kinase threonine tyrosine kinase (TTK; also known as Mps1) is a crit. component of the spindle assembly checkpoint and a promising drug target for the treatment of aggressive cancers, such as triple neg. breast cancer.  While the first TTK inhibitors have entered clin. trials, little is known about how the inhibition of TTK with small-mol. compds. affects cellular activity.  The authors studied the selective TTK inhibitor NTRC 0066-0, which was developed in the authors' own lab., together with 11 TTK inhibitors developed by other companies, including Mps-BAY2b, BAY 1161909, BAY 1217389 (Bayer), TC-Mps1-12 (Shionogi), and MPI-0479605 (Myrexis).  Parallel testing shows that the cellular activity of these TTK inhibitors correlates with their binding affinity to TTK and, more strongly, with target residence time.  TTK inhibitors are therefore an example where target residence time dets. activity in in vitro cellular assays.  X-ray structures and thermal stability expts. reveal that the most potent compds. induce a shift of the glycine-rich loop as a result of binding to the catalytic lysine at position 553.  This "lysine trap" disrupts the catalytic machinery.  Based on these insights, the authors developed TTK inhibitors, based on a (5,6-dihydro)pyrimido[4,5-e]indolizine scaffold, with longer target residence times, which further exploit an allosteric pocket surrounding Lys 553.  Their binding mode is new for kinase inhibitors and can be classified as hybrid Type I/Type III.  These inhibitors have very potent anti-proliferative activity that rivals classic cytotoxic therapy.  The authors' findings will open up new avenues for more applications for TTK inhibitors in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT_6mZVMoVTrVg90H21EOLACvtfcHk0lhx0JLa6Ulmhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1Wiuro%253D&md5=c02b149e673dec7b0212b37a4c7b0831</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2017.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2017.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DUitdehaag%26aufirst%3DJ.%2BC.%2BM.%26aulast%3Dde%2BMan%26aufirst%3DJ.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DPrinsen%26aufirst%3DM.%2BB.%2BW.%26aulast%3DLibouban%26aufirst%3DM.%2BA.%2BA.%26aulast%3DSterrenburg%26aufirst%3DJ.%2BG.%26aulast%3DdeWit%26aufirst%3DJ.%2BJ.%2BP.%26aulast%3Dde%2BVetter%26aufirst%3DJ.%2BR.%2BF.%26aulast%3Dde%2BRoos%26aufirst%3DJ.%2BA.%2BD.%2BM.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%2BR.%26atitle%3DTarget%2520Residence%2520Time-Guided%2520Optimization%2520on%2520TTK%2520Kinase%2520Results%2520in%2520Inhibitors%2520with%2520Potent%2520Anti-Proliferative%2520Activity%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2017%26volume%3D429%26spage%3D2211%26epage%3D2230%26doi%3D10.1016%2Fj.jmb.2017.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Younho Lee, Hyunkyung Kim, Haelee Kim, Ha Yeon Cho, Jun-Goo Jee, Kyung-Ah Seo, Jung Beom Son, Eunhwa Ko, Hwan Geun Choi, Nam Doo Kim, <span class="NLM_string-name hlFld-ContribAuthor">Ikyon Kim</span>. </span><span class="cited-content_cbyCitation_article-title">X-ray Crystal Structure-Guided Design and Optimization of 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile Scaffold as a Potent and Orally Active Monopolar Spindle 1 Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (10)
                                     , 6985-6995. <a href="https://doi.org/10.1021/acs.jmedchem.1c00542" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00542</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00542%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DX-ray%252BCrystal%252BStructure-Guided%252BDesign%252Band%252BOptimization%252Bof%252B7H-Pyrrolo%25255B2%25252C3-d%25255Dpyrimidine-5-carbonitrile%252BScaffold%252Bas%252Ba%252BPotent%252Band%252BOrally%252BActive%252BMonopolar%252BSpindle%252B1%252BInhibitor%26aulast%3DLee%26aufirst%3DYounho%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D25032021%26date%3D04052021%26volume%3D64%26issue%3D10%26spage%3D6985%26epage%3D6995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valentin  Wydra</span>, <span class="hlFld-ContribAuthor ">Stefan  Gerstenecker</span>, <span class="hlFld-ContribAuthor ">Dieter  Schollmeyer</span>, <span class="hlFld-ContribAuthor ">Stanislav  Andreev</span>, <span class="hlFld-ContribAuthor ">Teodor  Dimitrov</span>, <span class="hlFld-ContribAuthor ">Ricardo Augusto  Massarico Serafim</span>, <span class="hlFld-ContribAuthor ">Stefan  Laufer</span>, <span class="hlFld-ContribAuthor ">Matthias  Gehringer</span>. </span><span class="cited-content_cbyCitation_article-title">N-(6-Chloro-3-nitropyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)isoquinolin-3-amine. </span><span class="cited-content_cbyCitation_journal-name">Molbank</span><span> <strong>2021,</strong> <em>2021 </em>
                                    (1)
                                     , M1181. <a href="https://doi.org/10.3390/M1181" title="DOI URL">https://doi.org/10.3390/M1181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/M1181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2FM1181%26sid%3Dliteratum%253Aachs%26jtitle%3DMolbank%26atitle%3DN-%2525286-Chloro-3-nitropyridin-2-yl%252529-5-%2525281-methyl-1H-pyrazol-4-yl%252529isoquinolin-3-amine%26aulast%3DWydra%26aufirst%3DValentin%26date%3D2021%26date%3D2021%26volume%3D2021%26issue%3D1%26spage%3DM1181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ola  Rominiyi</span>, <span class="hlFld-ContribAuthor ">Aurelie  Vanderlinden</span>, <span class="hlFld-ContribAuthor ">Susan Jane  Clenton</span>, <span class="hlFld-ContribAuthor ">Caroline  Bridgewater</span>, <span class="hlFld-ContribAuthor ">Yahia  Al-Tamimi</span>, <span class="hlFld-ContribAuthor ">Spencer James  Collis</span>. </span><span class="cited-content_cbyCitation_article-title">Tumour treating fields therapy for glioblastoma: current advances and future directions. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Cancer</span><span> <strong>2021,</strong> <em>124 </em>
                                    (4)
                                     , 697-709. <a href="https://doi.org/10.1038/s41416-020-01136-5" title="DOI URL">https://doi.org/10.1038/s41416-020-01136-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41416-020-01136-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41416-020-01136-5%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Cancer%26atitle%3DTumour%252Btreating%252Bfields%252Btherapy%252Bfor%252Bglioblastoma%25253A%252Bcurrent%252Badvances%252Band%252Bfuture%252Bdirections%26aulast%3DRominiyi%26aufirst%3DOla%26date%3D2021%26date%3D2020%26volume%3D124%26issue%3D4%26spage%3D697%26epage%3D709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minhao  Huang</span>, <span class="hlFld-ContribAuthor ">Yongjun  Huang</span>, <span class="hlFld-ContribAuthor ">Jing  Guo</span>, <span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Yu  Chang</span>, <span class="hlFld-ContribAuthor ">Xiaolu  Wang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Yanhui  Huang</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113023. <a href="https://doi.org/10.1016/j.ejmech.2020.113023" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113023%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrido%25255B2%25252C%252B3-d%25255Dpyrimidin-7%2525288H%252529-ones%252Bas%252Bnew%252Bselective%252Borally%252Bbioavailable%252BThreonine%252BTyrosine%252BKinase%252B%252528TTK%252529%252Binhibitors%26aulast%3DHuang%26aufirst%3DMinhao%26date%3D2021%26volume%3D211%26spage%3D113023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Gütschow</span>, <span class="hlFld-ContribAuthor ">Jean Jacques  Vanden Eynde</span>, <span class="hlFld-ContribAuthor ">Josef  Jampilek</span>, <span class="hlFld-ContribAuthor ">CongBao  Kang</span>, <span class="hlFld-ContribAuthor ">Arduino A.  Mangoni</span>, <span class="hlFld-ContribAuthor ">Paola  Fossa</span>, <span class="hlFld-ContribAuthor ">Rafik  Karaman</span>, <span class="hlFld-ContribAuthor ">Andrea  Trabocchi</span>, <span class="hlFld-ContribAuthor ">Peter J. H.  Scott</span>, <span class="hlFld-ContribAuthor ">Jóhannes  Reynisson</span>, <span class="hlFld-ContribAuthor ">Simona  Rapposelli</span>, <span class="hlFld-ContribAuthor ">Stefania  Galdiero</span>, <span class="hlFld-ContribAuthor ">Jean-Yves  Winum</span>, <span class="hlFld-ContribAuthor ">Chiara  Brullo</span>, <span class="hlFld-ContribAuthor ">Katalin  Prokai-Tatrai</span>, <span class="hlFld-ContribAuthor ">Arun K.  Sharma</span>, <span class="hlFld-ContribAuthor ">Matthieu  Schapira</span>, <span class="hlFld-ContribAuthor ">Yasu-Taka  Azuma</span>, <span class="hlFld-ContribAuthor ">Laura  Cerchia</span>, <span class="hlFld-ContribAuthor ">Mariana  Spetea</span>, <span class="hlFld-ContribAuthor ">Giangiacomo  Torri</span>, <span class="hlFld-ContribAuthor ">Simona  Collina</span>, <span class="hlFld-ContribAuthor ">Athina  Geronikaki</span>, <span class="hlFld-ContribAuthor ">Alfonso T.  García-Sosa</span>, <span class="hlFld-ContribAuthor ">M. Helena  Vasconcelos</span>, <span class="hlFld-ContribAuthor ">Maria Emília  Sousa</span>, <span class="hlFld-ContribAuthor ">Ivan  Kosalec</span>, <span class="hlFld-ContribAuthor ">Tiziano  Tuccinardi</span>, <span class="hlFld-ContribAuthor ">Iola F.  Duarte</span>, <span class="hlFld-ContribAuthor ">Jorge A. R.  Salvador</span>, <span class="hlFld-ContribAuthor ">Massimo  Bertinaria</span>, <span class="hlFld-ContribAuthor ">Maurizio  Pellecchia</span>, <span class="hlFld-ContribAuthor ">Jussara  Amato</span>, <span class="hlFld-ContribAuthor ">Giulio  Rastelli</span>, <span class="hlFld-ContribAuthor ">Paula A. C.  Gomes</span>, <span class="hlFld-ContribAuthor ">Rita C.  Guedes</span>, <span class="hlFld-ContribAuthor ">Jean-Marc  Sabatier</span>, <span class="hlFld-ContribAuthor ">Ana  Estévez-Braun</span>, <span class="hlFld-ContribAuthor ">Bruno  Pagano</span>, <span class="hlFld-ContribAuthor ">Stefano  Mangani</span>, <span class="hlFld-ContribAuthor ">Rino  Ragno</span>, <span class="hlFld-ContribAuthor ">George  Kokotos</span>, <span class="hlFld-ContribAuthor ">Margherita  Brindisi</span>, <span class="hlFld-ContribAuthor ">Florenci V.  González</span>, <span class="hlFld-ContribAuthor ">Fernanda  Borges</span>, <span class="hlFld-ContribAuthor ">Mariarosaria  Miloso</span>, <span class="hlFld-ContribAuthor ">Jarkko  Rautio</span>, <span class="hlFld-ContribAuthor ">Diego  Muñoz-Torrero</span>. </span><span class="cited-content_cbyCitation_article-title">Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–7. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (13)
                                     , 2968. <a href="https://doi.org/10.3390/molecules25132968" title="DOI URL">https://doi.org/10.3390/molecules25132968</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25132968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25132968%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBreakthroughs%252Bin%252BMedicinal%252BChemistry%25253A%252BNew%252BTargets%252Band%252BMechanisms%25252C%252BNew%252BDrugs%25252C%252BNew%252BHopes%2525E2%252580%2525937%26aulast%3DG%25C3%25BCtschow%26aufirst%3DMichael%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D13%26spage%3D2968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0035.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples of MPS1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Representative Syntheses for the Triazolopyridine Derivatives: Compounds <b>4</b>, <b>9</b>, and <b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethoxycarbonyl isothiocyanate, dioxane, rt, 86%; (b) HONH<sub>2</sub>·HCl, Hünig’s base, EtOH, MeOH, 60 °C, 91%; (c) (4-hydroxy-3,5-dimethylphenyl)boronic acid pinacol ester, PPh<sub>3</sub>, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, 1-propanol, water, K<sub>2</sub>CO<sub>3</sub>, reflux, 45%; (d) thiophene-2-carboxylic acid, PyBOP, Hünig’s base, DMA, rt, 44%; (e) 1-bromo-2-methoxybenzene, Pd<sub>2</sub>(dba)<sub>3</sub>, (<i>R</i>)-(+)-BINAP, NaO<i>t</i>-Bu, toluene, NMP, 110 °C, 27%; (f) {4-[(<i>tert</i>-butoxycarbonyl)amino]phenyl}boronic acid, PPh<sub>3</sub>, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, 1-propanol, water, K<sub>2</sub>CO<sub>3</sub>, reflux, 80%; (g) TFA, DCM, rt, 92%; (h) (4-fluorophenyl)acetic acid, HATU, Hünig’s base, THF, rt, 75%; (i) 2-bromobenzonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, (<i>R</i>)-(+)-BINAP, Cs<sub>2</sub>CO<sub>3</sub>, toluene, NMP, 110 °C, 42%.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray costructure of triazolopyridine <b>16</b> cocrystallized with hMPS1. The PDB accession code is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TN9">6TN9</a>. The triazolopyridine core of <b>16</b> interacts with the hinge region of hMPS1, and the phenolic hydroxy group forms a hydrogen bond to Glu<sup>571</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Comparison of early compound <b>16</b> and clinical candidate <b>41</b> by binding kinetics studies, and comparison of their hMPS1 X-ray costructures: (a) SPR multicycle kinetics sensorgram corresponding to the titration of <b>16</b> (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf" class="ext-link">Supporting Information</a>); (b) SPR single-cycle kinetics sensorgram corresponding to the titration of <b>41</b>; (c) overlay of the structures of hMPS1 in complex with <b>16</b> (gray, PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TN9">6TN9</a>) and with <b>41</b> (blue, PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TNB">6TNB</a>), showing induction of a new pocket by the binding of <b>41</b>; (d) schematic representation of the hydrogen bonding of <b>41</b> in complex with hMPS1; (e) structure of hMPS1 in complex with <b>41</b>. The phenylpropionic acid moiety of <b>41</b> occupies the induced pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray co-structure of imidazopyrazine <b>46</b> cocrystallized with hMPS1. The PDB accession code is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TNC">6TNC</a>. The imidazopyrazine core of <b>46</b> interacts with the hinge region of hMPS1, and available space in the pocket can be found around positions 5 and 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Correlation of biochemical and cellular IC<sub>50</sub> values of the imidazo series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Possible Routes and Implemented Route (Green) for the Synthesis of BAY 1217389 (<b>79</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>N</i>-iodosuccinimide, DMF, 60 °C, 86%; (b) 3,3,3-trifluoropropylamine, DMF, 40 °C, 81%; (c) <i>N</i>-cyclopropyl-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide, PdCl<sub>2</sub>(dppf)·DCM, aq Cs<sub>2</sub>CO<sub>3</sub>, THF, 45 °C, 52%; (d) 2,3-difluoro-4-methoxyphenol, NaH, DMSO, 130 °C, 65%.</p></p></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) X-ray structure of BAY 1161909 (<b>41</b>, blue, PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TNB">6TNB</a>) and overlay with BAY 1217389 (<b>79</b>, green). (b) X-ray structure of BAY 1217389 (<b>79</b>, green, PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TND">6TND</a>) and overlay with BAY 1161909 (<b>41</b>, blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Snapshots of proliferating HeLa cells by microscopy upon addition of BAY 1217389 (<b>79</b>) and/or paclitaxel. Arrow indicates prolonged postmitotic bridge, and circle indicates multinucleated daughter cells/mitotic catastrophe.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Synergistic antitumor activity of MPS1 inhibitors in combination with paclitaxel in preclinical tumor xenograft models in mice: (a) BAY 1217389 (<b>79</b>); (b) BAY 1161909 (<b>41</b>). PDX = patient-derived xenograft.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/medium/jm9b02035_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of BAY 1161909 (<b>41</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.9b02035/20200806/images/large/jm9b02035_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02035&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaSMe, DMF, 65 °C, then MeI; (b) <i>m</i>-CPBA, CHCl<sub>3</sub>, rt; (c) LDA, THF, −78 °C, then MeI; (d) KOH, EtOH, water, 0 °C; (e) enantiomer separation using crystallization of the (1<i>S</i>)-1-phenylethanamine salt from EtOAc; (f) 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, HATU, NaHCO<sub>3</sub>, DMF, DCM, rt; (g) <b>88</b>, first generation XPhos Pd precatalyst, XPhos, K<sub>3</sub>PO<sub>4</sub>, toluene, NMP, reflux; (h) <b>91</b>, Pd(OAc)<sub>2</sub>, SPhos, K<sub>3</sub>PO<sub>4</sub>, KF, toluene, 85 °C, 5 h.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02870" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02870" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 25 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of Cancer: The Next Generation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+Cancer%3A+The+Next+Generation&doi=10.1016%2Fj.cell.2011.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0lgHyJPPWZLuYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520Cancer%253A%2520The%2520Next%2520Generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674%26doi%3D10.1016%2Fj.cell.2011.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pachis, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kops, G. J. P. L.</span></span> <span> </span><span class="NLM_article-title">Leader of the SAC: Molecular Mechanisms of Mps1/TTK Regulation in Mitosis</span>. <i>Open Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">180109</span>, <span class="refDoi"> DOI: 10.1098/rsob.180109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1098%2Frsob.180109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=30111590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVamurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=180109&author=S.+T.+Pachisauthor=G.+J.+P.+L.+Kops&title=Leader+of+the+SAC%3A+Molecular+Mechanisms+of+Mps1%2FTTK+Regulation+in+Mitosis&doi=10.1098%2Frsob.180109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Leader of the SAC: molecular mechanisms of Mps1/TTK regulation in mitosis</span></div><div class="casAuthors">Pachis, Spyridon T.; Kops, Geert J. P. L.</div><div class="citationInfo"><span class="NLM_cas:title">Open Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">180109/1-180109/10</span>CODEN:
                <span class="NLM_cas:coden">OBPICQ</span>;
        ISSN:<span class="NLM_cas:issn">2046-2441</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">A review.  Discovered in 1991 in a screen for genes involved in spindle pole body duplication, the monopolar spindle 1 (Mps1) kinase has since claimed a central role in processes that ensure error-free chromosome segregation.  As a result, Mps1 kinase activity has become an attractive candidate for pharmaceutical companies in the search for compds. that target essential cellular processes to eliminate, for example, tumor cells or pathogens.  Research in recent decades has offered many insights into the mol. function of Mps1 and its regulation.  In this review, we integrate the latest knowledge regarding the regulation of Mps1 activity and its spatio-temporal distribution, highlight gaps in our understanding of these processes and propose future research avenues to address them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTP5y-J8bKWrVg90H21EOLACvtfcHk0lgHyJPPWZLuYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVamurY%253D&md5=ac59e9362441cf9877c51f7d19f0d5ce</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1098%2Frsob.180109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frsob.180109%26sid%3Dliteratum%253Aachs%26aulast%3DPachis%26aufirst%3DS.%2BT.%26aulast%3DKops%26aufirst%3DG.%2BJ.%2BP.%2BL.%26atitle%3DLeader%2520of%2520the%2520SAC%253A%2520Molecular%2520Mechanisms%2520of%2520Mps1%252FTTK%2520Regulation%2520in%2520Mitosis%26jtitle%3DOpen%2520Biol.%26date%3D2018%26volume%3D8%26spage%3D180109%26doi%3D10.1098%2Frsob.180109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kops, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medema, R. H.</span></span> <span> </span><span class="NLM_article-title">Targeting the Mitotic Checkpoint to Kill Tumor Cells</span>. <i>Horm. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1007/s12672-010-0059-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1007%2Fs12672-010-0059-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=21475725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnot1Wkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=113-116&author=A.+Janssenauthor=G.+J.+Kopsauthor=R.+H.+Medema&title=Targeting+the+Mitotic+Checkpoint+to+Kill+Tumor+Cells&doi=10.1007%2Fs12672-010-0059-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the mitotic checkpoint to kill tumor cells</span></div><div class="casAuthors">Janssen Aniek; Kops Geert J; Medema Rene H</div><div class="citationInfo"><span class="NLM_cas:title">Hormones & cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">One of the most common hallmarks of cancer cells is aneuploidy or an abnormal number of chromosomes.  This abnormal chromosome content is a consequence of chromosome missegregation during mitosis, a defect that is seen more frequently in tumor cell divisions as in normal cell divisions.  In fact, a large fraction of human tumors display a chromosome instable phenotype, meaning that they very frequently missegregate chromosomes.  This can cause variegated aneuploidy within the tumor tissue.  It has been argued that this hallmark of cancer could be exploited in anti-cancer therapies.  Here we test this hypothesis by inactivation of the mitotic checkpoint through RNAi-mediated depletion of an essential checkpoint component, Mps1.  The mitotic checkpoint delays segregation of chromosomes during mitosis until all chromosomes are properly attached to the mitotic spindle.  Its inactivation will therefore lead to increased segregation errors.  Indeed, we show that this can lead to increased cell death in tumor cells.  We demonstrate that increased cell death is associated with a dramatic increase in segregation errors.  This suggests that inhibition of the mitotic checkpoint might represent a useful anti-cancer strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTx5ZlxKChceNts4TFFB11gfW6udTcc2eYPUxqBJcewArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnot1Wkug%253D%253D&md5=7ea1be16c9e26670ce447b0caca260c3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs12672-010-0059-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12672-010-0059-x%26sid%3Dliteratum%253Aachs%26aulast%3DJanssen%26aufirst%3DA.%26aulast%3DKops%26aufirst%3DG.%2BJ.%26aulast%3DMedema%26aufirst%3DR.%2BH.%26atitle%3DTargeting%2520the%2520Mitotic%2520Checkpoint%2520to%2520Kill%2520Tumor%2520Cells%26jtitle%3DHorm.%2520Cancer%26date%3D2011%26volume%3D2%26spage%3D113%26epage%3D116%26doi%3D10.1007%2Fs12672-010-0059-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jemaà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kepp, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senovilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boemer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prechtl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrieu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castedo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Characterization of Novel MPS1 Inhibitors with Preclinical Anticancer Activity</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1532</span>– <span class="NLM_lpage">1545</span>, <span class="refDoi"> DOI: 10.1038/cdd.2013.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1038%2Fcdd.2013.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=23933817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2gurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1532-1545&author=M.+Jema%C3%A0author=L.+Galluzziauthor=O.+Keppauthor=L.+Senovillaauthor=M.+Brandsauthor=U.+Boemerauthor=M.+Koppitzauthor=P.+Lienauauthor=S.+Prechtlauthor=V.+Schulzeauthor=G.+Siemeisterauthor=A.+M.+Wengnerauthor=D.+Mumbergauthor=K.+Ziegelbauerauthor=A.+Abrieuauthor=M.+Castedoauthor=I.+Vitaleauthor=G.+Kroemer&title=Characterization+of+Novel+MPS1+Inhibitors+with+Preclinical+Anticancer+Activity&doi=10.1038%2Fcdd.2013.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of novel MPS1 inhibitors with preclinical anticancer activity</span></div><div class="casAuthors">Jemaa, M.; Galluzzi, L.; Kepp, O.; Senovilla, L.; Brands, M.; Boemer, U.; Koppitz, M.; Lienau, P.; Prechtl, S.; Schulze, V.; Siemeister, G.; Wengner, A. M.; Mumberg, D.; Ziegelbauer, K.; Abrieu, A.; Castedo, M.; Vitale, I.; Kroemer, G.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1532-1545</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Monopolar spindle 1 (MPS1), a mitotic kinase that is overexpressed in several human cancers, contributes to the alignment of chromosomes to the metaphase plate as well as to the execution of the spindle assembly checkpoint (SAC).  Here, we report the identification and functional characterization of three novel inhibitors of MPS1 of two independent structural classes, N-(4-{2-[(2-cyanophenyl)amino][1,2,4]triazolo[1,5-a]pyridin-6-yl}phenyl)-2-phenylacetamide (Mps-BAY1) (a triazolopyridine), N-cyclopropyl-4-{8-[(2-methylpropyl)amino]-6-(quinolin-5-yl)imidazo[1,2-a]pyrazin-3-yl}benzamide (Mps-BAY2a) and N-cyclopropyl-4-{8-(isobutylamino)imidazo[1,2-a]pyrazin-3-yl}benzamide (Mps-BAY2b) (two imidazopyrazines).  By selectively inactivating MPS1, these small inhibitors can arrest the proliferation of cancer cells, causing their polyploidization and/or their demise.  Cancer cells treated with Mps-BAY1 or Mps-BAY2a manifested multiple signs of mitotic perturbation including inefficient chromosomal congression during metaphase, unscheduled SAC inactivation and severe anaphase defects.  Videomicroscopic cell fate profiling of histone 2B-green fluorescent protein-expressing cells revealed the capacity of MPS1 inhibitors to subvert the correct timing of mitosis as they induce a premature anaphase entry in the context of misaligned metaphase plates.  Hence, in the presence of MPS1 inhibitors, cells either divided in a bipolar (but often asym.) manner or entered one or more rounds of abortive mitoses, generating gross aneuploidy and polyploidy, resp.  In both cases, cells ultimately succumbed to the mitotic catastrophe-induced activation of the mitochondrial pathway of apoptosis.  Of note, low doses of MPS1 inhibitors and paclitaxel (a microtubular poison) synergized at increasing the frequency of chromosome misalignments and missegregations in the context of SAC inactivation.  This resulted in massive polyploidization followed by the activation of mitotic catastrophe.  A synergistic interaction between paclitaxel and MPS1 inhibitors could also be demonstrated in vivo, as the combination of these agents efficiently reduced the growth of tumor xenografts and exerted superior antineoplastic effects compared with either compd. employed alone.  Altogether, these results suggest that MPS1 inhibitors may exert robust anticancer activity, either as standalone therapeutic interventions or combined with microtubule-targeting chems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHoriIGxHO_rVg90H21EOLACvtfcHk0liTfYx5Npvxjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2gurjI&md5=867fb902b15b6df0f7049b069bd47a4c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2013.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2013.105%26sid%3Dliteratum%253Aachs%26aulast%3DJema%25C3%25A0%26aufirst%3DM.%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DKepp%26aufirst%3DO.%26aulast%3DSenovilla%26aufirst%3DL.%26aulast%3DBrands%26aufirst%3DM.%26aulast%3DBoemer%26aufirst%3DU.%26aulast%3DKoppitz%26aufirst%3DM.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DPrechtl%26aufirst%3DS.%26aulast%3DSchulze%26aufirst%3DV.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DAbrieu%26aufirst%3DA.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DCharacterization%2520of%2520Novel%2520MPS1%2520Inhibitors%2520with%2520Preclinical%2520Anticancer%2520Activity%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2013%26volume%3D20%26spage%3D1532%26epage%3D1545%26doi%3D10.1038%2Fcdd.2013.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldarelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennecozzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sola, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappella, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Re Depaolini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cucchi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colotta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moll, J.</span></span> <span> </span><span class="NLM_article-title">Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">10255</span>– <span class="NLM_lpage">10264</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-2101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1158%2F0008-5472.CAN-10-2101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=21159646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGrt7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=10255-10264&author=R.+Colomboauthor=M.+Caldarelliauthor=M.+Mennecozziauthor=M.+L.+Giorginiauthor=F.+Solaauthor=P.+Cappellaauthor=C.+Perreraauthor=S.+Re+Depaoliniauthor=L.+Rusconiauthor=U.+Cucchiauthor=N.+Avanziauthor=J.+A.+Bertrandauthor=R.+T.+Bossiauthor=E.+Pesentiauthor=A.+Galvaniauthor=A.+Isacchiauthor=F.+Colottaauthor=D.+Donatiauthor=J.+Moll&title=Targeting+the+Mitotic+Checkpoint+for+Cancer+Therapy+with+NMS-P715%2C+an+Inhibitor+of+MPS1+Kinase&doi=10.1158%2F0008-5472.CAN-10-2101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase</span></div><div class="casAuthors">Colombo, Riccardo; Caldarelli, Marina; Mennecozzi, Milena; Giorgini, Maria Laura; Sola, Francesco; Cappella, Paolo; Perrera, Claudia; Depaolini, Stefania Re; Rusconi, Luisa; Cucchi, Ulisse; Avanzi, Nilla; Bertrand, Jay Aaron; Bossi, Roberto Tiberio; Pesenti, Enrico; Galvani, Arturo; Isacchi, Antonella; Colotta, Francesco; Donati, Daniele; Moll, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10255-10264</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">MPS1 kinase is a key regulator of the spindle assembly checkpoint (SAC), a mitotic mechanism specifically required for proper chromosomal alignment and segregation.  It has been found aberrantly overexpressed in a wide range of human tumors and is necessary for tumoral cell proliferation.  Here the authors report the identification and characterization of NMS-P715, a selective and orally bioavailable MPS1 small-mol. inhibitor, which selectively reduces cancer cell proliferation, leaving normal cells almost unaffected.  NMS-P715 accelerates mitosis and affects kinetochore components localization causing massive aneuploidy and cell death in a variety of tumoral cell lines and inhibits tumor growth in preclin. cancer models.  Inhibiting the SAC could represent a promising new approach to selectively target cancer cells.  Cancer Res; 70(24); 10255-64.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJeGyiQf0_uLVg90H21EOLACvtfcHk0liTfYx5Npvxjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGrt7bK&md5=6478b34886d1d2f2a364d142bbd388fe</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-2101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-2101%26sid%3Dliteratum%253Aachs%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DCaldarelli%26aufirst%3DM.%26aulast%3DMennecozzi%26aufirst%3DM.%26aulast%3DGiorgini%26aufirst%3DM.%2BL.%26aulast%3DSola%26aufirst%3DF.%26aulast%3DCappella%26aufirst%3DP.%26aulast%3DPerrera%26aufirst%3DC.%26aulast%3DRe%2BDepaolini%26aufirst%3DS.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DCucchi%26aufirst%3DU.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DColotta%26aufirst%3DF.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DMoll%26aufirst%3DJ.%26atitle%3DTargeting%2520the%2520Mitotic%2520Checkpoint%2520for%2520Cancer%2520Therapy%2520with%2520NMS-P715%252C%2520an%2520Inhibitor%2520of%2520MPS1%2520Kinase%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D10255%26epage%3D10264%26doi%3D10.1158%2F0008-5472.CAN-10-2101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tardif, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassiano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimbora, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinnon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douce, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorweiler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostanin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papac, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baichwal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAlexander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willardsen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wettstein, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B. L.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Cellular and Antitumor Effects of MPI-0479605, a Small-Molecule Inhibitor of the Mitotic Kinase Mps1</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2267</span>– <span class="NLM_lpage">2275</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1158%2F1535-7163.MCT-11-0453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=21980130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2267-2275&author=K.+D.+Tardifauthor=A.+Rogersauthor=J.+Cassianoauthor=B.+L.+Rothauthor=D.+M.+Cimboraauthor=R.+McKinnonauthor=A.+Petersonauthor=T.+B.+Douceauthor=R.+Robinsonauthor=I.+Dorweilerauthor=T.+Davisauthor=M.+A.+Hessauthor=K.+Ostaninauthor=D.+I.+Papacauthor=V.+Baichwalauthor=I.+McAlexanderauthor=J.+A.+Willardsenauthor=M.+Saundersauthor=H.+Christopheauthor=D.+V.+Kumarauthor=D.+A.+Wettsteinauthor=R.+O.+Carlsonauthor=B.+L.+Williams&title=Characterization+of+the+Cellular+and+Antitumor+Effects+of+MPI-0479605%2C+a+Small-Molecule+Inhibitor+of+the+Mitotic+Kinase+Mps1&doi=10.1158%2F1535-7163.MCT-11-0453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Cellular and Antitumor Effects of MPI-0479605, a Small-Molecule Inhibitor of the Mitotic Kinase Mps1</span></div><div class="casAuthors">Tardif, Keith D.; Rogers, Aaron; Cassiano, Jared; Roth, Bruce L.; Cimbora, Daniel M.; McKinnon, Rena; Peterson, Ashley; Douce, Thomas B.; Robinson, Rosann; Dorweiler, Irene; Davis, Thaylon; Hess, Mark A.; Ostanin, Kirill; Papac, Damon I.; Baichwal, Vijay; McAlexander, Ian; Willardsen, J. Adam; Saunders, Michael; Christophe, Hoarau; Kumar, D. Vijay; Wettstein, Daniel A.; Carlson, Robert O.; Williams, Brandi L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2267-2275</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mps1 is a dual specificity protein kinase that is essential for the bipolar attachment of chromosomes to the mitotic spindle and for maintaining the spindle assembly checkpoint until all chromosomes are properly attached.  Mps1 is expressed at high levels during mitosis and is abundantly expressed in cancer cells.  Disruption of Mps1 function induces aneuploidy and cell death.  We report the identification of MPI-0479605, a potent and selective ATP competitive inhibitor of Mps1.  Cells treated with MPI-0479605 undergo aberrant mitosis, resulting in aneuploidy and formation of micronuclei.  In cells with wild-type p53, this promotes the induction of a postmitotic checkpoint characterized by the ATM- and RAD3-related-dependent activation of the p53-p21 pathway.  In both wild-type and p53 mutant cells lines, there is a growth arrest and inhibition of DNA synthesis.  Subsequently, cells undergo mitotic catastrophe and/or an apoptotic response.  In xenograft models, MPI-0479605 inhibits tumor growth, suggesting that drugs targeting Mps1 may have utility as novel cancer therapeutics.  Mol Cancer Ther; 10(12); 2267-75.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMIODujnZWCLVg90H21EOLACvtfcHk0liBdEZsZrdmSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnO&md5=e243764443e9dfda40fc84a329d776c2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0453%26sid%3Dliteratum%253Aachs%26aulast%3DTardif%26aufirst%3DK.%2BD.%26aulast%3DRogers%26aufirst%3DA.%26aulast%3DCassiano%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DCimbora%26aufirst%3DD.%2BM.%26aulast%3DMcKinnon%26aufirst%3DR.%26aulast%3DPeterson%26aufirst%3DA.%26aulast%3DDouce%26aufirst%3DT.%2BB.%26aulast%3DRobinson%26aufirst%3DR.%26aulast%3DDorweiler%26aufirst%3DI.%26aulast%3DDavis%26aufirst%3DT.%26aulast%3DHess%26aufirst%3DM.%2BA.%26aulast%3DOstanin%26aufirst%3DK.%26aulast%3DPapac%26aufirst%3DD.%2BI.%26aulast%3DBaichwal%26aufirst%3DV.%26aulast%3DMcAlexander%26aufirst%3DI.%26aulast%3DWillardsen%26aufirst%3DJ.%2BA.%26aulast%3DSaunders%26aufirst%3DM.%26aulast%3DChristophe%26aufirst%3DH.%26aulast%3DKumar%26aufirst%3DD.%2BV.%26aulast%3DWettstein%26aufirst%3DD.%2BA.%26aulast%3DCarlson%26aufirst%3DR.%2BO.%26aulast%3DWilliams%26aufirst%3DB.%2BL.%26atitle%3DCharacterization%2520of%2520the%2520Cellular%2520and%2520Antitumor%2520Effects%2520of%2520MPI-0479605%252C%2520a%2520Small-Molecule%2520Inhibitor%2520of%2520the%2520Mitotic%2520Kinase%2520Mps1%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2267%26epage%3D2275%26doi%3D10.1158%2F1535-7163.MCT-11-0453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tighe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santaguida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musacchio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. S.</span></span> <span> </span><span class="NLM_article-title">Sustained Mps1 Activity is Required in Mitosis to Recruit O-Mad2 to the Mad1–C-Mad2 Core Complex</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1083/jcb.201002133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1083%2Fjcb.201002133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=20624899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVOht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2010&pages=25-34&author=L.+Hewittauthor=A.+Tigheauthor=S.+Santaguidaauthor=A.+M.+Whiteauthor=C.+D.+Jonesauthor=A.+Musacchioauthor=S.+Greenauthor=S.+S.+Taylor&title=Sustained+Mps1+Activity+is+Required+in+Mitosis+to+Recruit+O-Mad2+to+the+Mad1%E2%80%93C-Mad2+Core+Complex&doi=10.1083%2Fjcb.201002133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex</span></div><div class="casAuthors">Hewitt, Laura; Tighe, Anthony; Santaguida, Stefano; White, Anne M.; Jones, Clifford D.; Musacchio, Andrea; Green, Stephen; Taylor, Stephen S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-34</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Mps1 is an essential component of the spindle assembly checkpoint.  In this study, we describe a novel Mps1 inhibitor, AZ3146, and use it to probe the role of Mps1's catalytic activity during mitosis.  When Mps1 is inhibited before mitotic entry, subsequent recruitment of Mad1 and Mad2 to kinetochores is abolished.  However, if Mps1 is inhibited after mitotic entry, the Mad1-C-Mad2 core complex remains kinetochore bound, but O-Mad2 is not recruited to the core.  Although inhibiting Mps1 also interferes with chromosome alignment, we see no obvious effect on aurora B activity.  In contrast, kinetochore recruitment of centromere protein E (CENP-E), a kinesin-related motor protein, is severely impaired.  Strikingly, inhibition of Mps1 significantly increases its own abundance at kinetochores.  Furthermore, we show that Mps1 can dimerize and transphosphorylate in cells.  We propose a model whereby Mps1 transphosphorylation results in its release from kinetochores, thus facilitating recruitment of O-Mad2 and CENP-E and thereby simultaneously promoting checkpoint signaling and chromosome congression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr40BfrYS2Vu7Vg90H21EOLACvtfcHk0liBdEZsZrdmSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVOht7Y%253D&md5=2b95cfba4b228bada877bdb6dc95be1f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201002133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201002133%26sid%3Dliteratum%253Aachs%26aulast%3DHewitt%26aufirst%3DL.%26aulast%3DTighe%26aufirst%3DA.%26aulast%3DSantaguida%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DA.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DMusacchio%26aufirst%3DA.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26atitle%3DSustained%2520Mps1%2520Activity%2520is%2520Required%2520in%2520Mitosis%2520to%2520Recruit%2520O-Mad2%2520to%2520the%2520Mad1%25E2%2580%2593C-Mad2%2520Core%2520Complex%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2010%26volume%3D190%26spage%3D25%26epage%3D34%26doi%3D10.1083%2Fjcb.201002133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Innocenti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westwood, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faisal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, G. W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Haven Brandon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Fee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saville, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matijssen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Montfort, R. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linardopoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoelder, S.</span></span> <span> </span><span class="NLM_article-title">Rapid Discovery of Pyrido[3,4-<i>d</i>]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3671</span>– <span class="NLM_lpage">3688</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01811</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01811" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsF2qsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3671-3688&author=P.+Innocentiauthor=H.+L.+Woodwardauthor=S.+Solankiauthor=S.+Naudauthor=I.+M.+Westwoodauthor=N.+Croninauthor=A.+Hayesauthor=J.+Robertsauthor=A.+T.+Henleyauthor=R.+Bakerauthor=A.+Faisalauthor=G.+W.-Y.+Makauthor=G.+Boxauthor=M.+Valentiauthor=A.+De+Haven+Brandonauthor=L.+O%E2%80%99Feeauthor=H.+Savilleauthor=J.+Schmittauthor=B.+Matijssenauthor=R.+Burkeauthor=R.+L.+M.+van+Montfortauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=S.+Linardopoulosauthor=J.+Blaggauthor=S.+Hoelder&title=Rapid+Discovery+of+Pyrido%5B3%2C4-d%5Dpyrimidine+Inhibitors+of+Monopolar+Spindle+Kinase+1+%28MPS1%29+Using+a+Structure-Based+Hybridization+Approach&doi=10.1021%2Facs.jmedchem.5b01811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach</span></div><div class="casAuthors">Innocenti, Paolo; Woodward, Hannah L.; Solanki, Savade; Naud, Sebastien; Westwood, Isaac M.; Cronin, Nora; Hayes, Angela; Roberts, Jennie; Henley, Alan T.; Baker, Ross; Faisal, Amir; Mak, Grace Wing-Yan; Box, Gary; Valenti, Melanie; De Haven Brandon, Alexis; O'Fee, Lisa; Saville, Harry; Schmitt, Jessica; Matijssen, Berry; Burke, Rosemary; van Montfort, Rob L. M.; Raynaud, Florence I.; Eccles, Suzanne A.; Linardopoulos, Spiros; Blagg, Julian; Hoelder, Swen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3671-3688</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monopolar spindle 1 (MPS1) plays a central role in the transition of cells from metaphase to anaphase and is one of the main components of the spindle assembly checkpoint.  Chromosomally unstable cancer cells rely heavily on MPS1 to cope with the stress arising from abnormal nos. of chromosomes and centrosomes and are thus more sensitive to MPS1 inhibition than normal cells.  We report the discovery and optimization of a series of new pyrido[3,4-d]pyrimidine based inhibitors via a structure-based hybridization approach from our previously reported inhibitor CCT251455 and a modestly potent screening hit.  Compds. in this novel series display excellent potency and selectivity for MPS1, which translates into biomarker modulation in an in vivo human tumor xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr42v6loNvM1bVg90H21EOLACvtfcHk0liBdEZsZrdmSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsF2qsro%253D&md5=dd858ed11744e0b036061baf5e2c181a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01811%26sid%3Dliteratum%253Aachs%26aulast%3DInnocenti%26aufirst%3DP.%26aulast%3DWoodward%26aufirst%3DH.%2BL.%26aulast%3DSolanki%26aufirst%3DS.%26aulast%3DNaud%26aufirst%3DS.%26aulast%3DWestwood%26aufirst%3DI.%2BM.%26aulast%3DCronin%26aufirst%3DN.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DJ.%26aulast%3DHenley%26aufirst%3DA.%2BT.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DMak%26aufirst%3DG.%2BW.-Y.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DDe%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Fee%26aufirst%3DL.%26aulast%3DSaville%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DJ.%26aulast%3DMatijssen%26aufirst%3DB.%26aulast%3DBurke%26aufirst%3DR.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%2BM.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DLinardopoulos%26aufirst%3DS.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DRapid%2520Discovery%2520of%2520Pyrido%255B3%252C4-d%255Dpyrimidine%2520Inhibitors%2520of%2520Monopolar%2520Spindle%2520Kinase%25201%2520%2528MPS1%2529%2520Using%2520a%2520Structure-Based%2520Hybridization%2520Approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3671%26epage%3D3688%26doi%3D10.1021%2Facs.jmedchem.5b01811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rymer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanochko, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trajkovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappin, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span> <span> </span><span class="NLM_article-title">Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e0138616</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0138616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1371%2Fjournal.pone.0138616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=26398286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ymsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0138616&author=R.+Martinezauthor=A.+Blasinaauthor=J.+F.+Hallinauthor=W.+Huauthor=I.+Rymerauthor=J.+Fanauthor=R.+L.+Hoffmanauthor=S.+Murphyauthor=M.+Marxauthor=G.+Yanochkoauthor=D.+Trajkovicauthor=D.+Dinhauthor=S.+Timofeevskiauthor=Z.+Zhuauthor=P.+Sunauthor=P.+B.+Lappinauthor=B.+W.+Murray&title=Mitotic+Checkpoint+Kinase+Mps1+Has+a+Role+in+Normal+Physiology+which+Impacts+Clinical+Utility&doi=10.1371%2Fjournal.pone.0138616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mitotic checkpoint kinase Mps1 has a role in normal physiology which impacts clinical utility</span></div><div class="casAuthors">Martinez, Ricardo; Blasina, Alessandra; Hallin, Jill F.; Hu, Wenyue; Rymer, Isha; Fan, Jeffery; Hoffman, Robert L.; Murphy, Sean; Marx, Matthew; Yanochko, Gina; Trajkovic, Dusko; Dinh, Dac; Timofeevski, Sergei; Zhu, Zhou; Sun, Peiquing; Lappin, Patrick B.; Murray, Brion W.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e0138616/1-e0138616/23</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Cell cycle checkpoint intervention is an effective therapeutic strategy for cancer when applied to patients predisposed to respond and the treatment is well-tolerated.  A crit. cell cycle process that could be targeted is the mitotic checkpoint (spindle assembly checkpoint) which governs the metaphase-to-anaphase transition and insures proper chromosomal segregation.  The mitotic checkpoint kinase Mps1 was selected to explore whether enhancement in genomic instability is a viable therapeutic strategy.  The basal-a subset of triple-neg. breast cancer was chosen as a model system because it has a higher incidence of chromosomal instability and Mps1 expression is up-regulated.  Depletion of Mps1 reduces tumor cell viability relative to normal cells.  Highly selective, extremely potent Mps1 kinase inhibitors were created to investigate the roles of Mps1 catalytic activity in tumor cells and normal physiol. (PF-7006, PF-3837; Ki<0.5 nM; cellular IC50 2-6 nM).  Treatment of tumor cells in vitro with PF-7006 modulates expected Mps1-dependent biol. as demonstrated by mol. and phenotypic measures (reduced pHH3-Ser10 levels, shorter duration of mitosis, micro-nucleation, and apoptosis).  Tumor-bearing mice treated with PF-7006 exhibit tumor growth inhibition concomitant with pharmacodynamic modulation of a downstream biomarker (pHH3-Ser10).  Unfortunately, efficacy only occurs at drug exposures that cause dose-limiting body wt. loss, gastrointestinal toxicities, and neutropenia.  Mps1 inhibitor toxicities may be mitigated by inducing G1 cell cycle arrest in Rb1-competent cells with the cyclin-dependent kinase-4/6 inhibitor palbociclib.  Using an isogenic cellular model system, PF-7006 is shown to be selectively cytotoxic to Rb1-deficient cells relative to Rb1-competent cells (also a measure of kinase selectivity).  Human bone marrow cells pretreated with palbociclib have decreased PF-7006-dependent apoptosis relative to cells without palbociclib pretreatment.  Collectively, this study raises a concern that single agent therapies inhibiting Mps1 will not be well-tolerated clin. but may be when combined with a selective CDK4/6 drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc-9LR3Gfty7Vg90H21EOLACvtfcHk0lguqxNEhc7pEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ymsLo%253D&md5=68fc918b70df2cd020be0c4fec209c12</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0138616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0138616%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DBlasina%26aufirst%3DA.%26aulast%3DHallin%26aufirst%3DJ.%2BF.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DRymer%26aufirst%3DI.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DMurphy%26aufirst%3DS.%26aulast%3DMarx%26aufirst%3DM.%26aulast%3DYanochko%26aufirst%3DG.%26aulast%3DTrajkovic%26aufirst%3DD.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DLappin%26aufirst%3DP.%2BB.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DMitotic%2520Checkpoint%2520Kinase%2520Mps1%2520Has%2520a%2520Role%2520in%2520Normal%2520Physiology%2520which%2520Impacts%2520Clinical%2520Utility%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0138616%26doi%3D10.1371%2Fjournal.pone.0138616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ide, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daigo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagashira, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanazawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishioka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kido, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Imidazo[1,2-<i>b</i>]pyridazine Derivatives: Selective and Orally Available Mps1 (TTK) Kinase Inhibitors Exhibiting Remarkable Antiproliferative Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1760</span>– <span class="NLM_lpage">1775</span>, <span class="refDoi"> DOI: 10.1021/jm501599u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501599u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2it7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1760-1775&author=K.+Kusakabeauthor=N.+Ideauthor=Y.+Daigoauthor=T.+Itohauthor=T.+Yamamotoauthor=H.+Hashizumeauthor=K.+Nozuauthor=H.+Yoshidaauthor=G.+Tadanoauthor=S.+Tagashiraauthor=K.+Higashinoauthor=Y.+Okanoauthor=Y.+Satoauthor=M.+Inoueauthor=M.+Iguchiauthor=T.+Kanazawaauthor=Y.+Ishiokaauthor=K.+Dohiauthor=Y.+Kidoauthor=S.+Sakamotoauthor=S.+Andoauthor=M.+Maedaauthor=M.+Higakiauthor=Y.+Babaauthor=Y.+Nakamura&title=Discovery+of+Imidazo%5B1%2C2-b%5Dpyridazine+Derivatives%3A+Selective+and+Orally+Available+Mps1+%28TTK%29+Kinase+Inhibitors+Exhibiting+Remarkable+Antiproliferative+Activity&doi=10.1021%2Fjm501599u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Imidazo[1,2-b]pyridazine Derivatives: Selective and Orally Available Mps1 (TTK) Kinase Inhibitors Exhibiting Remarkable Antiproliferative Activity</span></div><div class="casAuthors">Kusakabe, Ken-ichi; Ide, Nobuyuki; Daigo, Yataro; Itoh, Takeshi; Yamamoto, Takahiko; Hashizume, Hiroshi; Nozu, Kohei; Yoshida, Hiroshi; Tadano, Genta; Tagashira, Sachie; Higashino, Kenichi; Okano, Yousuke; Sato, Yuji; Inoue, Makiko; Iguchi, Motofumi; Kanazawa, Takayuki; Ishioka, Yukichi; Dohi, Keiji; Kido, Yasuto; Sakamoto, Shingo; Ando, Shigeru; Maeda, Masahiro; Higaki, Masayo; Baba, Yoshiyasu; Nakamura, Yusuke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1760-1775</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Monopolar spindle 1 (Mps1) is an attractive oncol. target due to its high expression level in cancer cells as well as the correlation of its expression levels with histol. grades of cancers.  An imidazo[1,2-a]pyrazine 10a was identified during an HTS campaign.  Although 10a exhibited good biochem. activity, its moderate cellular as well as antiproliferative activities needed to be improved.  The cocrystal structure of an analog of 10a guided our lead optimization to introduce substituents at the 6-position of the scaffold, giving the 6-aryl substituted 21b which had improved cellular activity but no oral bioavailability in rat.  Property-based optimization at the 6-position and a scaffold change led to the discovery of the imidazo[1,2-b]pyridazine-based 27f, an extremely potent (cellular Mps1 IC50 = 0.70 nM, A549 IC50 = 6.0 nM), selective Mps1 inhibitor over 192 kinases, which could be orally administered and was active in vivo.  This 27f demonstrated remarkable antiproliferative activity in the nanomolar range against various tissue cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8D9nRl5vWabVg90H21EOLACvtfcHk0lguqxNEhc7pEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2it7g%253D&md5=bee62a50247a363dc3e35fcdeac6a64f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm501599u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501599u%26sid%3Dliteratum%253Aachs%26aulast%3DKusakabe%26aufirst%3DK.%26aulast%3DIde%26aufirst%3DN.%26aulast%3DDaigo%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DNozu%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DTadano%26aufirst%3DG.%26aulast%3DTagashira%26aufirst%3DS.%26aulast%3DHigashino%26aufirst%3DK.%26aulast%3DOkano%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DIguchi%26aufirst%3DM.%26aulast%3DKanazawa%26aufirst%3DT.%26aulast%3DIshioka%26aufirst%3DY.%26aulast%3DDohi%26aufirst%3DK.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DSakamoto%26aufirst%3DS.%26aulast%3DAndo%26aufirst%3DS.%26aulast%3DMaeda%26aufirst%3DM.%26aulast%3DHigaki%26aufirst%3DM.%26aulast%3DBaba%26aufirst%3DY.%26aulast%3DNakamura%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Imidazo%255B1%252C2-b%255Dpyridazine%2520Derivatives%253A%2520Selective%2520and%2520Orally%2520Available%2520Mps1%2520%2528TTK%2529%2520Kinase%2520Inhibitors%2520Exhibiting%2520Remarkable%2520Antiproliferative%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1760%26epage%3D1775%26doi%3D10.1021%2Fjm501599u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brokx, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beletskaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awrey, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiarash, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madeira, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, H. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-(4-Aminopyrazolo[1,5-<i>a</i>][1,3,5]triazin-8-yl)benzamides as Novel, Highly Potent and Selective, Orally Bioavailable Inhibitors of Tyrosine Threonine Kinase, TTK</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3562</span>– <span class="NLM_lpage">3566</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1016%2Fj.bmcl.2016.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=27335255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKgtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3562-3566&author=R.+Lauferauthor=S.-W.+Liauthor=Y.+Liuauthor=G.+Ngauthor=Y.+Langauthor=M.+Feherauthor=R.+Brokxauthor=I.+Beletskayaauthor=R.+Hodgsonauthor=G.+Maoauthor=O.+Plotnikovaauthor=D.+E.+Awreyauthor=J.+M.+Masonauthor=X.+Weiauthor=D.+C.-C.+Linauthor=Y.+Cheauthor=R.+Kiarashauthor=B.+Madeiraauthor=G.+C.+Fletcherauthor=T.+W.+Makauthor=M.+R.+Brayauthor=H.+W.+Pauls&title=Discovery+of+4-%284-Aminopyrazolo%5B1%2C5-a%5D%5B1%2C3%2C5%5Dtriazin-8-yl%29benzamides+as+Novel%2C+Highly+Potent+and+Selective%2C+Orally+Bioavailable+Inhibitors+of+Tyrosine+Threonine+Kinase%2C+TTK&doi=10.1016%2Fj.bmcl.2016.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK</span></div><div class="casAuthors">Laufer, Radoslaw; Li, Sze-Wan; Liu, Yong; Ng, Grace; Lang, Yunhui; Feher, Miklos; Brokx, Richard; Beletskaya, Irina; Hodgson, Richard; Mao, Guodong; Plotnikova, Olga; Awrey, Donald E.; Mason, Jacqueline M.; Wei, Xin; Lin, Dan Chi-Chia; Che, Yi; Kiarash, Reza; Madeira, Brian; Fletcher, Graham C.; Mak, Tak W.; Bray, Mark R.; Pauls, Henry W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3562-3566</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">TTK/Mps1 is a key kinase controlling progression of cell division via participation in the mitotic spindle assembly checkpoint and is overexpressed in a no. of human cancers.  Herein the authors report the discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as a potent, novel class of TTK inhibitors.  The series was identified by bioisosteric replacement of the related imidazopyrazine and imidazopyridazine scaffolds.  Optimization led to the identification of compds. with excellent potency (Ki = 0.8 nM) and exceptional kinase selectivity.  The SAR indicates a strong dependence of activity on the presence of the N-cyclopropyl-2-methylbenzamide moiety delineating the geometry for 11/2 type kinase inhibitor.  Mol. modeling indicates the extensive and optimal contacts, mediated through H-bonds and hydrophobic interactions, are responsible for the selectivity and potency of the inhibitors.  The compds. demonstrate a strong anti-proliferative activity in a panel of human cancer cell lines (HCT116 GIC50 <15 nM) and good rodent pharmacokinetics (oral %F 97%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTb2Z2xtkAWLVg90H21EOLACvtfcHk0lj6wu_FSnGCug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKgtLnL&md5=d107d562ed4407d05bfbba57abcd6b98</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DS.-W.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DNg%26aufirst%3DG.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DBrokx%26aufirst%3DR.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DMao%26aufirst%3DG.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DD.%2BC.-C.%26aulast%3DChe%26aufirst%3DY.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DMadeira%26aufirst%3DB.%26aulast%3DFletcher%26aufirst%3DG.%2BC.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DBray%26aufirst%3DM.%2BR.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DDiscovery%2520of%25204-%25284-Aminopyrazolo%255B1%252C5-a%255D%255B1%252C3%252C5%255Dtriazin-8-yl%2529benzamides%2520as%2520Novel%252C%2520Highly%2520Potent%2520and%2520Selective%252C%2520Orally%2520Bioavailable%2520Inhibitors%2520of%2520Tyrosine%2520Threonine%2520Kinase%252C%2520TTK%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3562%26epage%3D3566%26doi%3D10.1016%2Fj.bmcl.2016.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abad-Zapatero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, J. T.</span></span> <span> </span><span class="NLM_article-title">Ligand Efficiency Indices as Guideposts for Drug Discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(05)03386-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1016%2FS1359-6446%2805%2903386-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=15809192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A280%3ADC%252BD2M7nsF2iug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=464-469&author=C.+Abad-Zapateroauthor=J.+T.+Metz&title=Ligand+Efficiency+Indices+as+Guideposts+for+Drug+Discovery&doi=10.1016%2FS1359-6446%2805%2903386-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency indices as guideposts for drug discovery</span></div><div class="casAuthors">Abad-Zapatero Cele; Metz James T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">464-9</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHqVfZXUq224qdXsLcGTEUfW6udTcc2ebeQNFNssJtvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7nsF2iug%253D%253D&md5=1720f263a306122c86a57463e5a39287</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2805%2903386-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252805%252903386-6%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26aulast%3DMetz%26aufirst%3DJ.%2BT.%26atitle%3DLigand%2520Efficiency%2520Indices%2520as%2520Guideposts%2520for%2520Drug%2520Discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D464%26epage%3D469%26doi%3D10.1016%2FS1359-6446%2805%2903386-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">Setting Expectations in Molecular Optimizations: Strengths and Limitations of Commonly used Composite Parameters</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5980</span>– <span class="NLM_lpage">5991</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1016%2Fj.bmcl.2013.08.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=24018190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSrs7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5980-5991&author=M.+D.+Shultz&title=Setting+Expectations+in+Molecular+Optimizations%3A+Strengths+and+Limitations+of+Commonly+used+Composite+Parameters&doi=10.1016%2Fj.bmcl.2013.08.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5980-5991</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Over the past 15 years there have been extensive efforts to understand and reduce the high attrition rates of drug candidates with an increased focus on physicochem. properties.  The fruits of this labor have been the generation of numerous efficiency indexes, metric-based rules and visualization tools to help guide medicinal chemists in the design of new compds. with more favorable properties.  This deluge of information may have had the unintended consequence of further obfuscating mol. optimizations by the inability of these scoring functions, rules and guides to reach a consensus on when a particular transformation is identified as beneficial.  In this manuscript, several composite parameters, or efficiency indexes, are examd. utilizing theor. and exptl. matched mol. pair analyses in order to understand the basis for how each will perform under varying scenarios of mol. optimizations.  In contrast to empirically derived composite parameters based on heavy atom count, lipophilic efficiency (LipE) sets consistent expectations regardless of mol. wt. or relative potency and can be used to generate consistent expectations for any matched mol. pair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJeTISXSJyLbVg90H21EOLACvtfcHk0lj6wu_FSnGCug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSrs7rI&md5=3b766e26254f482b75b8973888c13aec</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.029%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DSetting%2520Expectations%2520in%2520Molecular%2520Optimizations%253A%2520Strengths%2520and%2520Limitations%2520of%2520Commonly%2520used%2520Composite%2520Parameters%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5980%26epage%3D5991%26doi%3D10.1016%2Fj.bmcl.2013.08.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">The Thermodynamic Basis for the Use of Lipophilic Efficiency (LipE) in Enthalpic Optimizations</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5992</span>– <span class="NLM_lpage">6000</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1016%2Fj.bmcl.2013.08.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=24054120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOns73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5992-6000&author=M.+D.+Shultz&title=The+Thermodynamic+Basis+for+the+Use+of+Lipophilic+Efficiency+%28LipE%29+in+Enthalpic+Optimizations&doi=10.1016%2Fj.bmcl.2013.08.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5992-6000</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Approaches to improve the efficiency of mol. optimizations have received great attention and numerous efficiency metrics have been introduced to assist in this effort.  Optimization of properties is equally important to optimization of potency and therefore these metrics contain potency vs. property calcns.  Widespread use of a metric does not guarantee its accuracy and a further understanding of which, if any, metric increases the probability of success was sought.  An anal. of LE, LELP and LipE based on theor. and exptl. data was performed demonstrating that LipE most strongly correlates with compd. quality as defined by enthalpy-driven binding.  The basis for the prioritization of LipE over other metrics in enthalpic optimizations is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobuMO74LdKnbVg90H21EOLACvtfcHk0liiUi3TZCAbVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOns73P&md5=23d948d1135eeefdfebc60846f28ec2b</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.030%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DThe%2520Thermodynamic%2520Basis%2520for%2520the%2520Use%2520of%2520Lipophilic%2520Efficiency%2520%2528LipE%2529%2520in%2520Enthalpic%2520Optimizations%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5992%26epage%3D6000%26doi%3D10.1016%2Fj.bmcl.2013.08.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The Influence of Drug-like Concepts on Decision-making in Medicinal Chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+Influence+of+Drug-like+Concepts+on+Decision-making+in+Medicinal+Chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0liiUi3TZCAbVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520Influence%2520of%2520Drug-like%2520Concepts%2520on%2520Decision-making%2520in%2520Medicinal%2520Chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verček, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogorevc, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanovnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tišler, M.</span></span> <span> </span><span class="NLM_article-title">Cyanoamino Compounds in Synthesis. Syntheses of Some Heterocycles</span>. <i>Monatsh. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.1007/BF01134190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1007%2FBF01134190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADyaL2cXltFGitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1983&pages=789-798&author=B.+Ver%C4%8Dekauthor=B.+Ogorevcauthor=B.+Stanovnikauthor=M.+Ti%C5%A1ler&title=Cyanoamino+Compounds+in+Synthesis.+Syntheses+of+Some+Heterocycles&doi=10.1007%2FBF01134190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cyanoamino compounds in synthesis.  Syntheses of some heterocycles</span></div><div class="casAuthors">Vercek, Bojan; Ogorevc, Bozidar; Stanovnik, Branko; Tisler, Miha</div><div class="citationInfo"><span class="NLM_cas:title">Monatshefte fuer Chemie</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">789-98</span>CODEN:
                <span class="NLM_cas:coden">MOCMB7</span>;
        ISSN:<span class="NLM_cas:issn">0026-9247</span>.
    </div><div class="casAbstract">Transformations of some heterocyclic cyanoamino compds. leading to various heterocyclic systems are described.  s-Triazolo[1,5-a]azines, e.g. I, II, and III, are obtained either in a direct synthetic approach or via the substituted aminotetrazoles, substituted 3-amino-5-oxo-1,2,4-oxadiazolines, and from N-ethoxycarbonyl N'-heteroaryl thioureas or N-heteroaryl N'-hydroxyguanidine.  Thus, 2-(cyanoamino)pyridine cyclized with Me3SiN3 to give the tetrazole IV, which was cyclized with polyphosphoric acid to give I.  The cyanoamino group reacts also with o-difunctional benzenes to give the corresponding substituted derivs. of benzimidazole, benzoxazole or benzothiazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovqVshQOSm87Vg90H21EOLACvtfcHk0liiUi3TZCAbVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXltFGitQ%253D%253D&md5=32d36961bd0e42a34b73bbed4268a553</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2FBF01134190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01134190%26sid%3Dliteratum%253Aachs%26aulast%3DVer%25C4%258Dek%26aufirst%3DB.%26aulast%3DOgorevc%26aufirst%3DB.%26aulast%3DStanovnik%26aufirst%3DB.%26aulast%3DTi%25C5%25A1ler%26aufirst%3DM.%26atitle%3DCyanoamino%2520Compounds%2520in%2520Synthesis.%2520Syntheses%2520of%2520Some%2520Heterocycles%26jtitle%3DMonatsh.%2520Chem.%26date%3D1983%26volume%3D114%26spage%3D789%26epage%3D798%26doi%3D10.1007%2FBF01134190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, V.</span>; <span class="NLM_string-name">Koppitz, M.</span>; <span class="NLM_string-name">Kosemund, D.</span>; <span class="NLM_string-name">Schirok, H.</span>; <span class="NLM_string-name">Bader, B.</span>; <span class="NLM_string-name">Lienau, P.</span>; <span class="NLM_string-name">Wengner, A.</span>; <span class="NLM_string-name">Briem, H.</span>; <span class="NLM_string-name">Holton, S.</span>; <span class="NLM_string-name">Siemeister, G.</span>; <span class="NLM_string-name">Prechtl, S.</span>; <span class="NLM_string-name">Bömer, U.</span></span> <span> </span><span class="NLM_article-title">Triazolopyridines</span>. PCT Int. Appl. <span class="NLM_patent">WO 2011063908 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=V.+Schulze&author=M.+Koppitz&author=D.+Kosemund&author=H.+Schirok&author=B.+Bader&author=P.+Lienau&author=A.+Wengner&author=H.+Briem&author=S.+Holton&author=G.+Siemeister&author=S.+Prechtl&author=U.+B%C3%B6mer&title=Triazolopyridines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchulze%26aufirst%3DV.%26atitle%3DTriazolopyridines%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, V.</span>; <span class="NLM_string-name">Kosemund, D.</span>; <span class="NLM_string-name">Schirok, H.</span>; <span class="NLM_string-name">Bader, B.</span>; <span class="NLM_string-name">Lienau, P.</span>; <span class="NLM_string-name">Wengner, A. M.</span>; <span class="NLM_string-name">Briem, H.</span>; <span class="NLM_string-name">Holton, S.</span>; <span class="NLM_string-name">Siemeister, G.</span>; <span class="NLM_string-name">Prechtl, S.</span>; <span class="NLM_string-name">Koppitz, M.</span>; <span class="NLM_string-name">Stöckigt, D.</span>; <span class="NLM_string-name">Prien, O.</span></span> <span> </span><span class="NLM_article-title">Substituted Triazolopyridines</span>. PCT Int. Appl. <span class="NLM_patent">WO 2011157688 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=V.+Schulze&author=D.+Kosemund&author=H.+Schirok&author=B.+Bader&author=P.+Lienau&author=A.+M.+Wengner&author=H.+Briem&author=S.+Holton&author=G.+Siemeister&author=S.+Prechtl&author=M.+Koppitz&author=D.+St%C3%B6ckigt&author=O.+Prien&title=Substituted+Triazolopyridines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchulze%26aufirst%3DV.%26atitle%3DSubstituted%2520Triazolopyridines%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, V.</span>; <span class="NLM_string-name">Kosemund, D.</span>; <span class="NLM_string-name">Wengner, A. M.</span>; <span class="NLM_string-name">Siemeister, G.</span>; <span class="NLM_string-name">Stöckigt, D.</span>; <span class="NLM_string-name">Bruening, M.</span></span> <span> </span><span class="NLM_article-title">Substituted Triazolopyridines and Their Use as TTK Inhibitors</span>. PCT Int. Appl. <span class="NLM_patent">WO 2013087579 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=V.+Schulze&author=D.+Kosemund&author=A.+M.+Wengner&author=G.+Siemeister&author=D.+St%C3%B6ckigt&author=M.+Bruening&title=Substituted+Triazolopyridines+and+Their+Use+as+TTK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchulze%26aufirst%3DV.%26atitle%3DSubstituted%2520Triazolopyridines%2520and%2520Their%2520Use%2520as%2520TTK%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemeister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosemund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoeckigt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhaus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prechtl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raschke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frisk, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Ahsen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreft, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Nussbaum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brands, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span> <span> </span><span class="NLM_article-title">Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1158%2F1535-7163.MCT-15-0500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=26832791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVSqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=583-592&author=A.+M.+Wengnerauthor=G.+Siemeisterauthor=M.+Koppitzauthor=V.+Schulzeauthor=D.+Kosemundauthor=U.+Klarauthor=D.+Stoeckigtauthor=R.+Neuhausauthor=P.+Lienauauthor=B.+Baderauthor=S.+Prechtlauthor=M.+Raschkeauthor=A.-L.+Friskauthor=O.+von+Ahsenauthor=M.+Michelsauthor=B.+Kreftauthor=F.+von+Nussbaumauthor=M.+Brandsauthor=D.+Mumbergauthor=K.+Ziegelbauer&title=Novel+Mps1+Kinase+Inhibitors+with+Potent+Antitumor+Activity&doi=10.1158%2F1535-7163.MCT-15-0500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity</span></div><div class="casAuthors">Wengner, Antje M.; Siemeister, Gerhard; Koppitz, Marcus; Schulze, Volker; Kosemund, Dirk; Klar, Ulrich; Stoeckigt, Detlef; Neuhaus, Roland; Lienau, Philip; Bader, Benjamin; Prechtl, Stefan; Raschke, Marian; Frisk, Anna-Lena; von Ahsen, Oliver; Michels, Martin; Kreft, Bertolt; von Nussbaum, Franz; Brands, Michael; Mumberg, Dominik; Ziegelbauer, Karl</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">583-592</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Monopolar spindle 1 (Mps1) has been shown to function as the key kinase that activates the spindle assembly checkpoint (SAC) to secure proper distribution of chromosomes to daughter cells.  Here, we report the structure and functional characterization of two novel selective Mps1 inhibitors, BAY 1161909 and BAY 1217389, derived from structurally distinct chem. classes.  BAY 1161909 and BAY 1217389 inhibited Mps1 kinase activity with IC50 values below 10 nmol/L while showing an excellent selectivity profile.  In cellular mechanistic assays, both Mps1 inhibitors abrogated nocodazole-induced SAC activity and induced premature exit from mitosis ("mitotic breakthrough"), resulting in multinuclearity and tumor cell death.  Both compds. efficiently inhibited tumor cell proliferation in vitro (IC50 nmol/L range).  In vivo, BAY 1161909 and BAY 1217389 achieved moderate efficacy in monotherapy in tumor xenograft studies.  However, in line with its unique mode of action, when combined with paclitaxel, low doses of Mps1 inhibitor reduced paclitaxel-induced mitotic arrest by the weakening of SAC activity.  As a result, combination therapy strongly improved efficacy over paclitaxel or Mps1 inhibitor monotreatment at the resp. MTDs in a broad range of xenograft models, including those showing acquired or intrinsic paclitaxel resistance.  Both Mps1 inhibitors showed good tolerability without adding toxicity to paclitaxel monotherapy.  These preclin. findings validate the innovative concept of SAC abrogation for cancer therapy and justify clin. proof-of-concept studies evaluating the Mps1 inhibitors BAY 1161909 and BAY 1217389 in combination with antimitotic cancer drugs to enhance their efficacy and potentially overcome resistance.  Mol Cancer Ther; 15(4); 583-92. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGZQmIvWHFcLVg90H21EOLACvtfcHk0lideYqXzVMxlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVSqt7g%253D&md5=f2b5cf0daf178088479be4be2aefa6b7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0500%26sid%3Dliteratum%253Aachs%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DSiemeister%26aufirst%3DG.%26aulast%3DKoppitz%26aufirst%3DM.%26aulast%3DSchulze%26aufirst%3DV.%26aulast%3DKosemund%26aufirst%3DD.%26aulast%3DKlar%26aufirst%3DU.%26aulast%3DStoeckigt%26aufirst%3DD.%26aulast%3DNeuhaus%26aufirst%3DR.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DBader%26aufirst%3DB.%26aulast%3DPrechtl%26aufirst%3DS.%26aulast%3DRaschke%26aufirst%3DM.%26aulast%3DFrisk%26aufirst%3DA.-L.%26aulast%3Dvon%2BAhsen%26aufirst%3DO.%26aulast%3DMichels%26aufirst%3DM.%26aulast%3DKreft%26aufirst%3DB.%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DBrands%26aufirst%3DM.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DZiegelbauer%26aufirst%3DK.%26atitle%3DNovel%2520Mps1%2520Kinase%2520Inhibitors%2520with%2520Potent%2520Antitumor%2520Activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D583%26epage%3D592%26doi%3D10.1158%2F1535-7163.MCT-15-0500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klar, U.</span>; <span class="NLM_string-name">Koppitz, M.</span>; <span class="NLM_string-name">Jautelat, R.</span>; <span class="NLM_string-name">Kosemund, D.</span>; <span class="NLM_string-name">Bohlmann, R.</span>; <span class="NLM_string-name">Lienau, P.</span>; <span class="NLM_string-name">Siemeister, G.</span>; <span class="NLM_string-name">Wengner, A. M.</span></span> <span> </span><span class="NLM_article-title">Substituted Imidazopyridazines</span>. PCT Int. Appl. <span class="NLM_patent">WO 2012032031 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=U.+Klar&author=M.+Koppitz&author=R.+Jautelat&author=D.+Kosemund&author=R.+Bohlmann&author=P.+Lienau&author=G.+Siemeister&author=A.+M.+Wengner&title=Substituted+Imidazopyridazines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKlar%26aufirst%3DU.%26atitle%3DSubstituted%2520Imidazopyridazines%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brokx, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beletskaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awrey, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirgadze, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiarash, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, H. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of Pyrazolo[1,5-<i>a</i>]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">675</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00485</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00485" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC28Xntl2isLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=671-675&author=Y.+Liuauthor=R.+Lauferauthor=N.+K.+Patelauthor=G.+Ngauthor=P.+B.+Sampsonauthor=S.-W.+Liauthor=Y.+Langauthor=M.+Feherauthor=R.+Brokxauthor=I.+Beletskayaauthor=R.+Hodgsonauthor=O.+Plotnikovaauthor=D.+E.+Awreyauthor=W.+Qiuauthor=N.+Y.+Chirgadzeauthor=J.+M.+Masonauthor=X.+Weiauthor=D.+C.-C.+Linauthor=Y.+Cheauthor=R.+Kiarashauthor=G.+C.+Fletcherauthor=T.+W.+Makauthor=M.+R.+Brayauthor=H.+W.+Pauls&title=Discovery+of+Pyrazolo%5B1%2C5-a%5Dpyrimidine+TTK+Inhibitors%3A+CFI-402257+is+a+Potent%2C+Selective%2C+Bioavailable+Anticancer+Agent&doi=10.1021%2Facsmedchemlett.5b00485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent</span></div><div class="casAuthors">Liu, Yong; Laufer, Radoslaw; Patel, Narendra Kumar; Ng, Grace; Sampson, Peter B.; Li, Sze-Wan; Lang, Yunhui; Feher, Miklos; Brokx, Richard; Beletskaya, Irina; Hodgson, Richard; Plotnikova, Olga; Awrey, Donald E.; Qiu, Wei; Chirgadze, Nickolay Y.; Mason, Jacqueline M.; Wei, Xin; Lin, Dan Chi-Chia; Che, Yi; Kiarash, Reza; Fletcher, Graham C.; Mak, Tak W.; Bray, Mark R.; Pauls, Henry W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">671-675</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This work describes a scaffold hopping exercise that begins with known imidazo[1,2-a]pyrazines, briefly explores pyrazolo[1,5-a][1,3,5]triazines, and ultimately yields pyrazolo[1,5-a]pyrimidines as a novel class of potent TTK inhibitors.  An X-ray structure of a representative compd. is consistent with 11/2 type inhibition and provides structural insight to aid subsequent optimization of in vitro activity and physicochem. and pharmacokinetic properties.  Incorporation of polar moieties in the hydrophobic and solvent accessible regions modulates physicochem. properties while maintaining potency.  Compds. with enhanced oral exposure were identified for xenograft studies.  The work culminates in the identification of a potent (TTK Ki = 0.1 nM), highly selective, orally bioavailable anticancer agent (CFI-402257) for IND enabling studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8YPAge-MdqLVg90H21EOLACvtfcHk0lideYqXzVMxlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xntl2isLo%253D&md5=3eb4e1971e0c0a73e6eee657ac9d6fe0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00485%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DN.%2BK.%26aulast%3DNg%26aufirst%3DG.%26aulast%3DSampson%26aufirst%3DP.%2BB.%26aulast%3DLi%26aufirst%3DS.-W.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DBrokx%26aufirst%3DR.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DChirgadze%26aufirst%3DN.%2BY.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DD.%2BC.-C.%26aulast%3DChe%26aufirst%3DY.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DFletcher%26aufirst%3DG.%2BC.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DBray%26aufirst%3DM.%2BR.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DDiscovery%2520of%2520Pyrazolo%255B1%252C5-a%255Dpyrimidine%2520TTK%2520Inhibitors%253A%2520CFI-402257%2520is%2520a%2520Potent%252C%2520Selective%252C%2520Bioavailable%2520Anticancer%2520Agent%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D671%26epage%3D675%26doi%3D10.1021%2Facsmedchemlett.5b00485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiarash, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brokx, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beletskaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span> <span> </span><span class="NLM_article-title">Functional Characterization of CFI-402257, a Potent and Selective Mps1/TTK Kinase Inhibitor, for the Treatment of Cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">3127</span>– <span class="NLM_lpage">3132</span>, <span class="refDoi"> DOI: 10.1073/pnas.1700234114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1073%2Fpnas.1700234114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=28270606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvVyjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=3127-3132&author=J.+M.+Masonauthor=X.+Weiauthor=G.+C.+Fletcherauthor=R.+Kiarashauthor=R.+Brokxauthor=R.+Hodgsonauthor=I.+Beletskayaauthor=M.+R.+Brayauthor=T.+W.+Mak&title=Functional+Characterization+of+CFI-402257%2C+a+Potent+and+Selective+Mps1%2FTTK+Kinase+Inhibitor%2C+for+the+Treatment+of+Cancer&doi=10.1073%2Fpnas.1700234114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer</span></div><div class="casAuthors">Mason, Jacqueline M.; Wei, Xin; Fletcher, Graham C.; Kiarash, Reza; Brokx, Richard; Hodgson, Richard; Beletskaya, Irina; Bray, Mark R.; Mak, Tak W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3127-3132</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Loss of cell-cycle control is a hallmark of human cancer.  Cell-cycle checkpoints are essential for maintaining genome integrity and balanced growth and division.  They are specifically deregulated in cancer cells and contain regulators that represent potential therapeutic targets.  Monopolar spindle 1 (Mps1; also known as TTK protein kinase) is a core component of the spindle assembly checkpoint (SAC), a genome-surveillance mechanism that is important for cell survival, and has emerged as a candidate target for anticancer therapy.  Here, the authors report the cellular and antitumor effects of CFI-402257, a potent (Mps1 Ki = 0.09±0.02 nM; cellular Mps1 EC50 = 6.5±0.5 nM), highly selective, and orally active small-mol. inhibitor of Mps1 that was identified through a drug-discovery program.  Human cancer cells treated with CFI-402257 exhibit effects consistent with Mps1 kinase inhibition, specifically SAC inactivation, leading to chromosome missegregation, aneuploidy, and ultimately cell death.  Oral administration of CFI-402257 in monotherapy or in combination with an anti-programmed cell death 1 (PD-1) antibody in mouse models of human cancer results in inhibition of tumor growth at doses that are well-tolerated.  The authors' findings provide a rationale for the clin. evaluation of CFI-402257 in patients with solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFQJ3eg_c-qLVg90H21EOLACvtfcHk0lideYqXzVMxlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvVyjsL8%253D&md5=bb9742c8d07314e7d3c322bef71ef0ff</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1700234114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1700234114%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DFletcher%26aufirst%3DG.%2BC.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DBrokx%26aufirst%3DR.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DBeletskaya%26aufirst%3DI.%26aulast%3DBray%26aufirst%3DM.%2BR.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DFunctional%2520Characterization%2520of%2520CFI-402257%252C%2520a%2520Potent%2520and%2520Selective%2520Mps1%252FTTK%2520Kinase%2520Inhibitor%252C%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D3127%26epage%3D3132%26doi%3D10.1073%2Fpnas.1700234114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krissinel, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span> <span> </span><span class="NLM_article-title">Overview of the CCP4 Suite and Current Developments</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=21460441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+Suite+and+Current+Developments&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0li2pNADwUDjJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520Suite%2520and%2520Current%2520Developments%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uitdehaag, J. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Man, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willemsen-Seegers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinsen, M. B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libouban, M. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterrenburg, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">deWit, J. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vetter, J. R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Roos, J. A. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buijsman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, G. J. R.</span></span> <span> </span><span class="NLM_article-title">Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>429</i></span>,  <span class="NLM_fpage">2211</span>– <span class="NLM_lpage">2230</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2017.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=10.1016%2Fj.jmb.2017.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=28539250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1Wiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=429&publication_year=2017&pages=2211-2230&author=J.+C.+M.+Uitdehaagauthor=J.+de+Manauthor=N.+Willemsen-Seegersauthor=M.+B.+W.+Prinsenauthor=M.+A.+A.+Liboubanauthor=J.+G.+Sterrenburgauthor=J.+J.+P.+deWitauthor=J.+R.+F.+de+Vetterauthor=J.+A.+D.+M.+de+Roosauthor=R.+C.+Buijsmanauthor=G.+J.+R.+Zaman&title=Target+Residence+Time-Guided+Optimization+on+TTK+Kinase+Results+in+Inhibitors+with+Potent+Anti-Proliferative+Activity&doi=10.1016%2Fj.jmb.2017.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity</span></div><div class="casAuthors">Uitdehaag, Joost C. M.; de Man, Jos; Willemsen-Seegers, Nicole; Prinsen, Martine B. W.; Libouban, Marion A. A.; Sterrenburg, Jan Gerard; de Wit, Joeri J. P.; de Vetter, Judith R. F.; de Roos, Jeroen A. D. M.; Buijsman, Rogier C.; Zaman, Guido J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">429</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2211-2230</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The protein kinase threonine tyrosine kinase (TTK; also known as Mps1) is a crit. component of the spindle assembly checkpoint and a promising drug target for the treatment of aggressive cancers, such as triple neg. breast cancer.  While the first TTK inhibitors have entered clin. trials, little is known about how the inhibition of TTK with small-mol. compds. affects cellular activity.  The authors studied the selective TTK inhibitor NTRC 0066-0, which was developed in the authors' own lab., together with 11 TTK inhibitors developed by other companies, including Mps-BAY2b, BAY 1161909, BAY 1217389 (Bayer), TC-Mps1-12 (Shionogi), and MPI-0479605 (Myrexis).  Parallel testing shows that the cellular activity of these TTK inhibitors correlates with their binding affinity to TTK and, more strongly, with target residence time.  TTK inhibitors are therefore an example where target residence time dets. activity in in vitro cellular assays.  X-ray structures and thermal stability expts. reveal that the most potent compds. induce a shift of the glycine-rich loop as a result of binding to the catalytic lysine at position 553.  This "lysine trap" disrupts the catalytic machinery.  Based on these insights, the authors developed TTK inhibitors, based on a (5,6-dihydro)pyrimido[4,5-e]indolizine scaffold, with longer target residence times, which further exploit an allosteric pocket surrounding Lys 553.  Their binding mode is new for kinase inhibitors and can be classified as hybrid Type I/Type III.  These inhibitors have very potent anti-proliferative activity that rivals classic cytotoxic therapy.  The authors' findings will open up new avenues for more applications for TTK inhibitors in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT_6mZVMoVTrVg90H21EOLACvtfcHk0li2pNADwUDjJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1Wiuro%253D&md5=c02b149e673dec7b0212b37a4c7b0831</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2017.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2017.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DUitdehaag%26aufirst%3DJ.%2BC.%2BM.%26aulast%3Dde%2BMan%26aufirst%3DJ.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DPrinsen%26aufirst%3DM.%2BB.%2BW.%26aulast%3DLibouban%26aufirst%3DM.%2BA.%2BA.%26aulast%3DSterrenburg%26aufirst%3DJ.%2BG.%26aulast%3DdeWit%26aufirst%3DJ.%2BJ.%2BP.%26aulast%3Dde%2BVetter%26aufirst%3DJ.%2BR.%2BF.%26aulast%3Dde%2BRoos%26aufirst%3DJ.%2BA.%2BD.%2BM.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%2BR.%26atitle%3DTarget%2520Residence%2520Time-Guided%2520Optimization%2520on%2520TTK%2520Kinase%2520Results%2520in%2520Inhibitors%2520with%2520Potent%2520Anti-Proliferative%2520Activity%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2017%26volume%3D429%26spage%3D2211%26epage%3D2230%26doi%3D10.1016%2Fj.jmb.2017.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TN9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TN9','PDB','6TN9'); return false;">PDB: 6TN9</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TNB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TNB','PDB','6TNB'); return false;">PDB: 6TNB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TNC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TNC','PDB','6TNC'); return false;">PDB: 6TNC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TND" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TND','PDB','6TND'); return false;">PDB: 6TND</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i47"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02035">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_52558"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b02035?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02035</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Assay descriptions of biochemical and cellular assays and pharmacokinetic and physicochemical assays and <i>in vivo</i> efficacy studies; kinase panel data for compound <b>9</b>; crystallographic data and refinement statistics for compounds <b>16</b>, <b>41</b>, <b>46</b>, and <b>79</b>; chemical synthesis of compounds <b>4</b>, <b>5</b>, <b>7</b>–<b>86</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Live-cell imaging pictures and videos for compound <b>79</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_002.docx">DOCX</a>)</p></li><li><p class="inline">Molecular formula strings and IC<sub>50</sub> values and statistics for biochemical and cellular assay data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_001.pdf">jm9b02035_si_001.pdf (1.7 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_002.docx">jm9b02035_si_002.docx (13.04 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02035/suppl_file/jm9b02035_si_003.csv">jm9b02035_si_003.csv (10.01 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Coordinates and structure factors have been submitted to the RCSB Protein Data Bank (PDB) and are accessible via the codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TN9">6TN9</a> (<b>16</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TNB">6TNB</a> (<b>41</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TNC">6TNC</a> (<b>46</b>), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TND">6TND</a> (<b>79</b>). Authors will release the atomic coordinates upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b02035&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-15%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b02035%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b02035" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799cd4cbcb53cf4","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
